

CLASSIFICATION OF POLYPEPTIDES BY LIGAND GEOMETRY AND
RELATED METHODS

SvB A1)

BACKGROUND OF THE INVENTION

The present invention relates generally to
5 interactions between ligands and polypeptides and more
specifically to determining structure-related properties of
a ligand when bound to different polypeptides.

Structure determination plays a central role in
chemistry and biology due to the correlation between the
10 structure of a molecule and its function. Although a full
understanding of this correlation is not yet established,
one can gain insight into the function of a molecule from
its deduced structure. Thus, the structure can provide a
strong basis for formulating experiments to determine
15 function. Conversely, the eventual disclosure of a
structure for a well studied molecule can have a significant
effect in converging apparently disparate observations of
function into a consistent description of the molecule's
activity.

20 Practical applications which are becoming
increasingly dependent upon structure information include,
for example, the production of therapeutic drugs.
Therapeutic drugs can be designed by synthesizing a molecule
that mimics a ligand known to interact with a target
25 receptor. Alternatively, a therapeutic drug can be designed
by computer assisted methods in which a molecule is designed
to dock to a binding site on a receptor of known structure.

By structure-based methods such as these, lead compounds can be identified for further development.

Using a similar structure based approach a receptor can be engineered to yield improved or novel functions. For example, changes can be made at a ligand binding site in a polypeptide receptor based on the known structure of the receptor. Given that a polypeptide receptor can contain hundreds or even thousands of amino acid residues, of which only a few may contact a ligand, structural information is useful in identifying where changes should be made in the polypeptide to alter ligand binding. Polypeptide receptors engineered as such can be used for a variety of practical applications including, for example, industrial catalysis, therapeutics, and bioremediation.

Although methods for structure determination are evolving, it is currently difficult, costly and time consuming to determine the structure of a polypeptide or ligand. It can often be even more difficult to produce a polypeptide-ligand complex in a condition allowing determination of a structure for the bound complex. Resorting to determining a structure for the receptor individually can have limited value, particularly if the location of ligand binding is difficult to identify due to the large size of most polypeptide receptors. Similarly, determination of a structure of an unbound ligand can have limited usefulness because an unbound ligand has multiple conformations and the most stable conformation of an unbound ligand is often different from its conformation when bound to a receptor.

Theoretical modeling of ligand-polypeptide interactions is one alternative that has been attempted in cases where the structure of the polypeptide-ligand complex is not available. In this approach a ligand is fitted to a structure of a polypeptide. The polypeptide structure used can be determined empirically or theoretically. Theoretical determination of a hypothetical molecular structure for a polypeptide by *ab initio* methods is a relatively undeveloped method. Another theoretical approach, referred to as homology modeling, has been used to infer structure based on comparison with molecules of known structure.

The successful application of homology modeling to determining polypeptide-ligand interactions relies upon choosing a correct polypeptide template for comparison. In most cases criteria for comparison are unavailable or unreliable. For example, it is common to produce a hypothetical structure of a target polypeptide based on the empirically determined structure of a template polypeptide having similar sequence. However, similarities in sequence do not always yield similar structures and conversely, similar structures have been observed for two polypeptides having significantly diverged sequences.

Thus, there exists a need for efficient methods to identify properties of a ligand that confer binding specificity for polypeptide receptors. A need also exists for methods to classify polypeptides and ligands according to structural characteristics. The present invention satisfies this need and provides related advantages as well.

SUMMARY OF THE INVENTION

The invention provides a method for identifying a pharmacocluster. The method includes the steps of (a) determining bound conformations of a ligand bound to
5 different polypeptides, and (b) clustering two or more bound conformations of the ligand having substantially the same bound conformation, thereby identifying a pharmacocluster. The invention also provides a method for identifying a member of a pharmacocluster. The invention also provides a
10 method for identifying a polypeptide pharmacofamily. The method includes the steps of (a) determining bound conformations of a ligand bound to different polypeptides of a polypeptide family, and (b) identifying two or more bound conformations of the ligand having substantially different
15 bound conformations, thereby identifying at least two polypeptide pharmacofamilies exhibiting binding specificity for the two or more substantially different bound conformations of the ligand.

BRIEF DESCRIPTION OF THE DRAWINGS

20 Figure 1 shows pharmacoclusters identified from a database of 156 bound structures of nicotinamide adenine dinucleotide or nicotinamide adenine dinucleotide phosphate. Structures were generated using the overlay function in INSIGHT98 (Molecular Simulations Inc., San Diego, CA).

25 Figure 2 shows the nomenclature used herein for atom names in the NAD(P) molecule.

Figure 3 shows conformer models with interacting atoms from bound polypeptide and ordered waters overlayed. Models in parts A through H were derived from pharmacoclusters 1-8, respectively as described in the Examples. Overlayed atoms and waters are identified as either hydrogen bond donors (donors), hydrogen bond acceptors (acceptors), sulfurs (sulfurs), waters (waters), or atoms that can be hydrogen bond acceptors or hydrogen bond donors (acceptors/donors) according to the legends under each conformer model.

Figure 4 shows a portion of a 2D [^1H , ^1H] NOESY spectrum recorded with a 0.2 ml sample of 1 mM NADP and 200 μM of enzyme 1-deoxy D-xylulose 5-phosphate reductoisomerase (DOXP). Atoms are identified according to Figure 2. Spectra are reported as parts per million (ppm). Since the ligand is in fast exchange and is in excess over polypeptide, cross peaks represent transferred NOEs.

Figure 5 shows high affinity binding of compound TTE0001.001.A07 to polypeptide enzymes of pharmacofamily 1 (panel A) and pharmacofamily 8 (panel B). Double reciprocal plots of reaction rate versus concentration of NADH (panel A) or NADPH (panel B) are shown for each enzyme in the presence of various concentrations of compound TTE0001.001.A07. Concentrations of compound TTE0001.001.A07 shown to the right of the plot A correspond 7.1 μM (open triangles), 3.6 μM (closed triangles), 1.8 μM (open circles) and no added compound (closed circles). Concentrations of compound TTE0001.001.A07 shown to the right of the plot B correspond 56.2 μM (open triangles), 37.5 μM (closed

triangles), 18.7 μM (open circles) and no added compound (closed circles). Inhibitory dissociation constants (K_{is}) determined from the data are shown in the upper left corner of the respective plot.

5 Figure 6 shows high affinity binding of compound TTE0001.002.D02 to a polypeptide enzyme of pharmacofamily 1. A double reciprocal plot of reaction rate versus concentration of NADH is shown for the enzyme in the presence of various concentrations of compound
10 TTE0001.002.D02. Concentrations of compound TTE0001.002.D02 shown to the right of the plot A correspond 20.6 μM (open triangles), 13.7 μM (closed triangles), 6.9 μM (open circles) and no added compound (closed circles). An inhibitory dissociation constant (K_{is}) determined from the
15 data is shown in the upper left corner of the plot..

Figure 7 shows a pharmacophore model derived from the coordinates presented in Table 3 for pharmacofamily 1. Figure 7A shows a feature of the pharmacophore model including a volume defining the shape of conformer model 1
20 which is indicated by grey spheres and superimposed on the conformer model having coordinates listed in Table 3C. Figure 7B shows three features of the pharmacophore model including a hydrophobic region of the nicotinamide ring, a hydrogen bond acceptor positioned at the averaged
25 coordinates for the location of 17 hydrogen bond acceptors in the polypeptides of pharmacofamily 1, and a hydrogen bond donor positioned where a hydrogen bond donor of a ligand would be expected to have favorable interactions with hydrogen bond acceptors observed in 11 of the 17
30 polypeptides in pharmacofamily 1. Figure 7C shows a

combination of features of figures 7A and 7B present in a pharmacophore model and superimposed on the conformer model.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides pharmacoclusters and
5 methods for identifying a pharmacocluster from bound
conformations of a ligand bound to different polypeptides.
The methods are applicable for identifying a conformation-
dependent property of a ligand based on bound conformations
of the ligand in a pharmacocluster. The methods are also
10 applicable for classifying polypeptides, from a family of
polypeptides that bind the same ligand, into
pharmacofamilies based on bound conformations of the ligand.
Accordingly, methods are provided for grouping polypeptides
into pharmacofamilies by determining bound conformations of
15 a ligand or a conformation-dependent property of a ligand
independent of a determination of the structure of the
polypeptide. An advantage of classifying polypeptides
according to bound conformations of a ligand is that a
pharmacofamily is likely to contain polypeptides having
20 greater binding specificity for a particular molecule than
other polypeptides in the same family. Thus, the methods
allow identification of a pharmacofamily that can
specifically interact with a particular therapeutic agent or
drug.

25 Additionally, the methods of the invention can be
used to determine a conformer model or pharmacophore model
based on a bound conformation or conformation-dependent
property of a ligand bound to polypeptides in a
pharmacofamily. The invention is therefore advantageous in

providing a model for the design and identification of therapeutic compounds having specificity for a pharmacofamily of polypeptides.

Another advantage of the invention is that the methods provide a correlation between ligand conformation, a parameter that is relatively easy to measure, and polypeptide structure, a parameter of tremendous value but often difficult to measure. Therefore, the methods of the invention can be used to determine structural characteristics of a polypeptide based on a conformation-dependent property of a bound ligand.

As used herein, the term "pharmacocluster" refers to a collection of substantially the same bound conformations of a ligand, or portion thereof, bound to two or more polypeptides. A member conformation of a pharmacocluster can have (1) a conformation that is more similar to an average conformation of the members in its pharmacocluster than to any other pharmacocluster and (2) a conformation that is more similar to an average conformation of the members in its own pharmacocluster than the most similar average structures from different pharmacoclusters are to each other, wherein the pharmacoclusters consist of conformations of the same ligand or portion thereof. The pharmacocluster is determined for a ligand bound to different polypeptides but does not require that a structure of the polypeptide be known or included as part of a bound conformation of a ligand. A bound conformation of a ligand can include the entire ligand structure or selected atoms including a portion of the complete atomic composition of the ligand so long as the number of atoms provides

sufficient information to distinguish one pharmacocluster from another. A pharmacocluster can include both the bound conformations of a ligand, or portion thereof, and one or more atoms that both interact with the ligand and are from a bound polypeptide. Thus, a pharmacocluster can include conformational information of 1 or more, 2 or more, 5 or more, 10 or more, 20 or more, 30 or more, 40 or more, 50 or more or 100 or more atoms of a ligand bound conformation.

Accordingly, portions of bound conformations of two or more different ligands can be included in a ligand pharmacocluster so long as the portions selected from each ligand have a core bound conformation that is substantially the same. A core bound conformation can consist of portions of bound conformations of ligands wherein the portions have identical structural formula and conformation. A core bound conformation can also consist of portions of bound conformations of ligands wherein the portions have different structural formulas so long as the portions have substantially the same conformation. The structural formula, as it is understood in the art, is a 2 dimensional representation of a molecule that identifies the atoms and covalent bonds between each atom in the molecule. The structural formula does not necessarily include information sufficient to determine conformation of a molecule. For example, a common structural formula representation of cyclohexane can be a hexagon with 2 hydrogens attached to each carbon being in equivalent positions. However, a stable conformation of cyclohexane in solution may appear as a "chair" or "boat" shape with hydrogens in either axial or equitorial positions relative to the molecular plane.

As used herein, the term "conformation-dependent property," when used in reference to a ligand, refers to a characteristic of a ligand that specifically correlates with the three dimensional structure of a ligand or the orientation in space of selected atoms and bonds of the ligand. Thus, a ligand bound to a polypeptide in a distinct conformation will have at least one unique conformation-dependent property correlated with the bound conformation of the ligand. A conformation-dependent property can be derived from or include the entire ligand structure or selected atoms and bonds, including a fragment or portion of the complete atomic composition of the ligand. A conformation-dependent property that includes selected atoms and bonds of a ligand can include 2 or more, 3 or more, 5 or more, 10 or more, 15 or more, 20 or more, 25 or more, or 50 or more atoms of a bound conformation of a ligand.

A characteristic that specifically correlates with a three dimensional structure of a ligand is a characteristic that is substantially different between at least two different bound conformations of the same ligand and, therefore, distinguishes the two different bound conformations. A conformation-dependent property can include a physical or chemical characteristic of a ligand, for example, absorption and emission of heat, absorption and emission of electromagnetic radiation, rotation of polarized light, magnetic moment, spin state of electrons, or polarity. A conformation-dependent property can also include a structural characteristic of a ligand based, for example, on an X-ray diffraction pattern or a nuclear magnetic resonance (NMR) spectrum. A conformation-dependent property can additionally include a characteristic based on

a structural model, for example, an electron density map, atomic coordinates, or x-ray structure. A conformation-dependent property can include a characteristic spectroscopic signal based on, for example, Raman, circular
5 dichroism (CD), optical rotation, electron paramagnetic resonance (EPR), infrared (IR), ultraviolet/visible absorbance (UV/Vis), fluorescence, or luminescence spectroscopies. A conformation-dependent property can also include a characteristic NMR signal, for example, chemical
10 shift, J coupling, dipolar coupling, cross-correlation, nuclear spin relaxation, transferred nuclear Overhauser effect, or combinations thereof. A conformation-dependent property can additionally include a thermodynamic or kinetic characteristic based on, for example, calorimetric
15 measurement or binding affinity measurement. Furthermore, a conformation-dependent property can include characteristic based on electrical measurement, for example, voltammetry or conductance.

As used herein, "selected" conformation-dependent
20 properties are identified to form a set of conformation-dependent properties that can include, for example, the entire set of conformation-dependent properties associated with the bound conformations of a ligand in a pharmacocluster or a subset of conformation-dependent
25 properties associated with the bound conformations of a ligand in a pharmacocluster, so long as the subset of conformation-dependent properties are sufficient to identify a unique conformation of the ligand. A selected conformation-dependent property can include any of the above
30 described properties, for example, a physical or chemical property, structural data, a structural model, a

spectroscopic signal, a thermodynamic or kinetic measurement or an electrical measurement.

As used herein, the term "bound conformation," when used in reference to a ligand, refers to the location of atoms of a ligand relative to each other in three dimensional space, where the ligand is bound to a polypeptide. The location of atoms in a ligand can be described, for example, according to bond angles, bond distances, relative locations of electron density, probable occupancy of atoms at points in space relative to each other, probable occupancy of electrons at points in space relative to each other or combinations thereof.

As used herein, a "selected" bound conformation refers to a set of bound conformations that can include, for example, the entire set of defined bound conformations or a subset of bound conformations of a ligand.

As used herein, the term "clustering" refers to assigning related bound conformations of a ligand, or portion thereof, into a first collection such that the conformations residing in the first collection can be overlaid with substantial overlap and bound conformations from two different collections cannot be overlaid with a better overlap than that resulting from members of the first collection. Exemplary clustering of ligand conformations are disclosed herein (see Example I).

As used herein, the term "ligand" refers to a molecule that can specifically bind to a polypeptide. Specific binding, as it is used herein, refers to binding

that is detectable over non-specific interactions by quantifiable assays well known in the art. A ligand can be essentially any type of natural or synthetic molecule including, for example, a polypeptide, nucleic acid, 5 carbohydrate, lipid, amino acid, nucleotide or any organic derived compound. The term also encompasses a cofactor or a substrate of a polypeptide having enzymatic activity, or substrate that is inert to catalytic conversion by the bound polypeptide. Specific binding to a polypeptide can be due 10 to covalent or non covalent interactions.

As used herein, the term "bound to two or more polypeptides," when used in reference to a ligand is intended to refer to two or more complexes consisting of a ligand and a polypeptide. A complex can include, for 15 example, a single ligand bound to a single polypeptide. A complex can also include a single ligand bound to more than one polypeptides including, for example, a complex in which a ligand is bound at the interface of interacting polypeptides. A complex can also include multiple ligands, 20 however, conformation dependent properties of all ligands of the complex need not be identified. A complex results from a specific interaction between a polypeptide and a ligand.

As used herein, the term "substantially the same," when used in reference to bound conformations of a ligand, 25 or portion thereof, is intended to refer to two or more bound conformations that can be overlaid upon each other in 3 dimensional space such that all corresponding atoms between the two conformations are overlapped. Accordingly, "substantially different" bound conformations cannot be 30 overlaid upon each other in 3-dimensional space such that

all corresponding atoms between the two bound conformations are overlapped.

As used herein, the term "polypeptide" is intended to refer to a peptide polymer of two or more amino acids.

5 The term is similarly intended to include polymers containing amino acid stereoisomers, analogues and functional mimetics thereof. For example, derivatives can include chemical modifications of amino acids such as alkylation, acylation, carbamylation, iodination, or any
10 modification which derivatizes the polypeptide. Analogues can include modified amino acids, for example, hydroxyproline or carboxyglutamate, and can include amino acids, or analogs thereof, that are not linked by peptide bonds. Mimetics encompass chemicals containing chemical
15 moieties that mimic the function of the polypeptide regardless of the predicted three-dimensional structure of the compound. For example, if a polypeptide contains two charged chemical moieties in a functional domain, a mimetic places two charged chemical moieties in a spatial
20 orientation and constrained structure so that the corresponding charge is maintained in three-dimensional space. Thus, all of these modifications are included within the term "polypeptide" so long as the polypeptide retains its binding function.

25 As used herein, the term "root mean square deviation," or RMSD, refers to a standard deviation which quantifies the structural variability in a population of bound conformations of a ligand. The term is intended to be consistent with its meaning as understood in the art as
30 described for example in Doucet and Weber, Computer-Aided

Molecular Design: Theory and Applications, Academic Press,
San Diego CA (1996).

As used herein, the term "family," when used in
reference to characterizing polypeptides having ligand
5 binding activity, is intended to refer to polypeptides that
can bind to the same ligand, or portion thereof. A
polypeptide family can contain polypeptides having binding
activity for a common ligand with sufficient affinity,
avidity or specificity to allow measurement of the binding
10 event. As defined herein a "member" of a polypeptide family
refers to an individual polypeptide that can be classified
in a polypeptide family because the polypeptide binds a
ligand, or portion thereof, that binds another polypeptide
in a polypeptide family. The bound conformations of a
15 ligand bound by individual members of a family can be
substantially the same or different from each other.

As used herein, the term "pharmacofamily," when
used in reference to polypeptides, is intended to refer to
polypeptides that can be classified together in a population
20 because they individually bind a ligand such that the ligand
is bound in substantially the same conformation. As defined
herein a "member" of a polypeptide pharmacofamily refers to
an individual polypeptide that is classified in a
polypeptide pharmacofamily because the polypeptide binds a
25 conformation of a ligand that is substantially the same as a
conformation of the ligand bound to another polypeptide in
the pharmacofamily.

As used herein, the term "grouping" refers to assigning related polypeptides into a family or pharmacofamily such that the polypeptide members of a family bind the same ligand and the polypeptide members of a pharmacofamily bind substantially the same bound conformation of a ligand.

As used herein, the term "fold," when used in reference to a polypeptide, refers to a specific geometric arrangement and connectivity of a combination of secondary structure elements in a polypeptide structure. Secondary structure elements of a polypeptide that can be arranged into a fold including, for example, alpha helices, beta sheets, turns and loops are well known in the art. Folds of a polypeptide can be recognized by one skilled in the art and are described in, for example, Branden and Tooze, Introduction to protein structure, Garland Publishing, New York (1991) and Richardson, Adv. Prot. Chem. 34:167-339 (1981).

As used herein, "modeling the three dimensional structure" when used in reference to a polypeptide refers to determining a conformation for a polypeptide. A conformation of a polypeptide can be determined, for example, from empirical data specifying structure or from a compared conformation used as a template. A conformation can be determined at any desired level of resolution sufficient to identify, for example, overall shape of a polypeptide, tertiary structure elements, secondary structure elements, polypeptide backbone structure, amino acid residue identity or location of individual atoms.

As used herein, the term "structural model," when used in reference to a polypeptide, refers to a representation of a 3 dimensional structure of a polypeptide. A structural model can be determined from
5 empirical data derived from, for example, X-ray crystallography or nuclear magnetic resonance spectroscopy. A structural model can also be derived from a theoretical calculation including, for example, comparison to a known structure or *ab initio* molecular modeling. A representation
10 of a structural model can include, for example, an electron density map, atomic coordinates, x-ray structure model, ball and stick model, density map, space filling model, surface map, Connolly surface, Van der Waals surface or CPK model.

As used herein, the term "conformer model" refers
15 to a representation of points in a defined coordinate system wherein a point corresponds to a position of an atom in a bound conformation of a ligand. The coordinate system is preferably in 3 dimensions, however, manipulation or computation of a model can be performed in 2 dimensions or
20 even 4 or more dimensions in cases where such methods are preferred. A point in the representation of points can, for example, correlate with the center of an atom. Additionally, a point in the representation of points can be incorporated into a line, plane or sphere to include a shape
25 of one or more atom or volume occupied by one or more atom. A conformer model can be derived from 2 or more bound conformations of a ligand. For example a conformer model can be generated from 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 10 or more, 15 or more, 20 or
30 more or 25 or more bound conformations of a ligand.

As used herein, the term "average structure," when used in reference to bound conformations of a ligand in a pharmacocluster, refers to conformer model, derived by superimposing the bound conformations of a ligand in a pharmacocluster, and determining an average location in space for corresponding atoms.

As used herein, the term "pharmacophore model" refers to a representation of points in a defined coordinate system wherein a point corresponds to a position or other characteristic of an atom or chemical moiety in a bound conformation of a ligand and/or an interacting polypeptide or ordered water. An ordered water is an observable water in a model derived from structural determination of a polypeptide. A pharmacophore model can include, for example, atoms of a bound conformation of a ligand, or portion thereof. A pharmacophore model can include both the bound conformations of a ligand, or portion thereof, and one or more atoms that both interact with the ligand and are from a bound polypeptide. Thus, in addition to geometric characteristics of a bound conformation of a ligand, a pharmacophore model can indicate other characteristics including, for example, charge or hydrophobicity of an atom or chemical moiety. A pharmacophore model can incorporate internal interactions within the bound conformation of a ligand or interactions between a bound conformation of a ligand and a polypeptide or other receptor including, for example, van der Waals interactions, hydrogen bonds, ionic bonds, and hydrophobic interactions. A pharmacophore model can be derived from 2 or more bound conformations of a ligand. For example a conformer model can be generated from 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or

more, 10 or more, 15 or more, 20 or more or 25 or more bound conformations of a ligand.

A point in a pharmacophore model can, for example, correlate with the center of an atom or moiety.

- 5 Additionally, a point in the representation of points can be incorporated into a line, plane or sphere to indicate a characteristic other than a center of an atom or moiety including, for example, shape of an atom or moiety or volume occupied by an atom or moiety. The coordinate system of a
- 10 pharmacophore model is preferably in 3 dimensions, however, manipulation or computation of a model can be performed in 2 dimensions or even 4 or more dimensions in cases where such methods are preferred. Multidimensional coordinate systems in which a pharmacophore model can be represented include,
- 15 for example, cartesian coordinate systems, fractional coordinate systems, or reciprocal space. The term pharmacophore model is intended to encompass a conformer model.

- As used herein, the term "moiety" refers to a
- 20 group of atoms that form a part or portion of a larger molecule. A moiety can consist of any number of atoms in a portion of a ligand and can correlate with a physical or chemical property conferred upon the ligand by the combined atoms. Exemplary moieties of a nicotinamide adenine
- 25 dinucleotide ligand include a phosphate, nicotinamide ring, amino group, amide group or ribose ring. In addition, a nicotinamide adenine dinucleotide group can be a moiety. For example, a nicotinamide adenine dinucleotide can be a moiety of the 2'P phosphate in a nicotinamide adenine
- 30 dinucleotide phosphate molecule (see Figure 2 for location

of the 2'P phosphate in nicotinamide adenine dinucleotide phosphate).

The invention provides a method for identifying a
5 pharmacocluster. The method includes the steps of (a)
determining bound conformations of a ligand bound to
different polypeptides, and (b) clustering two or more bound
conformations of the ligand having substantially the same
bound conformation, thereby identifying a pharmacocluster.
10 The invention also provides a method for identifying a
member of a pharmacocluster. The method includes the steps
of (a) determining a bound conformation of a ligand bound to
a polypeptide; and (b) determining a pharmacocluster having
substantially the same bound conformation as the bound
15 conformation, thereby identifying the bound conformation of
the ligand as a member of the pharmacocluster.

A bound conformation of a ligand bound to a
polypeptide can be determined from a previously observed
molecular structure or from data specifying a molecular
20 structure for a bound conformation of a ligand. Previously
observed structures can be acquired for use in the invention
by searching a database of existing structures. An example
of a database that includes structures of bound
conformations of ligands bound to polypeptides is the
25 Protein Data Bank (PDB, operated by the Research
Collaboratory for Structural Bioinformatics, see Berman et
al., Nucleic Acids Research, 28:235-242 (2000)). A database
can be searched, for example, by querying based on chemical
property information or on structural information. In the
30 latter approach, an algorithm based on finding a match to a
template can be used as described, for example, in Martin,

"Database Searching in Drug Design," J. Med. Chem. 35:2145-2154 (1992).

A bound conformation of a ligand bound to a polypeptide can be determined from an empirical measurement, or from a database. Data specifying a structure can be acquired using any method available in the art for structural determination of a ligand bound to a polypeptide. For example, X-ray crystallography can be performed with a crystallized complex of a polypeptide and ligand to determine a bound conformation of the ligand bound to the polypeptide. Methods for obtaining such crystal complexes and determining structures from them are well known in the art as described for example in McRee et al., Practical Protein Crystallography, Academic Press, San Diego 1993; Stout and Jensen, X-ray Structure Determination: A practical guide, 2nd Ed. Wiley, New York (1989); and McPherson, The Preparation and Analysis of Protein Crystals, Wiley, New York (1982). Another method useful for determining a bound conformation of a ligand bound to a polypeptide is Nuclear Magnetic Resonance (NMR). NMR methods are well known in the art and include those described for example in Reid, Protein NMR Techniques, Humana Press, Totowa NJ (1997); and Cavanaugh et al., Protein NMR Spectroscopy: Principles and Practice, ch. 7, Academic Press, San Diego CA (1996).

A bound conformation of a ligand can also be determined from a hypothetical model. For example, a hypothetical model of a bound conformation of a ligand can be produced using an algorithm which docks a ligand to a polypeptide of known structure and fits the ligand to the polypeptide binding site. Algorithms available in the art

for fitting a ligand structure to a polypeptide binding site include, for example, DOCK (Kuntz et al., J. Mol. Biol. 161:269-288 (1982)) and INSIGHT98 (Molecular Simulations Inc., San Diego, CA).

5 A molecular structure can be conveniently stored and manipulated using structural coordinates. Structural coordinates can occur in any format known in the art so long as the format can provide an accurate reproduction of the observed structure. For example, crystal coordinates can
10 occur in a variety of file types including, for example, .fin, .df, .phs, or .pdb as described for example in McRee, *supra*. Although the examples above describe structural coordinates derived from X-ray crystallographic analysis or NMR spectroscopy, one skilled in the art will recognize that
15 structural coordinates can be derived from any method known in the art to determine a bound conformation of a ligand bound to a polypeptide.

Structures at atomic level resolution can be useful in the methods of the invention. Resolution, when
20 used to describe molecular structures, refers to the minimum distance that can be resolved in the observed structure. Thus, resolution where individual atoms can be resolved is referred to in the art as atomic resolution. Resolution is commonly reported as a numerical value in units of Angstroms
25 (\AA , 10^{-10} meter) correlated with the minimum distance which can be resolved such that smaller values indicate higher resolution. Bound conformations of a ligand useful in the methods of the invention can have a resolution better than about 10 \AA , 5 \AA , 3 \AA , 2.5 \AA , 2.0 \AA , 1.5 \AA , 1.0 \AA , 0.8 \AA , 0.6
30 \AA , 0.4 \AA , or about 0.2 \AA or better. Resolution can also be

reported as an all atom RMSD as used, for example, in reporting NMR data. Bound conformations of a ligand useful in the methods of the invention can have an all atom RMSD better than about 10 Å, 5 Å, 3 Å, 2.5 Å, 2.0 Å, 1.5 Å, 1.0 Å, 0.8 Å, 0.6 Å, 0.4 Å, or about 0.2 Å or better.

An advantage of the methods of the invention is that a structure of a polypeptide bound to a bound conformation of a ligand need not be determined to identify a pharmacocluster. Thus, methods that detect only the structure of the ligand can be used in the invention. In some cases determination or refinement of only the structure of the ligand in a polypeptide-ligand complex will be required. In addition, methods that detect a conformation-dependent property of the ligand can be used to identify a pharmacocluster. Methods that can be used to determine a conformation-dependent property of a ligand in a polypeptide-ligand complex without determining the structure of the polypeptide include, for example, Electron Nuclear Double Resonance spectroscopy (ENDOR, as described in Van Doorslaer and Schweiger, Naturwissenschaften 87:245-55(2000)), Electron Paramagnetic Resonance spectroscopy (EPR, described in Cantor and Schimmel Biophysical Chemistry, Part I: The conformation of biological macromolecules W. H. Freeman and Company (1980)), chemically induced dynamic nuclear polarization (CIDNP, described in Siebert et al., Glycoconj J. 14:945-9 (1997) and Consonni et al., FEBS Lett. 372:135-9 (1995)), solid state NMR (described in Mehring, M. High Resolution NMR spectroscopy in Solids, 2nd ed. Springer-Verlag, Berlin (1983) and liquid phase NMR (described in Wüthrich, NMR of Proteins and Nucleic Acids John Wiley & Sons, Inc. (1986)). Thus, the

invention can be performed in a manner whereby the time and cost associated with a full determination of a polypeptide structure is avoided.

5 Any representation that correlates with the structure of a bound conformation of a ligand can be used in the methods of the invention. For example, a convenient and commonly used representation is a displayed image of the structure. Displayed images that are particularly useful
10 for determining the bound conformation of a ligand bound to polypeptides include, for example, ball and stick models, density maps, space filling models, surface map, Connolly surfaces, Van der Waals surfaces or CPK model. Display of images as a computer output, for example, on a video screen
15 can be advantageous as described below.

Clustering can be performed with any ligand or any number of bound conformations of a ligand. The methods of the invention can be performed by clustering 2 or more bound conformations of a ligand. For example, clustering can be
20 performed with 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more or 20 or more bound conformations of a ligand. The methods of the invention can be used with any number bound conformations of a ligand.
25 Due to the large sizes of data sets required to represent bound conformations of a ligand, methods of clustering bound conformations are generally performed on a computer. The methods are compatible with any computer that can support molecular modeling software including for example a personal
30 computer, silicon graphics workstation, or supercomputer. A variety of computer software programs are available for

molecular modeling including, for example, GRASP (Nicholls, A., *supra*), ALADDIN (Van Drie et al. *supra*), INSIGHT98 (Molecular Simulations Inc., San Diego CA), RASMOL (Sayle et al., Trends Biochem Sci. 20:374-376 (1995)) and MOLMOL
 5 (Koradi et al., J. Mol. Graphics 14:51-55 (1996)).

Once a bound conformation of a ligand bound to different polypeptides has been determined, two or more bound conformations of the ligand can be compared and those having substantially the same bound conformation can be
 10 clustered. Methods of comparison include, for example, a method that provides alignment of two or more bound conformations of a ligand and evaluation of the degree of overlap in the two structures. Methods of comparison can be performed in an iterative fashion until a best fit is
 15 identified.

Methods of comparing bound conformations of bound ligands include, for example, cluster analysis, visual inspection and pairwise structural comparisons. Cluster analysis is commonly performed by, but not limited to,
 20 partitioning methods or hierarchical methods as described, for example, in Kauffman and Rousseeuw, Finding Groups in Data: An Introduction to Cluster Analysis, John Wiley and Sons Inc., New York (1990). Partitioning methods that can be used include, for example, partitioning around medoids,
 25 clustering large applications, and fuzzy analysis, as described in Kauffman and Rousseeuw, *supra*. Hierarchical methods useful in the invention include, for example, agglomerative nesting, divisive analysis, and monothetic analysis, as described in Kauffman and Rousseeuw, *supra*.
 30 Algorithms for cluster analysis of molecular structures are

known in the art and include, for example, COMPARE (Chiron Corp, 1995; distributed by Quantum Chemistry program Exchange, Indianapolis IN). COMPARE can be used to make all possible pairwise comparisons between a set of conformations of the same ligand(s). COMPARE reads PDB files and uses a Ferro-Hermanns ORIENT algorithm for a least squares root mean square (RMS) fit. The structures can be clustered into groups using the Jarvis-Patrick nearest neighbors algorithm. Based on the RMS deviation between ligand conformers, a list of 'nearest neighbors' for each conformer are generated. Two conformers are then grouped together or clustered if: (1) the RMS deviation is sufficiently small and (2) if both conformers share a determined number of common 'neighbors'. Both criteria are adjusted by the program to generate clusters based on a user defined cutoff for distance between individual clusters. Follow up analysis was conducted using InsightII to verify clusters. A member conformation is identified as being closer to the averaged coordinates of conformations within its family than to the averaged coordinates of any other family.

Using methods such as those described above, one skilled in the art will know how to identify conformations that are substantially the same. For example, similarity can be evaluated according to the goodness of fit between two or more bound conformations of a ligand. Goodness of fit can be represented by a variety of parameters known in the art including, for example, the root mean square deviation (RMSD). A lower RMSD between structures correlates with a better fit compared to a higher RMSD between structures. Bound conformations of a ligand having substantially the same conformations can be identified by

comparing mean RMSD values within and between pharmacoclusters. Accordingly, bound conformations of a ligand having substantially the same conformations can have a mean RMSD compared to an average structure for the pharmacocluster that is less than 1.1 Å. Two or more bound conformations of a ligand can be clustered by assigning bound conformations of a ligand into a collection such that the conformations of a ligand residing in the collection are substantially the same. Members of a pharmacocluster can also be identified as having RMSD values compared to an average structure for the pharmacocluster that are less than 1.0 Å, 0.9 Å, 0.8 Å, 0.7 Å, 0.6 Å, 0.5 Å, 0.4 Å, 0.3 Å, 0.2 Å or 0.1 Å.

A bound conformation of a ligand that is a member of a pharmacocluster can also be identified by comparing the RMSD for the bound conformation to an average conformation of the members in multiple pharmacoclusters. Using this value for comparison, a member conformation is identified as having a smaller RMSD when compared to the averaged coordinates of conformations within its family than when compared to the averaged coordinates of any other family. In addition, a member of a pharmacocluster can be identified as having an RMSD compared to an average conformation of the members in a pharmacocluster that is smaller than the RMSD between each family's average coordinates. For example, as described in Example I, RMSD values for members of pharmacoclusters 1-8 as presented in Tables 3A, 4A, 5A, 6A, 7A, 8A, 9A or 10A, respectively, can be compared to RMSD values between each pharmacocluster as presented in Table 2. Comparisons similar to those described above can be made for

bound conformations of any ligand according to the methods described in the Examples.

In addition, bound conformations of a ligand can be compared with respect to dihedral angles at particular
5 bonds. Exemplary methods for comparing dihedral angles between pharmacoclusters is described in Example I and Table 1. Comparison between dihedral angles can be used, for example, in combination with overall RMSD comparisons such as those described above. Therefore, bound conformations
10 that are not easily distinguished by comparison of overall RMSD alone, can be distinguished according to the combined comparison of RMSD and dihedral angle. Bound conformations of a ligand that are members of different pharmacoclusters can have dihedral angles that differ, for example, by at
15 least about 10 degrees, 30 degrees, 45 degrees, 90 degrees or 180 degrees.

The invention also provides a pharmacocluster selected from the cluster consisting of pharmacocluster 1, pharmacocluster 2, pharmacocluster 3, pharmacocluster 4,
20 pharmacocluster 5, pharmacocluster 6, pharmacocluster 7, and pharmacocluster 8 correlated with the pharmacofamilies listed in Table 11.

Pharmacoclusters 1 through 8 contain bound conformations of NAD(P)(H) determined from structures
25 deposited in the PDB for NAD(P)(H) bound to oxidoreductase polypeptides. Pharmacoclusters are shown in Figure 1 and described in further detail in Example I. The pharmacoclusters of Figure 1 display substantial overlap between bound conformations of NAD(P)(H) within the cluster,

as can be identified by visual inspection of the structures. Quantitative comparison of the bound conformations in each pharmacocluster demonstrates that each pharmacocluster displays less than about 1.1 Å difference in RMSD between
5 each conformation of NAD(P)(H) and the average bound conformation for the respective pharmacocluster as described in Example I.

Pharmacoclusters can be used to identify a ligand having specificity for one or more polypeptide
10 pharmacofamilies (see Example V). As described herein, a pharmacophore model or conformer model can be derived from one or more cluster. These models can be used to identify a ligand having specificity for one or more pharmacofamilies of oxidoreductases, for example, by using the model to query
15 a database of molecules for a potential ligand or by using the model to guide in the design of a synthetic ligand. An example of using a pharmacophore of the invention to identify a binding compound is provided in Example VI.

Pharmacoclusters, including, for example,
20 pharmacoclusters 1 through 8 can also be used to identify a new polypeptide member of a polypeptide pharmacofamily. Using the methods described herein, for example, a pharmacocluster can be used to produce a pharmacophore model or conformer model to which a bound conformation of a ligand
25 can be compared. A polypeptide bound to a bound conformation of a ligand that is similar to the model can be classified into an appropriate polypeptide pharmacofamily based on this comparison. By a similar method, a bound conformation of a ligand can be directly compared to a

pharmacocluster to classify the polypeptide bound to the conformation of a ligand into an appropriate pharmacofamily.

The methods of the invention can also be used with a portion of a bound conformation of a ligand to identify a pharmacocluster. The method consists of (a) determining a
5 bound conformation of a ligand, or portion thereof, bound to two or more polypeptides, and (b) clustering two or more bound conformations of the ligand, or portion thereof having substantially the same bound conformation, thereby
10 identifying a pharmacocluster.

A bound conformation of a portion of a ligand can include selected atoms and/or bonds of a ligand and can include, for example, a continuous sequence of atoms and/or bonds or a discontinuous sequence of selected atoms and/or
15 bonds that, when described independent of the complete ligand structure, may not appear to be attached to each other. Such a portion can include 2 or more atoms of a bound conformation of a ligand or 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or
20 more, 15 or more, 20 or more, 25 or more or 50 or more atoms of a bound conformation of a ligand. A bound conformation of a portion of a ligand bound to a polypeptide can be identified according to the same methods described above for identifying a bound conformation of a ligand bound to a
25 polypeptide. Two or more bound conformations of a portion of a ligand can be clustered as described above so long as the bound conformations that are clustered correspond to bound portions of the ligand having the same structural formula. For example, in a case where determination of the
30 complete structure of a ligand has not been achieved, a

complete structure of a ligand has not been achieved, a bound conformation of a portion of the ligand corresponding to the structurally determined portion can be used in the methods of the invention.

5 A pharmacocluster can include portions of bound conformations derived from different ligands so long as the portions have a core bound conformation that is substantially the same. For example, portions having the same structural formula and bond configuration can share a
10 core bound conformation. The bond configuration describes the relative position of atoms attached to a chiral atom of a ligand. Accordingly, R and S stereoisomers of a chiral atom have different bond configurations. Other terms used in the art to designate different bond configurations
15 include, for example, cis and trans configurations of atoms attached to carbons that are double bonded, or Z and E configurations of atoms attached to carbons that are double bonded. An example of portions of ligands having the same structural formula and bond configuration that can share a
20 core bound conformation are the nicotinamide adenine dinucleotide portions of nicotinamide adenine dinucleotide phosphate (NADP) and nicotinamide adenine dinucleotide (NAD). Additionally, portions of ligands having different charge, atom substitution or bond hybridization can share a
25 core bound conformation. An example of portions of ligands having different charge and bond hybridization that can share a core bound conformation are the nicotinamide adenine dinucleotide portions of oxidized nicotinamide adenine dinucleotide (NAD) and reduced nicotinamide adenine
30 core bound conformation. In cases where the core structures of two ligands bind with substantially the same conformation to

polypeptides, the core bound conformations can be clustered according to the methods of the invention (see Example I).

Substantially the same bound conformation of a portion of a bound conformation of a ligand, including non-continuous atoms, can be identified according to the root mean square deviation and compared directly. Conformations of portions having different numbers of atoms can also be compared via root mean square deviation per equivalent atom (RMSD/N, where N is the number of atoms compared). A lower value of RMSD/N indicates increased similarity between the two or more bound ligand conformations that are clustered. One skilled in the art will know that RMSD/N has a compensational origin and consideration of the effect of N is required for comparison of RMSD/N between pharmacoclusters having different values of N. For example, the lower the value of RMSD/N the lower should be the value of N to indicate substantial similarity.

The invention can be used with any ligand for which bound conformations of the ligand bound to different polypeptides can be determined including, for example, chemical or biological molecules such as simple or complex organic molecules, metal-containing compounds, carbohydrates, peptides, peptidomimetics, carbohydrates, lipids, nucleic acids, and the like.

In one embodiment, the compositions and methods of the invention can be used with a ligand that is a nucleotide derivative including, for example, a nicotinamide adenine dinucleotide-related molecule. Nicotinamide adenine dinucleotide-related (NAD-related) molecules that can be

used in the methods of the invention can be selected from the group consisting of oxidized nicotinamide adenine dinucleotide (NAD⁺), reduced nicotinamide adenine dinucleotide (NADH), oxidized nicotinamide adenine
 5 dinucleotide phosphate (NADP⁺), and reduced nicotinamide adenine dinucleotide phosphate (NADPH). An NAD-related molecule can also be a mimetic of the above-described molecules. Use of a NAD-related molecule to identify pharmacoclusters is described in Example I.

10 A mimetic is a molecule that has at least one function that is substantially the same as a function of a second molecule. A mimetic of a ligand can be identified according to its ability to bind to the same sites on a polypeptide as the ligand. For example, a mimetic can be
 15 identified by a binding competition assay using a ligand and a mimetic. The structure of a mimetic can be similar or different compared to the structure of the second molecule. The term can encompass molecules having portions similar to corresponding portions of the ligand in terms of structure
 20 or function.

Examples of mimetics to the common ligand NADH, for example cibacron blue, are described in Dye-Ligand Chromatography, Amicon Corp., Lexington MA (1980). Numerous other examples of NADH-mimics, including useful
 25 modifications to obtain such mimics, are described in Everse et al. (eds.), The Pyridine Nucleotide Coenzymes, Academic Press, New York NY (1982). Particular analogs include nicotinamide 2-aminopurine dinucleotide, nicotinamide 8-azidoadenine dinucleotide, nicotinamide 1-deazapurine
 30 dinucleotide, 3-aminopyridine adenine dinucleotide, 3-acetyl

pyridine adenine dinucleotide, thiazole amide adenine dinucleotide, 3-diazoacetylpyridine adenine dinucleotide and 5-aminonicotinamide adenine dinucleotide. Particular mimetics can be identified and selected by ligand-

- 5 displacement assays, for example using competitive binding assays with a known ligand as is well known in the art. Mimetic candidates can also be identified by searching databases of compounds for structural similarity with the common ligand or a mimetic.

- 10 In another embodiment, the methods of the invention can be used with a ligand that is an adenosine phosphate-related molecule. Adenosine phosphate-related molecules can be selected from the group consisting of adenosine triphosphate (ATP), adenosine diphosphate (ADP),
 15 adenosine monophosphate (AMP), and cyclic adenosine monophosphate (cAMP). An adenosine phosphate-related molecule can also be a mimetic of the above-described molecules. A mimetic of an adenosine phosphate-related molecule that can be used in the invention includes, for
 20 example, quercetin, adenylylimidodiphosphate (AMP-PNP) or olomoucine.

- A ligand useful in the methods of the invention can be a cofactor, coenzyme or vitamin including, for example, NAD, NADP, or ATP as described above. Other
 25 examples include thiamine (vitamin B₁), riboflavin (vitamin B₂), pyridoximine (vitamin B₆), cobalamin (vitamin B₁₂), pyrophosphate, flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), pyridoxal phosphate, coenzyme A, ascorbate (vitamin C), niacin, biotin, heme, porphyrin,
 30 folate, tetrahydrofolate, nucleotide such as guanosine

triphosphate, cytidine triphosphate, thymidine triphosphate, uridine triphosphate, retinol (vitamin A), calciferol (vitamin D₂), ubiquinone, ubiquitin, α -tocopherol (vitamin E), farnesyl, geranylgeranyl, pterin, pteridine or S-adenosyl methionine (SAM).

A polypeptide can be used as a ligand in the invention. For example, a ligand can be a naturally occurring polypeptide ligand such as a ubiquitin or polypeptide hormone including, for example, insulin, human growth hormone, thyrotropin releasing hormone, adrenocorticotrophic hormone, parathyroid hormone, follicle stimulating hormone, thyroid stimulating hormone, luteinizing hormone, human chorionic gonadotropin, epidermal growth factor, nerve growth factor and the like. In addition a polypeptide ligand can be a non-naturally occurring polypeptide that has binding activity. Such polypeptide ligands can be identified, for example, by screening a synthetic polypeptide library such as a phage display library or combinatorial polypeptide library as described below. A polypeptide ligand can also contain amino acid analogs or derivatives such as those described below. Methods of isolation of a polypeptide ligand are well known in the art and are described, for example, in Scopes, Protein Purification: Principles and Practice, 3rd Ed., Springer-Verlag, New York (1994); Duetscher, Methods in Enzymology, Vol 182, Academic Press, San Diego (1990); and Coligan et al., Current protocols in Protein Science, John Wiley and Sons, Baltimore, MD (2000).

A nucleic acid can also be used as a ligand in the invention. Examples of nucleic acid ligands useful in the invention include DNA, such as genomic DNA or cDNA or RNA such as mRNA, ribosomal RNA or tRNA. A nucleic acid ligand
5 can also be a synthetic oligonucleotide. Such ligands can be identified by screening a random oligonucleotide library for ligand binding activity, for example, as described below. Nucleic acid ligands can also be isolated from a natural source or produced in a recombinant system using
10 well known methods in the art including, for example, those described in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, Plainview, New York (1989); Ausubel et al., Current Protocols in Molecular Biology (Supplement 47), John Wiley &
15 Sons, New York (1999).

A ligand used in the invention can be an amino acid, amino acid analog or derivatized amino acid. An amino acid ligand can be one of the 20 essential amino acids or any other amino acid isolated from a natural source. Amino
20 acid analogs useful in the invention include, for example, neurotransmitters such as gamma amino butyric acid, serotonin, dopamine, or norepinephrine or hormones such as thyroxine, epinephrine or melatonin. A synthetic amino acid, or analog thereof, can also be used in the invention.
25 A synthetic amino acid can include chemical modifications of an amino acid such as alkylation, acylation, carbamylation, iodination, or any modification that derivatizes the amino acid. Such derivatized molecules include, for example, those molecules in which free amino groups have been
30 derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups,

chloroacetyl groups or formyl groups. Free carboxyl groups can be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives.

- 5 The imidazole nitrogen of histidine can be derivatized to form N-im-benzylhistidine. Naturally occurring amino acid derivatives of the twenty standard amino acids can also be included in a cluster of bound conformations including, for example, 4-hydroxyproline, 5-hydroxylysine,
 10 3-methylhistidine, homoserine, ornithine or carboxyglutamate.

- A lipid ligand can also be used in the invention. Examples of lipid ligands include triglycerides, phospholipids, glycolipids or steroids. Steroids useful in
 15 the invention include, for example, glucocorticoids, mineralocorticoids, androgens, estrogens or progestins.

- Another type of ligand that can be used in the invention is a carbohydrate. A carbohydrate ligand can be a monosaccharide such as glucose, fructose, ribose,
 20 glyceraldehyde, or erythrose; a disaccharide such as lactose, sucrose, or maltose; oligosaccharide such as those recognized by lectins such as agglutinin, peanut lectin or phytohemagglutinin, or a polysaccharide such as cellulose, chitin, or glycogen.

- 25 Methods for producing pluralities of compounds to use as ligands, including chemical or biological molecules such as simple or complex organic molecules, metal-containing compounds, carbohydrates, peptides, peptidomimetics, carbohydrates, lipids, nucleic acids, and

the like, are well known in the art (see, for example, in Huse, U.S. Patent No. 5,264,563; Francis et al., Curr. Opin. Chem. Biol. 2:422-428 (1998); Tietze et al., Curr. Biol., 2:363-371 (1998); Sofia, Mol. Divers. 3:75-94 (1998);

- 5 Eichler et al., Med. Res. Rev. 15:481-496 (1995); Gordon et al., J. Med. Chem. 37: 1233-1251 (1994); Gordon et al., J. Med. Chem. 37: 1385-1401 (1994); Gordon et al., Acc. Chem. Res. 29:144-154 (1996); Wilson and Czarnik, eds., Combinatorial Chemistry: Synthesis and Application, John Wiley & Sons, New York (1997), Gold et al., U.S. Pat Nos. 5,475,096 (1995), 5,789,157 (1998), and 5,270,163 (1993)).

The advantage of using such a combinatorial library is that molecules do not have to be individually generated to identify a ligand that binds a polypeptide. Also, no prior
15 knowledge of the exact characteristics of a binding polypeptide is required when using a combinatorial library. Libraries containing large numbers of natural and synthetic compounds also can be individually synthesized or obtained from commercial sources.

- 20 In addition, the invention provides a method for identifying a conformation-dependent property of a ligand. The method includes the steps of (a) determining bound conformations of a ligand bound to different polypeptides; (b) identifying two or more bound conformations of the
25 ligand having substantially the same bound conformation, and (c) identifying a conformation-dependent property of the bound conformations of the ligand having substantially the same bound conformation, the conformation-dependent property being correlated with the bound conformation of the ligand.

A conformation-dependent property can be identified as any property that correlates with a bound conformation of a ligand such that a change in the bound conformation results in a change in the conformation-dependent property. Accordingly, a bound conformation of a ligand, or a portion thereof, can be a conformation-dependent property. A portion of a bound conformation of a ligand can be a contiguous fragment or a non-contiguous set of atoms or bonds. A bound conformation of a ligand, or portion thereof, can be identified by any method for determining the three dimensional structure of a ligand including as disclosed herein.

Other conformation-dependent properties include, for example, absorption and emission of heat, absorption and emission of electromagnetic radiation, rotation of polarized light, magnetic moment, spin state of electrons, or polarity, as disclosed herein, or other properties that can be identified as a spectroscopic signal. Methods known in the art for measuring changes in absorption and emission of heat that correlate with changes in bound conformation of a ligand include, for example, calorimetry. Methods known in the art for measuring changes in absorption and emission of electromagnetic radiation as they correlate with changes in bound conformation of a ligand include, for example, UV/VIS spectroscopy, fluorimetry, luminometry, infrared spectroscopy, Raman spectroscopy, resonance Raman spectroscopy, X-ray absorption fine structure spectroscopy (XAFS) and the like. A change in a bound conformation of a ligand that is correlated with a change in rotation of polarized light can be measured with circular dichroism spectroscopy or optical rotation spectroscopy. A change in

magnetic moment or spin state of an electron that correlates with a change in a bound conformation can be measured, for example, with Electron paramagnetic resonance spectroscopy (EPR) or nuclear magnetic resonance spectroscopy (NMR).

5 When based on NMR data, a conformation-dependent property can be identified as an NMR signal including, for example, chemical shift, J coupling, dipolar coupling, cross-correlation, nuclear spin relaxation, transferred nuclear Overhauser effect, and any combination thereof. A
10 conformation-dependent property can be identified by NMR methods in both fast and slow exchange regimes. For example, in many cases, the exchange rate of a complex between ligand and polypeptide is faster than the ligand spin relaxation rate ($1/T_{1H}$). In this situation, referred
15 to as the "fast exchange regime," transferred nuclear Overhauser effect (NOE) experiments can be performed to measure an intra-ligand proton-proton distance (Wuthrich, NMR of proteins and Nucleic Acids, Wiley, New York (1986) and Gronenborn, J. Magn. Res. 53:423-442 (1983)). Labeling
20 of polypeptides is not required, and the ligand polypeptide concentration ratio can be adjusted to minimize line broadening of the ligand resonances while retaining strong NOE contribution from the bound form.

 In a fast exchange regime, cross-correlated
25 relaxation measurements can also provide structural information on ligand torsion angles (Carlomagno et al., J. Am. Chem. Soc. 121:1945-1948 (1999)). These measurements include the 1H - 1H dipole-dipole cross-correlation but can be extended to other cross-correlated relaxation mechanisms
30 involving also homo- and heteronuclear chemical shielding

anisotropy relaxation, as well as quadrupolar relaxation. For most of these heteronuclear experiments, the natural abundance of the isotope can be exploited. In cases where natural abundance of the isotope measured is not sufficient, isotope enriched ligands can be obtained from commercial sources such as Isotek (Miamisburg, OH) or Cambridge Isotope Laboratories (Andover, MA) or prepared by methods known in the art. Another method to determine a conformation-dependent property of a ligand in a fast exchange regime is use of residual homo- and heteronuclear dipolar couplings in partially aligned samples (Tolman et al. Proc. Natl. Acad. Sci. USA 92:9279-9283 (1995)).

In the slow exchange regime, the NMR signals arising from the bound conformation of the ligand are distinguished from those of the polypeptide to reduce resonance overlap. This can be achieved with different isotope labeling schemes of polypeptide, ligand or both. For large systems, perdeuteration of macromolecules and TROSY-type experiments (Pervushkin, Proc. Natl. Acad. Sci. USA 94:12366-12371 (1997)) can be used to minimize signal losses due to fast transverse relaxation of the resonances of the complex. With the appropriate sample requirements and isotope filtered experiments, cross-correlations, cross-relaxations and residual dipolar couplings can be measured and provide necessary structural information.

In addition, homo- and heteronuclear two and three bond J couplings can be obtained to provide information on torsion angles (Wuthrich, *supra*). For example, as shown in Table 1 the bound conformations of NADP in pharmacocluster 4 and pharmacocluster 5 differ by a torsion angle defined by

the atoms PN-O5'N-C5'N-C4'N (See Figure 2 for atom labeling and bond location). Specifically, pharmacocluster 4 has a PN-O5'N-C5'N-C4'N torsion angle of 145 degrees and pharmacocluster 5 has a PN-O5'N-C5'N-C4'N angle of -112 5 degrees. These torsion angles can be measured and distinguished by measuring the three bond ^{31}P - $^{13}\text{C4'}$ J coupling constants that correspond to this torsion angle (Marino, Acc. Chem. Res. 32:614-623 (1999)). Basically, two ^1H - ^{13}C correlation experiments can be performed with and 10 without ^{31}P decoupling during ^{13}C evolution. The intensity ratio of the ^1H 4' / $^{13}\text{C4'}$ cross peak from each experiment is proportional to the ^{31}P - $^{13}\text{C4'}$ J coupling constant.

Correlation of a conformation-dependent property with a bound conformation of a ligand can be achieved by any 15 method that has sufficient sensitivity to detect changes that correlate with changes in bound conformation of a ligand. Such a correlation can be determined by measuring a conformation-dependent property for various conformations of a ligand and determining the extent of change in the signal 20 with change in the conformation. Signal changes that correlate with changes in conformation and that are detectable with a signal to noise ratio accepted in the art as significant can be used in the invention.

Correlation between a conformation-dependent 25 property and a conformation can be determined for a ligand bound to any partner so long as binding is specific and stable. For example, for purposes of establishing a correlation, changes in a conformation dependent property that correlate with changes in bound conformation of a 30 ligand can be determined for a ligand bound to polypeptides

from different polypeptide pharmacofamilies. A bound conformation of the ligand in each complex can be determined and a conformation-dependent property can be measured for each complex. Comparison of bound conformations of the

5 ligand in each complex with a measured conformation-dependent property can be used to establish a correlation. Demonstration of a method for establishing a correlation between an NMR signal and bound conformations of a ligand is described herein (see Example IV). Other methods for

10 correlating spectroscopic signals with bound conformations of a ligand are known in the art including, for example, correlation of transferred NOE signals with anti and syn conformations of the nicotinamide ring in NADPH as described in Sem and Kasper Biochemistry 31:3391-3398 (1992).

15 Correlation of transferred NOE signals with conformation is also described in Clore and Gronenborn, J. Magn. Reson. 48:402-417 (1982).

A correlation between a bound conformation and a conformation-dependent property can also be established for

20 a ligand bound to a non-polypeptide binding partner because a conformation-dependent property of a ligand can be independent of interactions that differ between binding partners so long as the ligand is in the same bound conformation when bound to the binding partners. Other

25 binding partners include, for example, nucleic acids, carbohydrates, and synthetic organometallic complexes.

A method of the invention for identifying a conformation-dependent property of a ligand can also include the steps of (a) determining a bound conformation of a

30 ligand, or portion thereof, bound to two or more

polypeptides; (b) identifying two or more bound conformations of the ligand, or portion thereof, having substantially the same bound conformation, and (c) identifying a conformation-dependent property of the bound conformations of the ligand, or portion thereof, having substantially the same bound conformation, the conformation-dependent property being correlated with the bound conformation of the ligand, or portion thereof. A conformation-dependent property of a portion of a ligand can be identified, for example, by using the methods described above for identifying a conformation-dependent property of a ligand.

The invention also provides a method for identifying a polypeptide pharmacofamily. The method includes the steps of (a) determining bound conformations of a ligand bound to different polypeptides of a polypeptide family, and (b) identifying two or more bound conformations of the ligand having substantially different bound conformations, thereby identifying at least two polypeptide pharmacofamilies exhibiting binding specificity for the two or more substantially different bound conformations of the ligand.

A method for identifying a polypeptide pharmacofamily can include the steps of (a) determining bound conformations of a ligand bound to different polypeptides of a polypeptide family; (b) clustering bound conformations of a ligand having substantially the same conformations into pharmacoclusters; and (c) identifying a first polypeptide that binds a bound conformation of a ligand in one pharmacocluster and a second polypeptide that

binds a bound conformation of a ligand in a second pharmacocluster as belonging to separate polypeptide pharmacofamilies.

Polypeptides of a polypeptide family can be identified by their ability to specifically bind to the same ligand, or portion thereof. Specific binding between a polypeptide and a ligand can be identified by methods known in the art. Methods of determining specific binding include, for example, equilibrium binding analysis, competition assays, and kinetic assays as described in Segel, Enzyme Kinetics John Wiley and Sons, New York (1975), and Kyte, Mechanism in Protein Chemistry Garland Pub. (1995). Thermodynamic and kinetic constants can be used to identify and compare polypeptides and ligands that specifically bind each other and include, for example, dissociation constant (K_d), association constant (K_a), Michaelis constant (K_m), inhibitor dissociation constant (K_{is}) association rate constant (k_{on}) or dissociation rate constant (k_{off}). For example, a family can be identified as having members that can specifically bind a ligand with a K_d of at most 10^{-3} M, 10^{-4} M, 10^{-5} M, 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M, 10^{-10} M, 10^{-11} M, or 10^{-12} M or lower.

A family of polypeptides that bind a ligand can contain a pharmacofamily that binds substantially the same conformation of the ligand, or portion thereof. The methods can be used to identify any number of pharmacofamilies in a family according to the number of different bound conformations of a ligand identified. In cases where two or more polypeptide pharmacofamilies reside in a polypeptide family, the pharmacofamilies can be distinguished according

to differences in bound conformations of a ligand bound to the polypeptides. In this case, a bound conformation of a ligand can be determined and compared according to the methods described herein. Polypeptides bound to different bound conformations of a ligand can be identified as those that do not show substantial overlap of all corresponding atoms when bound conformations are overlaid. Thus, polypeptides that bind different bound conformations of a ligand can be separated into different pharmacofamilies. Pharmacofamilies in turn can be identified as containing polypeptides that bind substantially the same bound conformation of a ligand (see Examples II and III).

A pharmacofamily of polypeptides identified by the methods of the invention can have additional similarities that correlate with similarities in bound conformation of a ligand. For example, a polypeptide pharmacofamily identified by the methods of the invention can consist of polypeptide members that share characteristics that are unique to the pharmacofamily when compared to one or more other polypeptides in a different pharmacofamily of the same family. Such characteristics can include, for example, protein fold, evolutionary relatedness, enzymatic activity, domain structure, subcellular localization, interaction partners, or participation in a similar metabolic or signal transduction pathway. A demonstration of a correlation between ligand bound conformation and another characteristic of polypeptides in a pharmacofamily is provided in Example II, which describes correlation of bound conformation of a ligand with polypeptide structure.

An example of a polypeptide family having multiple pharmacofamilies that can be identified by the methods of the invention includes NAD(P)(H) binding polypeptides.

Polypeptide pharmacofamilies identified according to
 5 differences in bound conformations of NAD(P)(H) are described in Example II and Table 11. Thus, the methods can be used to identify a polypeptide pharmacofamily selected from the group consisting of pharmacofamily 1, pharmacofamily 2, pharmacofamily 3, pharmacofamily 4,
 10 pharmacofamily 5, pharmacofamily 6, pharmacofamily 7, and pharmacofamily 8.

The invention provides a polypeptide pharmacofamily, comprising polypeptides that bind to substantially the same bound conformation of a nicotinamide
 15 adenine dinucleotide-related molecule selected from pharmacofamily 1, pharmacofamily 2, pharmacofamily 3, pharmacofamily 4, pharmacofamily 5, pharmacofamily 6, pharmacofamily 7, and pharmacofamily 8 as listed in Table 11.

20 Pharmacofamilies 1 through 8 consist of the polypeptide members provided in Table 11 (see Example II). The polypeptides in pharmacofamily 1 have the NAD(P)(H) binding Rossmann fold in common, are all in the NAD(P)(H) binding Rossmann SCOP Superfamily, and fall into the SCOP
 25 families of the amino-terminal domain of glyceraldehyde-3-phosphate dehydrogenase, the carboxy-terminal domain of alcohol/glucose dehydrogenase, the NAD binding domain of formate/glycerate dehydrogenase, the carboxy-terminal domain of amino acid dehydrogenase, or the amino-terminal domain of
 30 lactate & malate dehydrogenase.

The polypeptides in pharmacofamily 2 have the NAD(P)(H) binding Rossman fold in common, are all in the NAD(P)(H) binding Rossman SCOP Superfamily, and fall into the SCOP families of the carboxy-terminal domain of amino
 5 acid dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase, and 6-phosphogluconate dehydrogenase.

The polypeptides in pharmacofamily 3 have the NAD(P)(H) binding Rossman fold in common, are all in the NAD(P)(H) binding Rossman SCOP Superfamily, and fall into
 10 the tyrosine-dependent oxidoreductase SCOP family.

The polypeptides in pharmacofamily 4 have the heme-linked catalase fold and are in the heme-linked catalase SCOP superfamily and heme-linked catalase SCOP family.

15 The polypeptides in pharmacofamily 5 have the β - α TIM barrel fold in common, are all in the NAD(P)(H) linked oxidoreductase SCOP Superfamily, and fall into the aldo-keto reductase SCOP family.

The polypeptides in pharmacofamily 6 are
 20 dihydrofolate reductases that all show the dihydrofolate reductase fold and fall into the dihydrofolate reductase SCOP superfamily and family.

The polypeptides in pharmacofamily 7 have the FAD/NAD(P)(H) binding domain fold in common, are all in the
 25 FAD/NAD(P)(H) binding domain SCOP Superfamily, and fall into the the amino-terminal and central domains of FAD/NAD linked reductase SCOP family.

The polypeptides in pharmacofamily 8 have the ferredoxin like fold in common, are all in the ferredoxin like SCOP Superfamily, and fall into the NADPH-cytochrome P450 reductase or reductase SCOP families.

5 Polypeptide pharmacofamilies 1 through 8 were identified according to binding interactions with bound conformations of NAD(P)(H) in pharmacoclusters 1 through 8, as described in Example II. Accordingly, the invention provides a polypeptide pharmacofamily, comprising
10 polypeptides that bind to a nicotinamide adenine dinucleotide-related molecule having a bound conformation selected from pharmacocluster 1, pharmacocluster 2, pharmacocluster 3, pharmacocluster 4, pharmacocluster 5, pharmacocluster 6, pharmacocluster 7, and pharmacocluster 8.

15 The invention additionally provides a method for identifying a member of a polypeptide pharmacofamily. The method consists of (a) determining a conformation-dependent property of a ligand bound to a polypeptide, and (b)
20 determining a pharmacocluster having substantially the same conformation-dependent property as the conformation-dependent property determined for the bound ligand, wherein a polypeptide pharmacofamily binds the ligand in a conformation of the pharmacocluster, thereby identifying the
25 polypeptide as a member of the polypeptide pharmacofamily. For example, the method can be used with a ligand such as a nicotinamide adenine dinucleotide-related molecule or adenosine phosphate-related molecule (see Examples II and III).

The methods of the invention allow a new member of a polypeptide pharmacofamily to be identified based on correlation of a conformation-dependent property of a bound conformation of a ligand bound to a polypeptide with a conformation-dependent property established for a bound conformation of the ligand bound to another polypeptide in the same pharmacofamily. Thus, a classification can be made based on ligand structure without requiring determination of the bound conformation of the ligand. In one embodiment, the conformation-dependent property can be a model of a bound conformation. A bound conformation of a ligand bound to a test polypeptide can be determined, and the bound conformation can be compared to a pharmacocluster according to the methods described herein. Substantial overlap between the bound conformation of the ligand bound to the test polypeptide and another bound conformation of the ligand bound to a polypeptide in a pharmacofamily can be used to identify the test polypeptide as a member of that polypeptide pharmacofamily.

In another embodiment, the conformation-dependent property can be a spectroscopic signal that is correlated with the conformation of a ligand. A spectroscopic signal can be measured for the ligand bound to a test polypeptide. The signal can be compared to a signal correlated with a bound conformation of a ligand bound to a polypeptide in a polypeptide pharmacofamily. Substantial similarity between the two signals indicates that the bound conformation of the ligand bound to the test polypeptide is substantially similar to the bound conformation of the ligand bound to the polypeptides of the pharmacofamily. Thus, the test

polypeptide can be identified as a member of the polypeptide pharmacofamily.

The invention provides rapid and efficient methods that can be used in a high-throughput screening format.

5 High-throughput methods can be useful for identifying a member of a polypeptide pharmacofamily. In a case where a conformation-dependent property can be rapidly detected and processed, automated methods can be created for measuring samples in rapid succession or measuring multiple samples in
10 parallel. Automated methods can be used for rapidly handling samples including, for example, robotic instruments. A combination of automated sample handling methods with detection of a conformation-dependent property can, therefore, be useful in a high-throughput screening
15 method.

According to the methods of the invention a compound can be identified that has greater specificity for the polypeptides of one pharmacofamily than for other polypeptides in the same family. Such a compound can be
20 used to identify new members of a pharmacophore family using a binding assay. For example, a mimetic or analog of a ligand can be identified that preferentially adopts a conformation more similar to conformations in a particular pharmacocluster than those in other pharmacoclusters. Such
25 a mimetic or analog can be used in a any binding assay capable of detecting interactions with a polypeptide, including, for example, high-throughput methods.

A member of a polypeptide pharmacofamily can also be identified by searching a database of bound conformations of a ligand. For example, a bound conformation of a ligand that binds to a polypeptide of an identified pharmacofamily
5 can be used as a query in a 3 dimensional search of a database containing bound conformations of a ligand. Overlap between the query conformation and a retrieved bound conformation of the ligand can be used to identify a polypeptide bound to the retrieved bound conformation of the
10 ligand as a member of the same polypeptide pharmacofamily as a polypeptide that binds the query bound conformation (see Example I).

The invention also provides a method of modeling the three dimensional structure of a polypeptide. The
15 method consists of (a) determining a conformation-dependent property of a ligand bound to a polypeptide; (b) determining a pharmacocluster having substantially the same conformation-dependent property as the conformation-dependent property determined for the bound ligand, wherein
20 a polypeptide pharmacofamily binds the ligand in a conformation of the pharmacocluster, thereby identifying the polypeptide as a member of the polypeptide pharmacofamily, and (c) modeling the three dimensional structure of the polypeptide according to a structural model of the second
25 member of the polypeptide pharmacofamily.

As disclosed herein, polypeptides in a pharmacofamily can have similar characteristics including, for example, similar 3 dimensional structure. Therefore, the 3 dimensional structure of a polypeptide identified by
30 the invention as a member of a pharmacofamily can be modeled

using a polypeptide that is in the same pharmacofamily and for which the structure is known. A variety of methods are known in the art for modeling the three dimensional structure of a polypeptide according to the amino acid
5 sequence of the polypeptide and a structure of a second polypeptide used as a template. Available algorithms include, for example, GRASP (Nicholls, A., *supra*), ALADDIN (Van Drie et al. *supra*), INSIGHT98 (Molecular Simulations Inc., San Diego CA), RASMOL (Sayle et al., Trends Biochem
10 Sci. 20:374-376 (1995)) and MOLMOL (Koradi et al., J. Mol. Graphics 14:51-55 (1996)).

A model of a polypeptide determined by the methods of the invention can be useful for identifying a function of the polypeptide. For example, residues of a polypeptide
15 that are involved in binding can be identified using a model of the invention. Residues identified as participating in binding can be modified, for example, to engineer new functions into a polypeptide, to reduce an intrinsic activity of a polypeptide, or to enhance an intrinsic
20 activity of a polypeptide. In another example, a model of a polypeptide can be compared to other polypeptide structures to identify similar functions. Exemplary functions that can be identified from a polypeptide structure include binding interactions with other polypeptides and catalytic
25 activities.

The invention also provides a method for constructing a ligand conformer model by determining an average structure of the bound conformations of a ligand in a pharmacocluster. A method for constructing a ligand
30 conformer model can include the steps of (a) determining

bound conformations of a ligand bound to different polypeptides; (b) clustering two or more bound conformations of the ligand having substantially the same bound conformation, thereby identifying a pharmacocluster, and (c) 5 determining an average structure of the bound conformations of the ligand in the pharmacocluster. Additionally, a method for constructing a ligand conformer model can include the steps of (a) determining a bound conformation of a ligand bound to a polypeptide; (b) determining a 10 pharmacocluster having substantially the same bound conformation as the bound conformation, thereby identifying the bound conformation of the ligand as a member of the pharmacocluster, and (c) determining an average structure of the bound conformations of the ligand in the 15 pharmacocluster.

An average structure of the bound conformations of a ligand in a pharmacocluster can be determined by a variety of methods known in the art. For example, an average structure can be determined by overlaying bound 20 conformations, or portions thereof, and identifying an average location for each atom. Bound conformations in a group to be averaged can be overlayed relative to a single member or relative to a centroid position for each atom. Algorithms for determining an average structure are known in 25 the art and include for example the OVERLAY routine in INSIGHT98 (Molecular Simulations Inc., San Diego CA).

The format of a ligand conformer model can be chosen based on the method used to generate the model and the desired use of the model. In this regard, a conformer 30 model can be represented as a single structure. The

resulting structure can be a unique structure compared to the conformations in the pharmacocluster from which it was derived. Thus, the conformer model can be a new structure never before observed in nature. A model represented by a single structure can be useful for making visual comparisons by overlaying other structures with the model. A conformer model can also be represented as a plurality of structures incorporating all or a subset of the bound conformations in the pharmacocluster. A model represented by multiple structures can be useful for identifying a range of minor deviations in the model.

In yet another representation, the conformer model can be a volume surrounding all or a subset of the bound conformations in the pharmacocluster. A model showing volume can be useful for comparing other structures in a fitting format such that a structure which fits within the volume of the model can be identified as substantially similar to the model. One approach that can be used to fit a structure to a volume is comparison of equivalent surface patches using gnomonic projection as described for example in Chau and Dean, J. Mol. Graphics 7:130 (1989). Use of a gnomonic projection to compare structures is also described in Doucet and Weber, Computer-Aided Molecular Design: Theory and Applications, Academic Press, San Diego CA (1996). Algorithms which can be used to fit a structure to a volume are known in the art and include, for example, CATALYST (Molecular Simulations Inc., San Diego, CA) and THREEDOM which is a part of the INTERCHEM package which makes use of an Icosahedral Matching Algorithm (Bladon, J. Mol. Graphics 7:130 (1989) for the comparison and alignment of structures. An exemplary method of identifying a binding compound by

searching a database of structures using a gnomonic projection is provided in Example V.

A conformer model can be useful in querying a database of polypeptide structures to find other members of a polypeptide pharmacofamily. For example, a member of a polypeptide pharmacofamily can be identified by querying a database of bound conformations of a ligand to identify a retrieved bound conformation of a ligand that is substantially similar to the query structure, thereby identifying a polypeptide bound to the retrieved bound conformation as a member of the same pharmacofamily as a polypeptide bound to the query bound conformation. A conformer model can also be used to identify a new member of a polypeptide pharmacofamily by querying a database of one or more polypeptide structures using an algorithm that docks the conformer model, wherein a favorable docking result with a retrieved polypeptide indicates that the retrieved polypeptide is a member of the same polypeptide pharmacofamily as a polypeptide bound to the bound conformation used as a query. In the latter mode, a potential new member of a pharmacofamily from which the conformer model was derived can be identified. The database queries described above can be performed with algorithms available in the art including, for example, THREEDOM and CATALYST.

An advantage of the invention is that a conformer model can be used to identify a binding compound that is specific for polypeptides of a pharmacofamily. For example, the conformer model can be compared to a structure of a compound or to a bound conformation of a ligand to identify

those having similar conformation. A conformer model can be further used to query a database of compounds to identify individual compounds having similar conformations.

A conformer model of the invention can also be
5 used to design a binding compound that is specific for polypeptides of one or more pharmacofamilies. The methods of the invention provide a conformer model that can be produced according to a cluster of bound conformations of a ligand that are specific for polypeptides of a
10 pharmacofamily. A conformer model identified by these criteria can be used as a scaffold structure for developing a compound having enhanced binding affinity or specificity for polypeptides of a pharmacofamily. Such a scaffold can also be used to design a combinatorial synthesis producing a
15 library of compounds which can be screened for enhanced binding affinity for polypeptide members of a pharmacofamily or specificity for polypeptide members of one pharmacofamily compared to polypeptide members of another pharmacofamily. An algorithm can be used to design a binding compound based
20 on a conformer model including, for example, LUDI as described by Bohm, J. Comput. Aided Mol. Des. 6:61-78 (1992).

A conformer model need not include all atoms of a pharmacocluster. Thus, a conformer model can include a
25 portion of atoms in a pharmacocluster so long as the portion consists of contiguous atoms of a bound conformation of a ligand and provides sufficient information to distinguish one pharmacocluster from another. Thus, a conformer model can be constructed by overlaying corresponding fragments of
30 bound conformations of a ligand and obtaining an average

structure according to the methods described above. A conformer model made from a portion of a ligand can be advantageous due to its small size compared to a complete structure of the ligand from which it was derived. A

- 5 conformer model based on a portion of a bound conformation of a ligand can also be used to more efficiently and rapidly query a database due to a reduced use of computer memory compared to the memory required to manipulate and store a structure containing all atoms of the ligand.

- 10 The invention provides a ligand conformer model, selected from the group consisting of conformer model 1 having coordinates listed in Table 3C, conformer model 2 having coordinates listed in Table 4C, conformer model 3 having coordinates listed in Table 5C, conformer model 4
15 having coordinates listed in Table 6C, conformer model 5 having coordinates listed in Table 7C, conformer model 6 having coordinates listed in Table 8C, conformer model 7 having coordinates listed in Table 9C, and conformer model 8 having coordinates listed in Table 10C. Conformer models 1-8
20 are average structures calculated from pharmacoclusters 1-8 respectively. The conformer models were determined as described in Example III and are shown in Figure 4.

- The invention also provides moiety, having coordinates listed in Table 3C, coordinates listed in Table
25 4C, coordinates listed in Table 5C, coordinates listed in Table 6C, coordinates listed in Table 7C, coordinates listed in Table 8C, coordinates listed in Table 9C, or coordinates listed in Table 10C or subsets of the respective coordinate sets thereof. In one embodiment the moiety is not

nicotinamide adenine dinucleotide or nicotinamide adenine dinucleotide phosphate.

Additionally, the invention provides a method for constructing a pharmacophore model by constructing a model
5 that contains one or more selected conformation-dependent properties of one or more pharmacoclusters. A method for constructing a pharmacophore model can include the steps of (a) determining bound conformations of a ligand bound to different polypeptides; (b) identifying two or more bound
10 conformations of the ligand having substantially the same bound conformation; (c) identifying a conformation-dependent property of the bound conformations of the ligand having substantially the same bound conformation, the conformation-dependent property being correlated with the bound
15 conformation of the ligand, and (d) constructing a model that contains one or more selected conformation-dependent properties of one or more pharmacoclusters.

Additionally, a method for constructing a pharmacophore model can include the steps of (a) determining
20 bound conformations of a ligand, or portion thereof, bound to different polypeptides; (b) clustering two or more bound conformations of the ligand, or portion thereof, having substantially the same bound conformation, thereby identifying a pharmacocluster, and (c) determining an
25 average structure of the bound conformations of the ligand, or portion thereof, in the pharmacocluster, wherein the average structure is a pharmacophore model. A method for constructing a ligand conformer model can also include the steps of (a) determining a bound conformation of a ligand,
30 or portion thereof, bound to a polypeptide; (b) determining

a pharmacocluster having substantially the same bound conformation as the bound conformation, thereby identifying the bound conformation of the ligand as a member of the pharmacocluster, and (c) determining an average structure of the bound conformations of the ligand in the pharmacocluster, wherein the average structure is a pharmacophore model.

A pharmacophore model constructed by the methods of the invention can be derived from any conformation-dependent property that is correlated with a pharmacocluster. An example of a pharmacophore model useful in the methods of the invention is a conformer model. Additionally, a pharmacophore model can include a portion of a bound conformation, wherein the portion need not contain contiguous atoms of a bound conformation of a ligand so long as the pharmacophore model provides sufficient information to distinguish one pharmacocluster from another. Thus, a pharmacophore model can appear as points in space unconnected by any semblance of a covalent bond due to absence of intervening atoms. For example, a pharmacophore model constructed from a pharmacocluster of nicotinamide adenine dinucleotide bound conformations can contain a phosphate moiety and nicotinamide ring moiety absent the ribose moiety which intervenes in a complete model of the structure.

A pharmacophore model can be any representation of points in a defined coordinate system that correspond to positions of atoms in a bound conformation of a ligand. For example, a point in a pharmacophore model can correlate with the center of an atom in a conformer model. An atom of a

conformer model can also be represented by a series of points forming a line, plane or sphere. A line, plane or sphere can form a geometric representation designating, for example, shape of one or more atoms or volume occupied by one or more atoms.

A pharmacophore model can be represented in any coordinate system including, for example, a 2 dimensional Cartesian coordinate system or 3 dimensional Cartesian coordinate system. Other coordinate systems that can be used include a fractional coordinate system or reciprocal space such as those used in crystallographic calculations which are described in Stout and Jensen, *supra*.

In addition to a geometric description of a bound conformation of a ligand, a pharmacophore model can include other characteristics of atoms or moieties of the ligand including, for example, charge or hydrophobicity. Thus, a pharmacophore model can be a generalized structure, which includes but does not unambiguously describe the bound conformations of the ligand bound to the polypeptides in the pharmacofamily from which it was derived. For example, atoms can be represented as units of charge such that an oxygen in a bound conformation of a ligand can be represented by an electronegative point in the pharmacophore model. In this example, the electronegative point in the pharmacophore model includes any electronegative atom at that particular location including, for example, an oxygen or sulfur.

A pharmacophore model can be constructed to include, in addition to characteristics of the ligand itself, characteristics of an atom or moiety that interacts with the ligand and from a bound polypeptide.

- 5 Characteristics of an interacting polypeptide atom or moiety that can be included in a pharmacophore model include, for example, atomic number, volume occupied, distance from an atom of the ligand, charge, hydrophobicity, polarity, or location relative to the ligand. Methods for constructing a
10 pharmacophore model to include interacting atoms from a polypeptide are provided in Example III.

- A characteristic included in a pharmacophore model can be incorporated into a geometric representation using any additional representation that can be correlated with
15 the characteristic. For example, use of color or shading can be used to identify regions having characteristics such as charge, polarity, or hydrophobicity. As such, the depth of shading or color or the hue of color can be used to determine the degree of a characteristic. By way of
20 example, a common convention used in the art is to identify regions of increased positive charge with deeper shades of blue, areas of increased negative charge with deeper shades of red and neutral regions with white. Numeric representations can also be used in a pharmacophore model
25 including, for example, values corresponding to potential energy for an interaction, or degree of polarity.

- In addition, a pharmacophore model can incorporate constraints of a physical or chemical property of the bound conformations of a ligand in a pharmacocluster. A
30 constraint of a physical property can be, for example, a

distance between two atoms, allowed torsion angle of a bond, or volume of space occupied by an atom or moiety. A constraint of a chemical property can be, for example, polarity, van der Waals interaction, hydrogen bond, ionic
5 bond, or hydrophobic interaction. Such constraints can be included in a pharmacophore model using the representations described above.

A pharmacophore model can include two or more pharmacoclusters. In order to identify a ligand having
10 broad specificity for two or more polypeptide pharmacofamilies, a pharmacophore model can be derived from the two or more corresponding pharmacoclusters. Additionally, in order to identify a ligand that can preferentially bind a first polypeptide which belongs to a
15 first polypeptide pharmacofamily compared to a second polypeptide of a second polypeptide pharmacofamily, a pharmacophore model can incorporate constraints on geometry or any other characteristic so as to exclude a characteristic of the bound conformation of the ligand bound
20 to the second polypeptide. For example, a geometric constraint can be a forbidden region for one or more atom of a bound conformation of a ligand. A forbidden region can be identified by overlaying two conformer models in a coordinate system and identifying a coordinate or set of
25 coordinates differentially occupied by one or more atoms of the conformer models. A pharmacophore model incorporating a forbidden region as such will be specific for a polypeptide of one pharmacofamily over a polypeptide of a second pharmacofamily correspondent with the constraint
30 incorporated.

An advantage of the invention is that a pharmacophore model can be created based on multiple structures of the same ligand. In comparison to a pharmacophore model derived from a single structure or
5 different ligands, a pharmacophore model derived from multiple bound conformations of the same ligand can include a greater degree of geometric information. For example, averaging of multiple bound conformations of the same ligand can provide torsion angle constraints that are not available
10 from a single structure and not evident from comparing different ligands.

The invention further provides a method for identifying a binding compound for one or more members of a
15 polypeptide pharmacofamily by identifying a compound having a selected conformation-dependent property of a pharmacocluster. A binding compound can be any molecule having selected conformation-dependent properties of a ligand such that the binding compound can form a complex
20 with one or more members of one or more polypeptide pharmacofamily. A method for identifying a binding compound for one or more members of a polypeptide pharmacofamily can include the steps of contacting a ligand with a polypeptide member of a pharmacofamily; identifying a conformation-
25 dependent property associated with a bound conformation of the ligand bound to the polypeptide; comparing the conformation-dependent property of the bound conformation of the ligand bound to the polypeptide with a conformation-
dependent property of a bound conformation of a ligand bound
30 to another polypeptide in the same pharmacofamily; and identifying a ligand bound to the polypeptide with a conformation-dependent property similar to a bound

conformation of a ligand bound to another polypeptide in the same pharmacofamily, thereby identifying a compound that binds one or more polypeptide members of a pharmacofamily. A compound that binds to one or more members of a

5 polypeptide pharmacofamily can be identified by determining a conformation-dependent property by any of the methods described herein. For example, a ligand conformation or spectroscopic signal can provide a conformation-dependent property useful in identifying a compound that binds to one

10 or more members of a polypeptide pharmacofamily.

The methods described herein for identifying a binding compound for one or more members of a polypeptide pharmacofamily can readily be adapted to a high throughput screening method. For example, methods of rapidly detecting

15 a conformation-dependent property in a sequence of samples or detecting a conformation-dependent property in parallel samples can be applied to a high-throughput screen. One skilled in the art will know how to adapt the methods described here to a high throughput screening format using,

20 for example, robotic manipulation of samples.

A method for identifying a binding compound for one or more members of a polypeptide pharmacofamily can include the steps of determining a bound conformation of a ligand bound to a polypeptide member of a polypeptide

25 pharmacofamily; comparing the bound conformation of the ligand bound to the polypeptide member of the polypeptide pharmacofamily to a pharmacophore model; and identifying the bound conformation of the ligand bound to the polypeptide member of the polypeptide pharmacofamily that satisfies the

30 constraints of the pharmacophore model as a binding compound

for one or more members of the pharmacofamily in which the polypeptide member belongs.

A pharmacophore model can be useful in querying a database of polypeptide structures to find other members of a polypeptide pharmacofamily. For example, a member of a polypeptide pharmacofamily can be identified by querying a database of bound conformations of a ligand to retrieve a structure that fits the constraints of the query pharmacophore model, thereby identifying the retrieved polypeptide as a member of the pharmacofamily from which the pharmacophore model was derived. A pharmacophore model can also be used to identify a new member of a polypeptide pharmacofamily by querying a database of one or more polypeptide structures using an algorithm that docks or compares the pharmacophore model to polypeptide structures, wherein a favorable docking or comparison identifies a polypeptide as a member of the same polypeptide pharmacofamily from which the pharmacophore model was derived. The database queries described above can be performed with algorithms available in the art including, for example, THREEDOM and CATALYST.

An advantage of the invention is that a pharmacophore model can also be used to identify a binding compound that is specific for polypeptides of one or more pharmacofamilies. For example, a pharmacophore model can be compared to a structure of a compound or to a bound conformation of a ligand to identify those having similar properties. A conformer model can be further used to query a database of compounds to identify individual compounds having similar properties.

A pharmacophore model of the invention can also be used to design a binding compound that is specific for polypeptides of one or more pharmacofamilies. A pharmacophore model identified by these criteria can be used
5 as a scaffold or set of constraints for developing a compound having enhanced binding affinity or specificity for polypeptides of one or more pharmacofamilies. Using similar methods a pharmacophore model can be used to design a combinatorial synthesis producing a library of compounds
10 having properties consistent or similar to the model which can be then be screened for enhanced binding affinity or specificity for polypeptide members of one or more pharmacofamilies. An algorithm can be used to design a binding compound based on a pharmacophore model including,
15 for example, LUDI as described by Bohm, J. Comput. Aided Mol. Des. 6:61-78 (1992).

A compound can be identified as satisfying the constraints of a pharmacophore model by a variety of methods for comparing structures. For example, a pharmacophore
20 model that is a geometric representation such as a conformer model can be overlaid with a compound, and the best fit determined as described herein. Substantial overlap between a compound and a pharmacophore model can be indicated by a visual comparison and/or computation based comparison based
25 on for example, RMSD values or torsion angle values as described above. In a case where a pharmacophore model is represented by constraints, a compound can be fitted to the pharmacophore model to identify if the properties of the compound satisfy the constraints of the pharmacophore model.
30 For example, if a pharmacophore model contains, as a constraint, a maximum distance between atoms, a compound

that satisfies the constraint can be identified as having a bond distance between corresponding atoms that is at least the maximum value. One skilled in the art will know how to extend such methods of comparison to any physical or
5 chemical constraint.

A compound can also be identified as satisfying the constraints of a pharmacophore model by demonstrating the same characteristics for one or more specific atom located within a volume of space defined by the geometric
10 constraints of the pharmacophore model. For example, in a case where polarity is a constraint and where a conformation of a compound can be overlaid with a pharmacophore model, an atom that overlaps a volume of space indicated by the pharmacophore and having polarity within the defined limits
15 can be identified as satisfying constraints of the pharmacophore. By extension, a compound having atoms which satisfy all constraints of a pharmacophore is identified as a binding compound for one or more members of a polypeptide pharmacofamily from which the pharmacophore was produced.

20 Therefore, the invention provides a binding compound identified by the above described methods. For example, the invention provides a binding compound identified using a pharmacophore model or a conformer model derived from a pharmacocluster and/or pharmacofamily.

25 The invention provides a pharmacophore model, selected from the group consisting of pharmacophore model 1 having coordinates listed in Tables 3B and 3C, pharmacophore model 2 having coordinates listed in Tables 4B and 4C, pharmacophore model 3 having coordinates listed in Tables 5B

and 5C, pharmacophore model 4 having coordinates listed in Tables 6B and 6C, pharmacophore model 5 having coordinates listed in Tables 7B and 7C, pharmacophore model 6 having coordinates listed in Tables 8B and 8C, pharmacophore model 5 7 having coordinates listed in Tables 9B and 9C, and pharmacophore model 8 having coordinates listed in Tables 10B and 10C.

The invention also provides a medium comprising a storage medium and stored in the medium, atom coordinates
10 selected from the atomic coordinates listed in Table 3B, 3C, 4B, 4C, 5B, 5C, 6B, 6C, 7B, 7C, 8B, 8C, 9B, 9C, 10B or 10C, or a subset thereof. In one embodiment the medium comprises a computer readable medium. The use of a computer apparatus is convenient since atomic coordinates can be conveniently
15 stored and accessed for manipulation including, for example, docking to a polypeptide structure or comparison to coordinates for other bound conformations of a ligand. Exemplary methods for manipulating atomic coordinates are described above.

20 It is understood that a computer apparatus of the invention need not itself store atomic coordinates of the invention. The computer apparatus contains an algorithm for viewing a structure from the coordinates or otherwise manipulating the coordinates. By using various hardware,
25 software and network combinations, the atomic coordinates can be manipulated in a variety of configurations. Such a separate medium can be another computer apparatus, a storage medium such as a floppy disk, Zip disk or a server such as a file-server, which can be accessed by a carrier wave such as
30 an electromagnetic carrier wave. One skilled in the art

will know or can readily determine appropriate hardware, software or network interfaces that allow interconnection of an invention computer apparatus.

The methods of the invention described herein can
5 be performed in a computer apparatus using the atomic coordinates listed in Table 3B, 3C, 4B, 4C, 5B, 5C, 6B, 6C, 7B, 7C, 8B, 8C, 9B, 9C, 10B or 10C by adding the step of entering the coordinates or a subset of the coordinates to the computer apparatus that performs a method of the
10 invention. One skilled in the art will know or can readily determine an algorithm instructing a computer apparatus to carry out the methods of the invention.

It is understood that modifications which do not substantially affect the activity of the various embodiments
15 of this invention are also provided within the definition of the invention provided herein. Accordingly, the following examples are intended to illustrate but not limit the present invention.

EXAMPLE I

20 Identification of Polypeptide Pharmacofamilies Based on Bound Conformations of NAD(P)(H) Ligands

This example describes identification of ligand conformer groups and corresponding polypeptide pharmacofamilies based on bound conformations of NAD(P)(H)
25 bound to polypeptide oxidoreductases.

The oxidoreductases form a family of polypeptides that bind NAD(H) and NADP(H). In order to identify pharmacofamilies within the family of oxidoreductases, bound conformations of NAD(P)(H) were determined by searching the protein databank. Bound conformations from 156 structures were clustered into separate pharmacoclusters, and pharmacofamilies were identified according to binding to bound conformations of NAD(P)(H) in separate pharmacoclusters.

Structure files containing polypeptides with bound NAD(P)(H) were identified from the protein databank by keyword searches using the database software. Keywords included "NAD," "NADH," "NADP," "NADPH," "oxidoreductase," "dehydrogenase" and "reductase." Cluster analysis was performed using the algorithm COMPARE (Chiron Corp, 1995; distributed by Quantum Chemistry program Exchange, Indianapolis IN) in combination with visual inspection. All clusters were visually inspected using Insight 98 for outliers that demonstrated poor overlay with the rest of the pharmacocluster as a whole. These outliers were compared against each other and existing pharmacoclusters to find other possible matches. Those that did not fit any family were removed. Comparison between bound conformations was made based on the RMSD equations supplied in COMPARE.

Eight pharmacoclusters were identified by this method, as shown in Figure 1. Visual inspection of the clusters in Figure 1 demonstrates that members within a cluster are substantially overlapped. Comparison between clusters demonstrates substantial differences. For example, the bound conformations in cluster 5 have an extended

structure compared to the bound conformations in cluster 4, which form a horseshoe like shape. Other differences include, for example, a flip in the nicotinamide between cluster 1 and cluster 2 such that the nicotinamide
5 ring is anti to the ribose in cluster 1 and syn to the ribose in cluster 2 and a change in torsion angle in the bonds connecting the adenine ribose to the adenine phosphate for the bound conformations of cluster 3 compared to those of cluster 2.

10 The dihedral angles for various bonds in the bound conformations of the NADP(H) ligand can be used to distinguish the pharmacoclusters. As shown in Table 1 (see Figure 2 for atom and bond locations), although many
15 dihedral angles are similar between two or more pharmacoclusters, each pharmacocluster can be distinguished from the others by comparison of the full set of dihedral angles. For example, pharmacoclusters 2 and 3 can be distinguished by comparison between the dihedral angles at
20 O4'A-C4'A-C5'A-O5'A which are 154 degrees and -131 degrees respectively and by comparison between the dihedral angles at C5'A-O5'A-PA-O3 which are 105 degrees and 57 degrees respectively.

Table 1: Dihedral Angles for Pharmacoclusters

Dihedral angle	PC1	PC2	PC3	PC4	PC5	PC6	PC7	PC8
	Avg. std	Avg. std	Avg. std	Avg. std	Avg. std	Avg. std	Avg. std	Avg. std
O4'A-C1'A- N9A-C8A	75 24	75 11	69 18	85 7	72 3	18 16	81 12	105 6
O4'A-C4'A-C5'A-O5'A	180 19	154 30	-131 99	-166 12	65 4	79 11	168 12	-84 38
C4'A-C5'A-O5'A- PA	138 86	137 15	121 93	-152 2	180 6	-156 9	150 21	-171 3
C5'A-O5'A- PA- O3	65 39	105 44	57 44	55 0	-71 6	-82 7	58 10	-34 10
O5'A- PA- O3- PN	97 61	42 77	74 24	115 20	121 30	139 17	75 12	-188 16
PA- O3- PN-O5'N	-143 72	-165 53	-136 29	-152 10	50 27	84 15	107 27	128 39
O3- PN-O5'N-C5'N	70 44	56 86	101 36	-64 22	-92 13	64 25	27 45	72 7
PN-O5'N-C5'N-C4'N	181 14	176 41	162 27	145 7	-112 26	139 15	-136 13	191 18
O5'N-C5'N-C4'N-O4'N	-73 46	-58 40	-54 26	-55 10	-60 4	65 10	-69 13	183 20
O4'N-C1'N- N1N- C2 N	-120 24	69 17	53 11	59 5	-132 6	-117 10	-178 16	-122 6
C1'A-C2'A-C3'A-C4'A	-25 10	-29 5	-29 10	-37 23	-30 8	42 6	-1 46	-33 3
C1'N-C2'N-C3'N-C4'N	-36 44	-35 6	-28 20	22 9	40 2	-39 5	17 38	-17 3

Tables 3A, 4A, 5A, 6A, 7A, 8A, 9A and 10A show RMSD values for subsets of members of pharmacoclusters 1-8, respectively. The RMSD values for each member were calculated as comparisons to an average structure for the subsets shown in each table respectively. For each pharmacocluster a subset of the possible ligands that belong to each cluster were identified. Each subset was chosen to maximize the diversity of the family and to minimize over-representation of ligand conformations from enzymes that exist multiply in the PDB database. The goal of the subset selection was to fully represent characteristics from oxidoreductases belonging to a range of species and catalyzing a range of different reactions. For example, there exists over ten alcohol dehydrogenases in the PDB database; however, for purposes of this study, only three were chosen from three different species for use in the 3D overlay and the pharmacophore construction. Average coordinates for the above described pharmacocluster subsets were obtained by overlaying ligand structures in MSI InsightII using the overlay function. The three dimensional coordinates for each atom in each ligand were used to calculate an average position and a standard deviation for the pharmacofamily.

Comparison of the RMSD values in part A of Tables 3 through 10 with the RMSD values in Table 2 demonstrate that a member of a pharmacocluster can be identified as having a lower RMSD compared to an average conformation of the members in its pharmacocluster than the RMSD between each family's average coordinates. In some cases it can be beneficial to combine two or more methods of comparison. For example, as described above pharmacoclusters 2 and 3

Table 11: Pharmacofamilies

Table 11: Pharmacofamilies					
Family 1: NAD(P) Rossman Binding Domain (anti)					
Polypeptide	Source	PDB	Fold	SCOP-Superfamily	SCOP-Family
Alcohol Dehydrogenase	Horse Liver	1a71	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	human	1agn	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	Human	1dlt	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	Horse Liver	1axe	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	Horse Liver	1axg	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	cod fish	1cdo	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	Horse Liver	1deh	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	Human	1dls	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	human	1hdx	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	human	1hdy	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	Horse Liver	1hdz	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	Horse Liver	1hld	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	human	1htb	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	Cod liver	1kev	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.
Alcohol Dehydrogenase	Horse Liver	1lde	NAD(P) binding Rossman	NAD(P) binding Rossman	Alcohol/glucose dehydrog.

L-2-hydroxyisocaproate dehydrogenase	Lactobacillus Confusus	lhyh	NAD(P) binding Rossman	NAD(P) binding Rossman	Formate/glycerate dehydrog.
L-Alanine Dehydrogenase	Phormidium Lapideum	lpjc	NAD(P) binding Rossman	NAD(P) binding Rossman	Formate/glycerate dehydrog.
L-Lactate Dehydrogenase	Plasmodium Falciparum	lldg	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
L-Lactate Dehydrogenase	Bacillus Delbreuckii	lldl	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
L-Lactate Dehydrogenase	B. Stearothermophilus	lldn	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
L-Lactate Dehydrogenase	Bifidobacterium Longum	lldd	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
L-Lactate Dehydrogenase	Bifidobacterium Longum	llth	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
L-Lactate Dehydrogenase	B. Stearothermophilus	2ldb	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)

TABLE 1. NAD(P) binding of dehydrogenases

L-Lactate Dehydrogenase	Pig Muscle	9ldb	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
L-Lactate Dehydrogenase	Pig Muscle	9ldt	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
Malate Dehydrogenase	Aquaspirillum Arcticum	1b8u	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
Malate Dehydrogenase	Thermus Flavis	1bmd	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
Malate Dehydrogenase	E. Coli	1cme	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
Malate Dehydrogenase	E. Coli	1emd	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
Malate Dehydrogenase	Haloarcula Marismortui	1hlp	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
Malate Dehydrogenase	Pig Heart	4mdh	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)
Malate Dehydrogenase	Pig Heart	5mdh	NAD(P) binding Rossman	NAD(P) binding Rossman	Lactate & malate dehydrog. (N-term)

Malic Enzyme	human	1qr6	NAD(P) binding Rossman	NAD(P) binding Rossman	Amino-acid dehydrog (C-term)
S-AdenosylHomocysteine Hydrolase	Rat	1b3r	NAD(P) binding Rossman	NAD(P) binding Rossman	Formate/glycerate dehydrog.
Tetrahydrofolate Dehydrogenase	Human	1a4i	NAD(P) binding Rossman	NAD(P) binding Rossman	Amino-acid dehydrog (C-term)
Family 2: NAD(P) Rossman Binding Domain (Syn)					
Polypeptide	Source	PDB	Fold	SCOP-Superfamily	SCOP-Family
Glutamate Dehydrogenase	Bovine Liver	1ch6	NAD(P) binding Rossman	NAD(P) binding Rossman	Amino-acid dehydrog (C-term)
Glyceraldehyde -3- phosphate Dehydrogenase	Leishman ia Mexicana	1a7k	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3- phosphate dehydrog. (N-term)
Glyceraldehyde -3- phosphate Dehydrogenase	Thermus aquaticu s	1cer	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3- phosphate dehydrog. (N-term)
Glyceraldehyde -3- phosphate Dehydrogenase	B.Stearo thermoph ilus	1dbv	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3- phosphate dehydrog. (N-term)
Glyceraldehyde -3- phosphate Dehydrogenase	E. Coli	1gad	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3- phosphate dehydrog. (N-term)

Glyceraldehyde -3-phosphate Dehydrogenase	E. Coli	lgae	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3-phosphate dehydrog. (N-term)
Glyceraldehyde -3-phosphate Dehydrogenase	B.Steart thermophilus	lgd1	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3-phosphate dehydrog. (N-term)
Glyceraldehyde -3-phosphate Dehydrogenase	Trypanosoma Brucei Brucei	lgga	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3-phosphate dehydrog. (N-term)
Glyceraldehyde -3-phosphate Dehydrogenase	Leishmania Mexicana	lgyp	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3-phosphate dehydrog. (N-term)
Glyceraldehyde -3-phosphate Dehydrogenase	Thermatoga Marinata	lhdg	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3-phosphate dehydrog. (N-term)
Glyceraldehyde -3-phosphate Dehydrogenase	Palinurus Versicolor or	lszj	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3-phosphate dehydrog. (N-term)
Glyceraldehyde -3-phosphate Dehydrogenase	B.Steart thermophilus	2dbv	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3-phosphate dehydrog. (N-term)
Glyceraldehyde -3-phosphate Dehydrogenase	B.Steart thermophilus	3dbv	NAD(P) binding Rossman	NAD(P) binding Rossman	Glyceraldehydes-3-phosphate dehydrog. (N-term)

L-3-Hydroxyacyl CoA Dehydrogenase	Human Heart	2hdh	NAD(P) binding Rossman	NAD(P) binding Rossman	6-phosphogluconate dehydrog. (N-term)
Phenylalanine Dehydrogenase	Rhodococcus Sp.	1bxg	NAD(P) binding Rossman	NAD(P) binding Rossman	Amino-acid dehydrog (C-term)
Family 3: NAD(P) Rossman Binding Domain (Syn) Tyrosine Dependent Oxidoreductases					
Polypeptide	Source	PDB	Fold	SCOP-Superfamily	SCOP-Family
17 β -Hydroxysteroid Dehydrogenase	Human	1a27	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
2 α -20 β -Hydroxysteroid Dehydrogenase	Strep. Hydrogenans	2hsd	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
7 α -Hydroxysteroid Dehydrogenase	E. Coli	1ahh	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
7 α -Hydroxysteroid Dehydrogenase	E. Coli	1ahi	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
7 α -Hydroxysteroid Dehydrogenase	E. Coli	1fmc	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Carbonyl Reductase	Mouse	1cyd	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Cis-Biphenyl-2,3-Dihydrodiol-2,3-Dehydrogenase	Pseudomonas sp.	1bdb	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Dihydropteridine Reductase	Rat Liver	1dir	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Dihydropteridine Reductase	Human	1hdr	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent

Q U A R T E R L Y R E V I E W

Enoyl Acyl Carrier Protein Reductase	M. Tuberculosi	lbvr	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Enoyl Acyl Carrier Protein Reductase	Brassica Napus (rape)	lcwu	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Enoyl Acyl Carrier Protein Reductase	E. Coli	ldfg	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Enoyl Acyl Carrier Protein Reductase	E. Coli	ldfh	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Enoyl Acyl Carrier Protein Reductase	E. Coli	ldfi	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Enoyl Acyl Carrier Protein Reductase	Myobacterium Tuberculosi	leny	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Enoyl Acyl Carrier Protein Reductase	Myobacterium Tuberculosi	lenz	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Enoyl Acyl Carrier Protein Reductase	E. Coli	lqg6	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Enoyl Acyl Carrier Protein Reductase	Common Bacteria	lqsg	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
GDP-Fucose Synthase	E. Coli	lbsv	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Sepiapterin Reductase	E. Coli	lnas	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Sepiapterin Reductase	mouse	lsep	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent
Trihydroxynaphthalene Reductase	Rice Fungus	lybv	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine-dependent

Tropinone Reductase-I	Jimson Weed	lael	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
Tropinone Reductase-II	Jimsonweed	2ae2	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1a9y	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1a9z	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1kvq	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1kvr	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1kvs	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1kvt	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1kvu	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1nai	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1uda	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1udb	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1udc	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
UDP-Galactose Epimerase	E. Coli	1xel	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
3 α , 20 β - hydroxysteroid dehydrogenase	Strep. Hydrogen as	2hsd	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent
17- β hydroxy steroid Dehydr.	Human	1fdu	NAD(P) binding Rossman	NAD(P) binding Rossman	Tyrosine- dependent

17- β hydroxy steroid Dehydr.	Human	1fdv	NAD(P) binding Rossmann	NAD(P) binding Rossmann	Tyrosine- dependent
Family 4: Catalases					
Polypeptide	Source	PDB	Fold	SCOP-Superfamily	SCOP-Family
Catalase	Proteus Mirabilis	2cah	Heme linked catalase	Heme linked catalase	Heme linked catalase
Catalase	cow Liver	7cat	Heme linked catalase	Heme linked catalase	Heme linked catalase
Catalase	cow Liver	8cat	Heme linked catalase	Heme linked catalase	Heme linked catalase
Family 5: β-α TIM Barrel					
Polypeptide	Source	PDB	Fold	SCOP-Superfamily	SCOP-Family
2,5-Diketo-D-Gluconic Acid Reductase	Cornybac terium sp.	1a80	β - α TIM Barrel	NAD(P)-linked Oxidoreductase	Aldo-keto Reductase
3- α -hydroxysteroid Dehydrogenase	Rat	1afs	β - α TIM Barrel	NAD(P)-linked Oxidoreductase	Aldo-keto Reductase
Aldehyde Reductase	Pig	1ae4	β - α TIM Barrel	NAD(P)-linked Oxidoreductase	Aldo-keto Reductase
Aldehyde Reductase	Pig	1cwn	β - α TIM Barrel	NAD(P)-linked Oxidoreductase	Aldo-keto Reductase
Aldo-keto Reductase	Mouse	1frb	β - α TIM Barrel	NAD(P)-linked Oxidoreductase	Aldo-keto Reductase

Aldose Reductase	Human	1abn	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Aldose Reductase	Human	1ads	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Aldose Reductase	Pig	1ah0	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Aldose Reductase	Pig eye	1ah3	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Aldose Reductase	Pig	1ah4	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Aldose Reductase	Human	1az1	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Aldose Reductase	Human	1az2	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Aldose Reductase	Human	1mar	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Aldose Reductase	Human	2acq	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Aldose Reductase	Human	2acr	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Aldose Reductase	Human	2acs	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Aldose Reductase	Human	2acu	β - α TIM Barrel	NAD (P) -linked Oxidoreductase	Aldo-keto Reductase
Family 6: Dihydrofolate Reductases					
Polypeptide	Source	PDB	Fold	SCOP-Superfamily	SCOP-Family
Dihydrofolate Reductase	Candida Albicans	1ai9	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase

Dihydrofolate Reductase	Candida Albicans	laae	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Pneumocystis carinii	ldaj	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Human	ldlr	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Human	ldls	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Chicken Liver	ldr1	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Chicken Liver	ldr4	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Chicken Liver	ldr5	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Chicken Liver	ldr6	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Chicken Liver	ldr7	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	E. Coli	ldre	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	E. Coli	ldrh	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Pneumocystis carinii	ldyr	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Human	lhfp	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Human	lhfq	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Human	lhfr	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Human	lohj	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase

Dihydrofolate Reductase	Human	1ohk	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	E. Coli	1ra2	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	E. Coli	1rb2	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	E. Coli	1rh3	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	E. Coli	1rx1	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	E. Coli	1rx2	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	E. Coli	1rx3	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Lactobacillus casei	3dfr	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	E. Coli	7dfr	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Dihydrofolate Reductase	Chicken Liver	8dfr	Dihydrofolate Reductase	Dihydrofolate Reductase	Dihydrofolate Reductase
Family 7: FAD/NAD(P) Binding Oxidoreductases ('Disulfide Oxidoreductases')					
Polypeptide	Source	PDB	Fold	SCOP-Superfamily	SCOP-Family
Glutathione Reductase	E. Coli	1get	FAD/NAD(P) Binding Domain	FAD/NAD(P) Binding Domain	FAD/NAD-linked reductases
Glutathione Reductase	E. Coli	1geu	FAD/NAD(P) Binding Domain	FAD/NAD(P) Binding Domain	FAD/NAD-linked reductases
Glutathione Reductase	Human	1grb	FAD/NAD(P) Binding Domain	FAD/NAD(P) Binding Domain	FAD/NAD-linked reductases

NADH Peroxidase	Streptococcus Faecalis	2npv	FAD/NAD(P) Binding Domain	FAD/NAD(P) Binding Domain	FAD/NAD-linked reductases
Thioredoxin Reductase	E. Coli	1tdf	FAD/NAD(P) Binding Domain	FAD/NAD(P) Binding Domain	FAD/NAD-linked reductases
Trypanothione Reductase* (by active site)	Crithidia fasciculata	1typ	FAD/NAD(P) Binding Domain	FAD/NAD(P) Binding Domain	FAD/NAD-linked reductases
Family 8: Ferredoxin-like					
Polypeptide	Source	PDB	Fold	SCOP-Superfamily	SCOP-Family
Ferredoxin Reductase	Pea	1qga	Ferredoxin like	Ferredoxin like	Reductases
P450 Reductase	Rat	-	Ferredoxin like	Ferredoxin like	NADPH-cytochrome P450 reductase

The results shown in Table 11 demonstrate that bound conformation of NAD(P) (H) can be correlated with protein fold. Grouping oxidoreductases into pharmacofamilies based on the bound conformations of NAD(P) (H) resulted in a correlation with protein fold. Pharmacofamilies 1-3 consist of polypeptides having the NAD(P) (H) binding Rossman fold. Pharmacofamily 4 consists of polypeptides having heme-linked catalase fold. Pharmacofamily 5 consists of polypeptides having the β - α TIM barrel fold. Pharmacofamily 6 consists of polypeptides having the dihydrofolate reductase fold. Pharmacofamily 7 consists of polypeptides having the FAD/NAD(P) (H) binding domain fold. Trypanathione reductase was added to family 7 by homology of its active site to the active sites of other members of pharmacofamily 7 independent of bound ligand conformation. Pharmacofamily 8 consists of polypeptides having the ferredoxin like fold. Pharmacofamilies 1 and 2 were identified based on anti or syn conformation, respectively, of the nicotinamide ring relative to the ribose. Additionally, a change in the torsion angles in the bonds connecting the adenine ribose to the adenine phosphate separates the family members having a Rossman fold into a third pharmacofamily, identified as pharmacofamily 3.

The results described in this example demonstrate that a bound conformation of a ligand can be correlated with polypeptide fold. Furthermore, the results obtained by the method are consistent with results obtained by SCOP. Therefore, classification based on bound conformation of ligands can be used to classify polypeptides according to structure.

EXAMPLE III**Determination of a conformer model and pharmacophore for
pharmacoclusters 1-8**

This example demonstrates determination of the
5 average bound conformations from pharmacoclusters 1-8 and
construction of conformer models based on the average bound
conformations. This example also demonstrates construction
of a pharmacophore model based on the average bound
conformations and interactions with polypeptides.

10 Conformer models for each pharmacocluster were
produced by determining an average structure for the subset
of members of each pharmacocluster as described in Example
I. The coordinates for conformer models of pharmacoclusters
1-8 are shown in Part C of Tables 3-10 respectively.

15 Pharmacophore models were constructed by aligning
the active sites of a pharmacofamily of oxidoreductases.
Three-dimensional overlays were achieved using Insight II
overlay module to overlay the NAD(P) ligands of each enzyme-
ligand complex. Heteroatoms in the surrounding protein that
20 could function as hydrogen bond acceptors or hydrogen bond
donors were identified in each complex that made
interactions with the NAD(P) ligand. These heteroatoms that
had common positions in three dimensional space (within 3Å
of each other in the overlay) in each enzyme complex and
25 that made a common interaction with the ligand were then
grouped together and tabulated for pharmacophore
construction. Water molecules were similarly identified and
grouped. The grouped heteroatoms and water molecules are
listed in Part D of Tables 3-10 below. Finally the average

coordinates and the standard deviation for each interaction group were calculated. The final pharmacophore model was produced by overlaying interaction groups on the conformer model (average ligand structure).

5 The coordinates for pharmacophore models of pharmacoclusters 1-8 are shown in parts B and C of Tables 3-10, respectively. Specifically, each conformer model includes the average NAD(P) coordinates (in part C of each Table) and the pharmacophore model includes both the average
10 NADP coordinates, average water coordinates and the average protein heteroatom coordinates (including coordinates in both part B and C of each Table). An exception is the pharmacophore model derived from pharmacofamily 7 which includes average water coordinates and average protein
15 heteroatom coordinates for all polypeptides listed but has a conformer model derived from NAD(P) bound to each polypeptide listed except trypanathione reductase.

A structural representation of each conformer model with overlaid interaction groups used to determine
20 respective pharmacophore models 1-8 is provided in Figure 3. The structures shown in Figure 3 reflect the average NAD(P) coordinates shown in Part C of Tables 3-10 and the coordinates for all interacting groups used to calculate the average water coordinates and the average protein heteroatom
25 coordinates as shown in Part D of Tables 3-10. Hydrogen bond acceptors are labeled with an 'A' followed by a number for each group. These are listed in the pharmacophore Tables and designated on the pharmacophore figures. Donors are labeled with a 'D'; and water molecules are labeled with
30 a 'W'.

This example demonstrates construction of conformer models based on the bound conformations of ligands in pharmacoclusters. This example also demonstrates construction of a pharmacophore model based on the bound conformations of ligands in pharmacoclusters and their interactions with polypeptides in their respective pharmacofamilies.

Example IV

Correlation Between the Bound Conformation of Ligands and a Conformation-Dependent Property

This example describes a conformation-dependent property that is correlated with a bound conformation of a ligand.

A 2D [^1H , ^1H] NOESY spectrum was recorded with a 0.2 ml sample of 1 mM NADP and 200 μM of enzyme 1-deoxy D-xylulose 5-phosphate reductoisomerase (DOXP). The spectrum was measured with a Bruker DRX700 spectrometer operating at 700 MHz ^1H frequency. The total measuring time was about 12 h.

The spectrum is shown in Figure 4 and atoms are identified according to Figure 2. The relative intensities of the observed transferred NOEs (trNOEs) between the ribose proton H-C1'N(NC1') and the protons on the nicotinamide ring, H-C4N and H-C2N shown in Figure 4, reveal that the NADP adopts a *syn* conformation when bound to the enzyme.

The bound conformations in Pharmacocluster 1 and 2 can be distinguished according to anti or syn conformation, respectively, of the nicotinamide ring relative to the ribose. Therefore, these results demonstrate that the
5 relative intensities of the observed trNOE's between the ribose proton H-C1'N(NC1') and the protons on the nicotinamide ring, H-C4N and H-C2N can provide a conformation dependent property useful in distinguishing members of pharmacoclusters 1 and 2.

10

Example V

Binding compounds having specificity for one or more polypeptide pharmacofamilies.

This example demonstrates querying a database of compounds to identify individual compounds having similar
15 conformations. This example also demonstrates preferential binding of a compound to a polypeptide of one pharmacofamily over another.

The TTE0001.001.A07 AND TTE0001.002.D02 compounds were identified by using the THREEDOM algorithm to query a
20 database of commercially available molecules (ASINEX; Moscow, Russia) by shape matching with cibacron blue. Coordinates of cibacron blue were obtained from the published 3D structure (Li et al., Proc. Natl. Acad. Sci. USA 92:8846-8850 (1995)). The database was created by
25 converting an SD format file of structures from ASINEX to INTERCHEM format coordinates using the batch2to3 program. Cibacron blue was compared against each structure in the database in multiple orientations to generate a matching score. Out of 37,926 structures searched, the 750 best

matching scores were selected. From these 750 structures, TTE0001.001.A07 AND TTE0001.002.D02 were selected and purchased based on objective criteria such as likely favorable binding interactions, pharmacophore properties, 5 synthetic accessibility and likely pharmacokinetic, toxicological, adsorption and metabolic properties.

Kinetic studies were carried out in 1-cm cuvettes in a 1 mL volume at 25°C. Lactate dehydrogenase reactions were monitored spectrophotometrically with a Cary 300 by 10 following the decrease in absorbance at 340 nm due to the oxidation of NADH by pyruvate. Lactate dehydrogenase reaction mixtures contained 100 mM Hepes buffer at pH 7.4, as well as 2.5 mM pyruvate, 10 μ M NADH, 5 ng/mL lactate dehydrogenase. NADPH, NADH, Hepes buffer, and rabbit muscle 15 lactate dehydrogenase were purchased from Sigma. Cytochrome P450 reductase reactions were monitored by following the decrease in absorbance at 550 nm due to the reduction of ferric cytochrome c by NADPH. Cytochrome P450 reductase reaction mixtures contained 100 mM Hepes buffer at pH 7.4, 20 as well as 80 μ M ferric cytochrome c, 10 μ M NADPH, and 80 ng/mL cytochrome P450 reductase. Data were fitted using the FORTRAN programs of Cleland, Adv. Enzymol. 45: 273-387 (1977) which perform nonlinear least squares fits to the appropriate equations. Substrates were varied around their 25 Michaelis constants, while nonvaried substrate was kept at a concentration close to its Michaelis constant. The concentration of inhibitor that gives 50% inhibition (IC₅₀) values were obtained by fitting data to the equation for a line, where Y values are 1/rate and X values are the 30 concentration of inhibitor, as in a Dixon plot (Segel, *supra*). The X-intercept is the IC₅₀. If a full kinetic

profile was done, then K_{is} values were obtained by fitting the data to the equation for a competitive inhibitor:

$$\text{rate} = \frac{V_{\max}A}{K_m(1 + I/K_{is}) + A}$$

where rate is the rate of reaction in units of absorbance/minute, V_{\max} is the maximum velocity, K_m is the Michaelis constant for A, K_{is} is the inhibition dissociation constant for the inhibitor, I is the inhibitor concentration, and A is the concentration of NADH or NADPH. In all cases, the fit to the above equation was used only after establishing that the fit to equations for noncompetitive and uncompetitive inhibition were less appropriate based on values for sigma (overall fit) as well as standard deviations for fitted constants (K_{is} and K_{ii}).

As shown in Figure 5, compound TTE0001.001.A07 could inhibit binding of NADH to lactate dehydrogenase and NADPH to cytochrome P450 reductase which are polypeptide members of pharmacofamily 1 and 8 respectively. Compound TTE0001.001.A07 demonstrated high binding affinity for both lactate dehydrogenase and cytochrome P450 reductase.

Analysis of inhibition of binding between NADH and lactate dehydrogenase is shown in Figure 6. Compound TTE0001.002.D02 inhibited lactate dehydrogenase with a K_{is} of 2.1 μM . Similar measurements of cytochrome P450 reductase with concentrations of compound TTE0001.002.D02 up to 0.5 mM did not indicate inhibition. These results indicated that compound TTE0001.002.D02 had a K_{is} of greater

than 1 mM with cytochrome P450 reductase. Thus, compound TTE0001.002.D02 demonstrated preferential binding for pharmacofamily 1 having an inhibitory dissociation constant (K_{is}) that was at least 500 fold lower than for
5 pharmacofamily 8.

The results described in this example demonstrate that a binding compound can be identified by structural comparison to a bound conformation of a ligand. Furthermore, the results demonstrate that binding compounds
10 that interact with polypeptides from multiple pharmacofamilies or compounds that preferentially bind to polypeptides of one pharmacofamily compared to polypeptides of another pharmacofamily can be identified by structural comparison to a bound conformation of a ligand.

15

Example VI

Identification of a ligand using a pharmacophore model

This example demonstrates construction of a pharmacophore model, use of the model to identify a binding ligand and confirmation of the ability of the identified
20 compound to bind a polypeptide member of the pharmacofamily from which the pharmacophore model was derived.

Pharmacophore models were constructed to include part or all of the NAD(P) shape, hydrogen bond donors, hydrogen bond acceptors and/or other chemical features
25 described in Tables 3-10. The combination of chemical features chosen for each search pharmacophore in a search set were chosen in an attempt to cover a diverse range of combinations of possible chemical interactions and to

represent the protein ligand interactions that occur most frequently in the particular pharmacofamily.

Pharmacophore shape was derived using the program CATALYST, and was calculated using the Van der Waals surface
5 for part or all of the structure of the averaged NAD(P) coordinates determined for a pharmacocluster. Desired hydrogen bonding features, water molecules and other chemical motifs were positioned in the pharmacophore model using the average coordinates determined for both the
10 pharmacofamily and pharmacocluster.

The components of a pharmacophore model derived from the coordinates presented in Table 3 for pharmacofamily 1 are shown in Figure 7. Figure 7A shows the structure for the conformer model having coordinates listed in Table 3C
15 with a superimposed volume defining the shape of the ligand and indicated by grey spheres. A hydrophobic feature was added to the pharmacophore model at the average position of the hydrophobic region of the nicotinamide ring as shown in Figure 7B. Also shown in Figure 7B is a hydrogen bond
20 acceptor positioned at the average coordinates for the pyrophosphate using the averaged coordinates for the location of hydrogen bond acceptors utilized in all of the 17 polypeptides of the pharmacofamily. Finally, Figure 7B shows a hydrogen bond donor positioned according to a
25 position where a hydrogen bond donor of a ligand would be expected to have favorable interactions with hydrogen bond acceptors observed in 11 of the polypeptides of pharmacofamily 1. Thus, the hydrogen bond donor does not identify a position of an actual hydrogen bond donor in the
30 NAD(P) ligand, but instead a location to where a potential

ligand's hydrogen bond donor could make favorable interactions with the polypeptides of pharmacofamily 1. Figure 7C shows the combined features of figures 7A and 7B present in a pharmacophore model used to search a database
5 of compounds.

To identify potential ligands that bind to polypeptides of pharmacofamily 1, computational searches were conducted using CATALYST. Searches were made by comparing the shape and combination of chemical features of
10 the pharmacophore model, shown in Figure 7, to the shape and features of molecules in the database.

An example of a compound identified using the pharmacophore model shown in figure 7C is TTE0008.025.D08. Using a binding assay similar to that described in Example
15 V, compound TTE0008.025.D08 was shown to have inhibitory activity against pharmacofamily 1 member, dihydrodipicolinate reductase ($IC_{50} = 2.8 \mu M$).

Table 3A: Pharmacofamily 1 Subset

Molecule #	pdb	type	RMSD from Family Avg.
1	1A4I	Tetrahydrofolate Reductase (human)	0.75
2	1AXE	Alcohol Dehydrogenase (horse)	0.27
3	1DXY	D2-Hydroxyisocaproate Dehydrogenase (L. Casei)	0.92
4	1LDN	L-Lactate Dehydrogenase (B. Stearothermophilus)	0.41
5	1QR6	Malic Enzyme (human)	0.77
6	4MDH	Malate Dehydrogenase (pig)	0.65
7	1AGN	Alcohol Dehydrogenase (human class IV sigma)	0.63
8	1B3R	Adenosylhomocysteine (rat)	0.93
9	1EMD	Malate Dehydrogenase (E. Coli)	0.90
10	1PJC	L-Alanine (Phormidium Lipideum)	0.79
11	1YKF	Alcohol Dehydrogenase (Thermoanaerobium Brockii)	1.06
12	9LDB	Lactate Dehydrogenase (pig)	0.36
13	1ARZ	Dihydropyridine Reductase (E. Coli)	0.81
14	1BMD	Malate Dehydrogenase (Thermus Flavis)	0.68
15	1HYH	L2-Hydroxyisocaproate Dehydrogenase (Lactobacillus Confusus)	0.57
16	1PSD	D3-Phosphoglycerate Dehydrogenase (E.Coli)	0.78
17	2NAD	Formate Dehydrogenase (methylophilic bacterium pseudomonas sp 101)	0.91

Table 3B: Polypeptide and Solvent Interactors (average coordinates)

atom name	name	total	x	σx	y	σy	z	σz
A15	ACC	15	-3.51	0.52	-1.48	0.44	-4.24	0.49
A22	ACC	17	3.14	0.41	-2.17	0.33	-4.13	1.01
A32	ACC	5	7.37	0.45	1.75	1.11	-8.24	0.79
A34	ACC	6	1.20	0.42	6.08	0.33	-1.83	1.39
A47	ACC	13	-12.03	0.32	-1.22	0.56	-3.63	0.52
A48	ACC	14	-10.58	0.37	-0.79	0.39	-4.81	0.25
A53	ACC	11	-2.66	0.31	-2.95	0.58	-1.04	0.46
A57	ACC	11	7.56	0.73	-2.50	0.42	-6.36	0.45
A96	ACC	6	10.24	0.42	0.50	0.64	-2.97	0.32
A99	ACC	4	1.44	0.22	6.19	0.26	-5.24	0.38
D9	DON	17	-7.70	0.67	2.30	0.43	-6.27	0.29
D10	DON	17	-5.49	0.58	5.00	0.44	-5.79	0.28
D12	DON	17	-3.06	0.53	4.22	0.42	-7.05	0.38
D34	DON	2	7.05	0.16	1.64	0.42	-7.81	0.74
D36	DON	4	1.28	0.39	6.13	0.37	-1.01	0.70
D53	DON	5	-14.97	0.29	3.01	0.15	-1.95	0.55
D61	DON	11	2.46	0.64	-2.82	0.54	-0.35	0.58
D84	DON	11	4.78	0.45	0.00	0.90	-0.25	0.46
D105	DON	7	10.22	0.38	0.54	0.59	-3.10	0.45
D148	DON	4	-3.98	0.86	7.02	0.14	-1.61	0.33
W1	WAT	14	-4.88	0.34	1.26	0.38	-5.81	0.27
W6	WAT	6	-10.83	0.37	3.79	0.41	-3.11	0.70
W19	WAT	3	-12.43	0.10	2.22	0.31	-5.57	0.42

Table 3C: NAD(P) Conformer Model

atom name	total	x	ox	y	oy	z	oz
PA	17	-5.47	0.22	3.43	0.30	-1.84	0.27
O2A	17	-5.82	0.31	4.60	0.37	-2.38	0.65
O1A	17	-5.72	0.50	3.38	0.60	-0.59	0.64
O5'A	17	-6.13	0.25	2.22	0.25	-2.57	0.37
C5'A	17	-6.23	0.13	0.92	0.22	-2.20	0.23
C4'A	17	-7.50	0.39	0.21	0.43	-2.82	0.24
O4'A	17	-7.46	0.19	-1.07	0.14	-2.48	0.34
C3'A	17	-8.76	0.20	0.85	0.28	-2.35	0.43
O3'A	17	-9.62	0.37	1.13	0.33	-3.41	0.67
C2'A	17	-9.32	0.23	-0.09	0.31	-1.58	0.37
O2'A	17	-10.69	0.36	-0.06	0.51	-1.72	0.54
C1'A	17	-8.69	0.37	-1.29	0.45	-2.19	0.31
N9A	17	-8.88	0.18	-2.60	0.08	-1.36	0.24
C8A	17	-8.67	0.23	-2.75	0.20	-0.03	0.24
N7A	17	-8.84	0.32	-4.00	0.25	0.37	0.15
C5A	17	-9.17	0.33	-4.65	0.16	-0.75	0.14
C6A	17	-9.46	0.45	-6.00	0.16	-0.92	0.24
N6A	17	-9.49	0.52	-6.85	0.31	0.08	0.37
N1A	17	-9.74	0.48	-6.40	0.12	-2.17	0.29
C2A	17	-9.75	0.40	-5.55	0.19	-3.19	0.18
N3A	17	-9.49	0.29	-4.26	0.16	-3.07	0.11
C4A	17	-9.20	0.23	-3.82	0.08	-1.83	0.13
O3	17	-4.01	0.22	3.14	0.33	-2.03	0.34
PN	17	-2.81	0.17	3.31	0.22	-2.96	0.33
O1N	17	-2.32	0.49	4.39	0.63	-2.89	0.71
O2N	17	-3.16	0.47	3.27	0.61	-4.13	0.54
O5'N	17	-1.87	0.29	2.15	0.26	-2.49	0.48
C5'N	17	-1.92	0.27	0.87	0.27	-2.66	0.46

TABLE 1. Data for the 1990-1991 season

C4'N	17	-0.83	0.19	0.02	0.24	-2.14	0.36
O4'N	17	0.32	0.21	0.20	0.36	-2.95	0.27
C3'N	17	-0.36	0.23	0.40	0.28	-0.74	0.32
O3'N	17	-0.18	0.47	-0.71	0.40	0.01	0.35
C2'N	17	0.91	0.23	1.05	0.40	-0.94	0.21
O2'N	17	1.65	0.44	0.84	0.85	0.08	0.32
C1'N	17	1.45	0.18	0.41	0.23	-2.17	0.22
N1N	17	2.44	0.15	1.17	0.24	-2.89	0.19
C2N	17	3.61	0.20	0.61	0.24	-3.24	0.16
C3N	17	4.53	0.22	1.30	0.35	-3.97	0.23
C7N	17	5.81	0.29	0.71	0.58	-4.39	0.38
O7N	17	6.57	0.47	1.16	0.94	-4.83	0.51
N7N	17	6.03	0.44	-0.27	0.96	-4.27	0.71
C4N	17	4.30	0.34	2.55	0.41	-4.33	0.47
C5N	17	3.12	0.39	3.09	0.48	-3.96	0.64
C6N	17	2.19	0.27	2.41	0.44	-3.24	0.51
P2'	2	-11.69	0.02	1.32	0.36	-1.90	0.73
OP1	2	-12.69	0.51	0.79	0.45	-1.31	1.66
OP2	2	-12.01	0.86	1.94	0.08	-3.01	0.74
OP3	2	-11.04	0.61	2.17	0.59	-1.12	0.07

Table 3D: Polypeptide and Solvent Interactors

Acceptors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
O	ALA 1	215		-4.41		-1.37		-4.378	
O	VAL 2	268		-3.415		-1.508		-4.259	
O	CYS 4	95		-3.525		-1.391		-4.201	
O	VAL 5	392		-4.035		-1.223		-4.42	
O	VAL 6	86		-2.622		-2.525		-3.463	
O	VAL 7	268		-3.739		-1.583		-4.801	
O	THR 8	274		-3.374		-1.505		-3.621	
O	SER 9	76		-3.338		-0.96		-4.215	
O	ALA10	237		-4.168		-1.334		-4.262	
O	ALA11	242		-3.642		-1.13		-4.963	
O	THR12	97		-2.827		-1.527		-3.709	
O	PHE13	79		-3.279		-1.095		-4.527	
O	VAL14	86		-2.698		-2.451		-3.496	
O	THR15	96		-3.708		-1.231		-4.403	
O	ASN17	254		-3.847		-1.386		-4.942	
Al5	ACC	15	15	-3.508	0.51867	-1.481	0.444684	-4.244	0.48666
O	CYS 1	236		3.015		-2.169		-3.644	
O	VAL 2	292		3.319		-2.239		-3.966	
O	THR 3	232		3.626		-2.073		-5.277	
O	ALA 4	136		2.873		-1.964		-3.884	
O	LEU 5	419		3.566		-2.603		-2.54	
O	VAL 6	128		2.902		-2.638		-3.394	
O	VAL 7	292		3.435		-2.183		-4.536	
O	ILE 8	298		2.705		-2.013		-5.149	
O	ILE 9	117		3.267		-2.016		-3.572	
O	VAL10	266		3.531		-1.908		-3.445	

O	VAL11	265	2.245	-2.153	-5.774			
O	VAL12	138	3.423	-2.49	-3.658			
O	GLY13	102	3.045	-2.197	-3.332			
O	VAL14	128	2.473	-2.343	-3.403			
O	ILE15	141	3.095	-2.691	-3.316			
O	ALA16	238	3.132	-1.372	-5.812			
O	THR17	282	3.668	-1.893	-5.571			
A22	ACC	22	3.1365	0.40729	-2.173	0.325811	-4.134	1.01093
OG1	THR 1	279	6.933	1.937	-8.332			
O	ALA 3	297	7.27	2.615	-9.402			
OD1	ASN 8	345	7.341	0.057	-7.801			
SG	CYS11	295	8.12	2.802	-8.368			
OG	SER17	334	7.164	1.343	-7.29			
A32	ACC	32	7.3656	0.44907	1.7508	1.109256	-8.239	0.78586
SG	CYS 2	46	1.759	6.095	-1.597			
OG	SER 6	240	1.154	5.714	-0.415			
SG	CYS 7	46	1.39	6.091	-1.637			
OD1	ASN 8	190	1.47	6.205	-3.174			
OG	SER 9	222	0.831	6.625	-0.409			
OG	SER10	133	0.616	5.761	-3.752			
A34	ACC	34	1.2033	0.42444	6.0818	0.331268	-1.831	1.38661
OD1	ASP 2	223	-12.06	-1.364	-3.72			
OD1	ASP 3	175	-12.31	-1.116	-2.892			
OD1	ASP 4	52	-12.29	-1.122	-4.018			
OD2	ASP 6	41	-12.14	-1.461	-3.317			
OD2	ASP 7	223	-12.26	0.192	-5.072			
OE1	GLU 8	242	-12.17	-0.604	-3.687			
OD1	ASP 9	34	-11.26	-2.188	-3.753			
OD2	ASP10	197	-12.39	-1.306	-3.358			
OD1	ASP12	53	-11.79	-1.526	-3.647			
OE1	GLU14	41	-11.76	-1.641	-3.303			

OD1	ASP15	53	-11.95	-1.38	-3.606
OD1	ASP16	181	-12.33	-1.128	-3.23
OD1	ASP17	221	-11.74	-1.235	-3.585
A47	ACC	47	13 -12.03	0.32497 -1.221	0.556926 -3.63
OD2	ASP 2	223	-10.46	-0.712	-5.067
OD2	ASP 3	175	-10.78	-0.582	-4.327
OD2	ASP 4	52	-10.23	-0.845	-4.641
OD1	ASP 6	41	-10.8	-0.87	-4.98
OD1	ASP 7	223	-10.78	-1.36	-4.58

OD1	ASP17	308	7.288	-2.414	-6.878
A57	ACC	57	7.5561	0.73228	-2.498
ND1	HIS 4	193	10.626	0.61	-3.116
ND1	HIS 6	186	10.014	-0.093	-2.576
ND1	HIS 9	177	10.504	1.695	-3.436
ND1	HIS12	195	10.555	0.375	-3.145
ND1	HIS14	186	9.53	0.058	-2.803
ND1	HIS15	198	10.182	0.378	-2.754
A96	ACC	96	10.235	0.41864	0.5038
O	THR 4	247	1.697	6.212	-4.932
O	SER 6	241	1.512	5.836	-4.992
O	THR12	246	1.401	6.459	-5.282
O	THR15	248	1.165	6.252	-5.758
A99	ACC	99	1.4438	0.22235	6.1898
					0.25949
					-5.241
					0.37703

Donors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
N	SER 1	174		-6.971		2.982		-6.833	
N	GLY 2	201		-7.051		2.265		-6.475	
N	GLY 3	154		-8.12		2.219		-6.064	
N	GLY 4	29		-7.293		1.675		-6.476	
N	GLY 5	313		-7.132		2.483		-6.314	
N	GLY 6	13		-8.808		2.734		-6.39	
N	GLY 7	201		-7.089		2.378		-6.44	
N	GLY 8	221		-7.171		2.192		-6.095	
N	GLY 9	10		-8.673		2.272		-6.033	
N	GLY10	176		-7.708		1.61		-6.214	
N	GLY11	176		-7.166		2.546		-5.844	
N	GLY12	30		-7.358		1.997		-6.529	
N	GLY13	15		-8.347		3.129		-5.659	
N	GLY14	13		-8.993		2.681		-6.03	
N	GLY15	30		-7.35		1.898		-6.417	
N	GLY16	160		-7.754		2.152		-6.234	
N	GLY17	200		-7.84		1.819		-6.562	
D9	DON	9	17	-7.696	0.66531	2.296	0.431519	-6.271	0.292226
OG	SER 1	174		-4.169		3.811		-6	
N	GLY 2	202		-5.086		5.296		-6.262	
N	HIS 3	155		-6.067		5.154		-5.788	
N	PHE 4	30		-5.313		4.474		-6.084	
N	GLU 5	314		-5.224		5.566		-5.679	
N	GLN 6	14		-6.138		5.075		-5.705	
N	GLY 7	202		-5.115		5.35		-5.842	
N	ASP 8	222		-4.822		4.792		-5.908	
N	GLY 9	11		-6.29		5.058		-5.51	
N	VAL10	177		-5.677		4.573		-6.103	

SG	CYS 7	46	1.39	6.091	-1.637
OG	SER 9	222	0.831	6.625	-0.409
D36	DON	36	4	1.2835 0.39114 6.1313 0.374531	-1.015 0.6959
ND2	ASN 2	225	-14.56	3.056	-1.923
ND2	ASN 7	225	-15.12	3.202	-1.587
ND2	ASN10	199	-14.92	2.944	-1.285
N	ARG11	200	-15.34	3.078	-2.669
ND2	ASN15	55	-14.92	2.794	-2.271
D53	DON	53	5	-14.97 0.2886 3.0148 0.153705	-1.947 0.54651
N	VAL 2	294	2.334	-2.69	-0.397
N	ASN 4	138	2.277	-2.379	0.029
N	ASN 5	421	2.644	-2.578	0.583
N	ASN 6	130	2.063	-2.785	-0.349
N	VAL 7	294	2.742	-3.152	-1.066
N	ASN 9	119	2.504	-2.09	-0.346
N	VAL10	268	4.124	-4.101	-1.602
N	ASN12	140	2.522	-2.522	-0.359
N	THR13	104	2.237	-3.331	0.05
N	ASN14	130	1.53	-2.648	-0.196
N	ASN15	143	2.106	-2.7	-0.15
D61	DON	61	11	2.4621 0.64303 -2.816 0.543046	-0.346 0.5762
NH1	ARG 3	234	4.587	-0.618	0.683
ND2	ASN 4	138	5.58	-1.025	-0.579
ND2	ASN 5	421	4.967	-0.91	-0.857
ND2	ASN 6	130	4.796	0.498	-0.376
ND2	ASN 9	119	4.776	1.072	-0.333
ND2	ASN12	140	4.874	0.88	-0.41
ND2	ASN14	130	3.87	0.241	-0.144
ND2	ASN15	143	4.582	0.661	-0.159
NH1	ARG16	240	5.381	-0.809	-0.472
NH2	ARG16	240	4.57	1.118	0.462

THE FUTURE OF THE FUTURE

[illegible]

Wat rs

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
O	HOH 1	37		-4.852		0.916		-5.955	
O	HOH 2	6		-4.639		1.155		-5.586	
O	HOH 3	341		-5.542		1.121		-5.837	
O	HOH 4	4		-4.423		0.776		-5.661	
O	HOH 5	8		-4.893		1.328		-5.536	
O	HOH 6	58		-4.815		1.672		-6.392	
O	HOH 9	316		-5.086		1.405		-5.627	
O	HOH10	3		-4.816		0.793		-5.596	
O	HOH12	21		-4.532		0.966		-5.406	
O	HOH13	810		-4.598		2.049		-5.765	
O	HOH14	20		-5.549		1.612		-6.137	
O	HOH15	370		-4.601		1.061		-5.784	

00222T 44T 44T 60

O	HOH16	566		-4.928	1.656		-6.021
O	HOH17	35		-5.091	1.06		-5.977
W1	WAT	1	14	-4.883	0.34302	1.255	0.378799 -5.806 0.26779
O	HOH 1	238		-11.09	4.575		-3.702
O	HOH 4	62		-10.9	3.609		-3.539
O	HOH 6	71		-10.22	3.569		-2.078
O	HOH10	92		-11.17	3.592		-2.43
O	HOH15	395		-10.54	3.897		-3.702
O	HOH17	199		-11.04	3.484		-3.197
W6	WAT	6	6	-10.83	0.37024	3.7877	0.410386 -3.108 0.69569
O	HOH 3	360		-12.48	2.562		-5.14
O	HOH 5	495		-12.31	1.96		-5.591
O	HOH17	439		-12.49	2.145		-5.979
W19	WAT	19	3	-12.43	0.09854	2.2223	0.308361 -5.57 0.41989

Table 4A: Pharmacofamily 2 Subset

molecule #	pdb	type	rmsd from Family Avg.
1	1CH6	Glutamine Dehydrogenase (cow)	0.58
2	1CER	Glyceraldehyde-3-phosphate D. (Thermus aquaticus)	0.31
3	1GYP	Glyceraldehyde-3-phosphate D. (Leishmania Mexicana)	0.34
4	2HDH	L3-hydroxyacyl CoA D. (human)	0.33
5	1BXG	Phenylalanine D. (Rhodococcus sp.)	0.59

Table 4B: Polypeptide and Solvent Interactors (average coordinates)

Acceptors atom name	residue- mol. #	total	x	ox	y	oy	z	oz
A4	ACC	1	1.10	-	-4.12	-	7.02	-
A21	ACC	5	-7.31	0.94	7.30	0.23	1.70	0.42
A24 (D28)	ACC	2	-9.52	0.99	4.80	0.06	-0.72	0.16
A26	ACC	3	-0.46	0.40	0.62	0.26	1.22	0.20
A31	ACC	5	5.50	0.30	1.15	0.72	4.41	0.31
A36	ACC	4	8.61	0.66	-1.12	0.22	6.56	0.54
A45	ACC	2	-5.73	0.51	5.08	0.20	-7.62	0.21
A47	ACC	2	-2.38	0.16	1.11	0.32	1.01	0.14
A57	ACC	3	4.82	0.39	1.19	0.27	12.29	0.39
A74	ACC	1	1.86	-	-2.87	-	1.92	-
A75	ACC	1	3.26	-	-4.52	-	2.27	-
A80	ACC	1	5.45	-	-2.88	-	6.60	-

Donors	atom name	residue- mol. #	total	x	σ_x	y	σ_y	z	σ_z
	D21	DON	5	-3.69	0.38	6.81	0.18	5.90	0.25
	D22	DON	6	-2.46	0.68	4.98	0.17	8.91	0.34
	D24	DON	3	0.28	0.18	4.88	0.18	8.67	0.22
	D27	DON	5	-8.64	0.42	7.78	0.77	-0.88	0.39
	D28 (A24)	DON	3	-9.48	0.70	4.58	0.39	-0.74	0.11
	D37	DON	2	4.89	0.32	-0.97	0.08	1.99	0.02
	D38	DON	2	5.09	0.86	-3.25	0.34	4.18	0.69
	D84	DON	1	-10.79	-	7.18	-	0.38	-

atom name	residue- mol. #	total	x	σ_x	y	σ_y	z	σ_z
Water								
W1	WAT	2	-1.68	0.35	5.44	0.29	5.49	0.17

Tabl 4C: NAD(P) Conformer Model

atom name	total	x	ox	y'	oy	z	oz
PA	5	-4.24	0.19	1.80	0.11	6.48	0.23
O1A	5	-5.08	0.52	0.75	0.25	6.07	0.45
O2A	5	-4.62	0.23	2.55	0.14	7.71	0.23
O5'A	5	-3.99	0.30	2.36	0.25	5.34	0.17
C5'A	5	-4.32	0.41	2.73	0.18	4.00	0.21
C4'A	5	-4.89	0.25	4.02	0.13	3.50	0.21
O4'A	5	-4.66	0.06	4.05	0.14	2.08	0.25
C3'A	5	-6.39	0.28	4.19	0.08	3.68	0.05
O3'A	5	-6.70	0.35	5.46	0.12	4.28	0.08
C2'A	5	-6.97	0.10	3.99	0.10	2.31	0.09
O2'A	5	-8.13	0.10	4.75	0.15	2.08	0.23
C1'A	5	-5.83	0.08	4.47	0.05	1.44	0.09

Table 4D: Polypeptide and Solvent Interactors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
OD1	ASN 1	168		1.095		-4.122		7.015	
A4	ACC	4	1	1.095		-4.122		7.015	
O	PHE 1	252		-5.191		8.539		6.797	
O	PHE 2	8		-5.255		8.065		6.21	
O	PHE 3	10		-4.805		8.465		5.853	
O	GLY 4	23		-4.854		8.511		7.292	
O	LEU 5	183		-5.255		8.273		6.6	
A14	ACC	14	5	-5.072	0.22358	8.3706	0.199937	6.5504	0.55124
OE1	GLU 1	275		-6.7		7.256		2.045	
OD1	ASP 2	32		-8.197		7.417		1.98	
OD1	ASP 3	38		-5.963		7.483		1.973	
OD1	ASP 4	45		-7.792		7.445		1.259	
OD1	ASP 5	205		-7.896		6.916		1.22	
A21	ACC	21	5	-7.31	0.94194	7.3034	0.233204	1.6954	0.41735
OG	SER 1	276		-10.22		4.761		-0.611	
OG1	THR 5	206		-8.824		4.845		-0.836	
A24	ACC	24	2	-9.523	0.98783	4.803	0.059397	-0.724	0.1591
O	ALA 1	326		-0.312		0.409		1.158	
O	ILE 4	108		-0.908		0.539		1.439	
O	ALA 5	239		-0.153		0.904		1.064	
A26	ACC	26	3	-0.458	0.39802	0.6173	0.256629	1.2203	0.19512
O	GLY 1	347		5.243		2.256		4.521	
O	THR 2	119		5.496		1.074		4.297	
O	SER 3	134		5.492		0.484		4.132	
O	ASN 4	135		5.99		0.551		4.206	
O	ALA 5	260		5.254		1.362		4.897	
A31	ACC	31	5	5.495	0.30275	1.1454	0.720452	4.4106	0.30869

COLETT 44 F 44 60

OD1	ASN 1	374	9.186	-0.987	5.966
NE2	HIS 4	158	7.894	-1.364	7.028
OD1	ASN 5	288	8.756	-0.995	6.691
A36	ACC	36	8.612	0.65793	-1.115 0.215389 6.5617 0.54268
O	LYS 2	77	-6.092	4.938	-7.77
O	GLN 3	91	-5.369	5.217	-7.467
A45	ACC	45	-5.731	0.51124	5.0775 0.197283 -7.619 0.21425
O	THR 2	96	-2.488	1.334	0.905
O	THR 3	111	-2.265	0.887	1.109
A47	ACC	47	-2.377	0.15768	1.1105 0.316077 1.007 0.14425
O	GLY 2	97	-0.425	-2.183	-0.802
O	GLY 3	112	-0.663	-2.629	-0.591
O	VAL 4	109	-1.565	-1.362	-0.563
A49	ACC	49	-0.884	0.60137	-2.058 0.642683 -0.652 0.13066
O	ASN 2	313	4.587	0.929	12.609
O	ASN 3	335	5.271	1.175	12.408
OG1	THR 5	153	4.596	1.474	11.859
A57	ACC	57	4.818	0.39234	1.1927 0.272929 12.292 0.38822
OE1	GLU 4	110	1.86	-2.87	1.915
A74	ACC	74	1.86	-2.87	1.915
OE2	GLU 4	110	3.257	-4.521	2.267
A75	ACC	75	3.257	-4.521	2.267
OG	SER 4	137	5.445	-2.882	6.6
A80	ACC	80	5.445	-2.882	6.6

Donors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
N	PHE 1	252		-3.795		8.382		3.66	
N	PHE 2	8		-3.513		8.186		3.399	
N	PHE 3	10		-3.274		8.183		2.802	
N	GLY 4	23		-3.891		8.194		3.841	
N	LEU 5	183		-3.951		8.196		3.424	
D20	DON	20	5	-3.685	0.28452	8.2282	0.086146	3.4252	0.39277
N	GLY 1	253		-3.608		7.062		6.079	
N	GLY 2	9		-3.411		6.805		5.974	
N	GLY 3	11		-3.279		6.847		5.562	
N	GLY 4	24		-3.951		6.79		6.145	
N	GLY 5	184		-4.182		6.562		5.718	
D21	DON	21	5	-3.686	0.37537	6.8132	0.17801	5.8956	0.24739
N	ASN 1	254		-2.527		5.077		8.825	
N	ARG 2	10		-2.87		4.723		8.75	
N	ARG 3	12		-2.609		4.907		8.456	
N	LEU 4	25		-3		5.05		9.249	
N	VAL 5	186		-1.3		5.165		9.257	
D22	DON	22	6	-2.461	0.67675	4.9844	0.173072	8.9074	0.34432
N	VAL 1	255		0.427		5.067		8.691	
N	ILE 2	11		0.083		4.702		8.883	
N	ILE 3	13		0.32		4.862		8.448	
D24	DON	24	3	0.2767	0.17605	4.877	0.182962	8.674	0.218
N	SER 1	276		-8.021		6.758		-1.068	
N	LEU 2	33		-8.808		8.195		-0.527	
N	MET 3	39		-9.137		8.038		-0.417	
N	GLN 4	46		-8.461		8.672		-1.048	
N	THR 5	206		-8.757		7.228		-1.324	
D27	DON	27	5	-8.637	0.41955	7.7782	0.77195	-0.877	0.38718

COORDED ATOM

OG	SER 1	276	-10.22	4.761	-0.611
NE2	GLN 4	46	-9.404	4.137	-0.763
OG1	THR 5	206	-8.824	4.845	-0.836
D28	DON	28	-9.483	0.70184	4.581
N	ASN 1	349	4.665	-0.919	1.972
N	ASN 5	262	5.113	-1.03	1.998
D37	DON	37	4.889	0.31678	-0.975
ND2	ASN 1	349	4.485	-3.489	4.665
N	SER 4	137	5.697	-3.011	3.686
D38	DON	38	5.091	0.85701	-3.25
N	ASP 5	207	-10.79	7.181	0.384
D84	DON	84	-10.79	7.181	0.384

Waters

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
O	HOH 4	888		-1.436		5.238		5.606	
O	HOH 5	888		-1.931		5.647		5.365	
W1	WAT	1	1	-1.684	0.35002	5.4425	0.289207	5.4855	0.17041

Table 5A: Pharmacofamily 3 Subset

Molecule #	pdb	type	RMSD from Family Avg.
1	1A27	17b-Hydroxysteroid Dehydrogenase (human)	0.35
2	1AE1	Tropinone Reductase	0.33
3	1AHH	7a-Hydroxysteroid Dehydrogenase	0.51
4	1BDB	Cis-Biphenyl-2,3-Dihydrodiol-2,3-Dehydrogenase	0.28
5	1BSV	GDP-Fucose Synthase	0.87
6	1CYD	Carbonyl Reductase	0.26
7	1ENZ	Enoyl Acyl Carrier Protein Reductase	0.66
8	1NAI	UDP-Galactose Epimerase	0.45
9	1SEP	Sepiapterin Reductase	0.43
10	1YBV	Trihydroxynaphthalene Reductase	0.70
11	1HSD	2a-20b-Hydroxysteroid Dehydrogenase	0.55
12	1DIR	Dihydropteridine Reductase	0.75

Table 5B: Polypeptide and Solvent Interactors (average coordinates)

Acceptors		Name	total	x	σ_x	y	σ_y	z	σ_z
A5 (D5)	ACC	4	-9.243	0.6136	-6.385	0.485759	7.5835	0.60521	
	ACC	10	-2.055	0.62558	-12.31	0.344913	15.347	0.71676	
	ACC	12	-0.64	0.89267	-1.309	0.373379	8.7658	0.6637	
	ACC	12	2.8272	0.30273	5.1573	0.670541	10.018	0.502	
	ACC	9	1.8439	0.50418	7.7642	0.274322	13.139	0.30794	
A34 (D34)	ACC	12	-0.113	0.24453	4.7021	0.586493	13.952	0.24008	
	ACC	11	1.2485	0.72569	9.7629	0.441462	9.482	0.48385	
A40	ACC	10	-2.496	0.41035	10.064	0.558296	8.9034	0.77733	
	ACC	9	-7.86	0.22197	8.1173	0.560664	9.1394	0.53745	
A44 (D47)	ACC	8	-8.336	0.72492	4.1414	0.508189	9.0466	0.81437	
	ACC	5	-6.27	0.3454	-7.233	0.556879	7.5474	0.30836	

Donors		total						
atom name	Name	x	σ_x	y	σ_y	z	σ_z	
D5 (A5)	DON	-9.892	1.12248	-6.493	0.603878	7.9562	0.75319	
	D7	-9.66	0.00919	-1.343	0.165463	8.0065	0.15061	
	D9	-6.057	0.41875	1.6692	0.293883	4.914	0.25367	
	D21	0.0467	0.43511	-11.62	0.342553	11.981	0.91633	
	D34 (A34)	DON	1.8439	0.50418	7.7642	0.274322	13.139	0.30794
D38 (A36)	DON	-0.113	0.24453	4.7021	0.586493	13.952	0.24008	
	D40	2.4988	0.36354	1.5627	0.445563	12.367	0.3007	
D45	DON	-5.476	0.54512	9.6232	0.478163	8.6938	0.41629	
D47 (A44)	DON	-7.675	0.22275	3.8397	0.368935	9.5875	1.11949	

total	x	ox	y'	oy	z	oz
9	-4.738	0.3561	-1.037	0.298174	6.477	0.47268
4	2.6995	0.66749	-0.925	0.394841	9.7795	0.39679
9	3.273	0.73202	-1.012	0.573841	12.802	0.86657
6	-6.007	0.19132	-1.329	0.200188	13.702	0.2296

Table 5C: NAD(P) Conformer Model

atom name	total	x	ox	y	oy	z	oz
PA	12	-6.94	0.27682	-0.359	0.12062	10.196	0.3132
O1A	12	-7.187	0.50362	-0.724	0.311997	11.568	0.35149
O2A	12	-8.039	0.23033	0.0836	0.236246	9.4105	0.49965
O5'A	12	-6.324	0.33618	-1.599	0.152174	9.5178	0.48615
C5'A	12	-5.31	0.27378	-2.37	0.252109	9.8483	0.42032
C4'A	12	-5.39	0.23487	-3.716	0.196458	9.4463	0.27041
O4'A	12	-4.443	0.17889	-4.486	0.362347	10.152	0.45942
C3'A	12	-6.677	0.26263	-4.369	0.172555	9.6349	0.38881
O3'A	12	-7.077	0.60241	-4.969	0.317672	8.502	0.51095
C2'A	12	-6.427	0.2192	-5.392	0.18758	10.719	0.34471
O2'A	12	-7.207	0.43164	-6.53	0.229629	10.538	0.52325
C1'A	12	-4.996	0.2692	-5.707	0.273621	10.514	0.28506
N9A	12	-4.338	0.16157	-6.335	0.231445	11.625	0.21234
C8A	12	-4.321	0.18366	-5.957	0.287413	12.906	0.25525
N7A	12	-3.708	0.19062	-6.853	0.38173	13.663	0.14123
C5A	12	-3.345	0.167	-7.802	0.336217	12.81	0.08303
C6A	12	-2.685	0.29854	-8.972	0.409416	13.085	0.20366
N6A	12	-2.353	0.40839	-9.302	0.557888	14.313	0.25603
N1A	12	-2.439	0.38208	-9.778	0.395034	12.051	0.30817
C2A	12	-2.826	0.38939	-9.443	0.393263	10.824	0.25264
N3A	12	-3.468	0.30202	-8.33	0.362823	10.533	0.10763
C4A	12	-3.726	0.15519	-7.514	0.288774	11.545	0.09427

Table 5D: Polypeptide and Solvent Interactors
Acceptors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
O	GLY 1	9		-4.643		-4.27		6.043	
O	GLY 2	28		-4.558		-4.117		5.821	
O	GLY 3	18		-4.048		-4.273		6.088	
O	GLY 4	12		-4.135		-3.933		6.033	
O	GLY 5	10		-4.432		-4.169		5.555	
O	GLY 6	14		-4.284		-4.355		6.044	
O	GLY 7	14		-6.249		-5.065		6.52	
O	GLY 8	7		-4.849		-3.848		5.762	
O	GLY 9	15		-4.591		-3.878		5.357	
O	GLY10	36		-4.346		-4.384		5.754	
O	GLY11	13		-5.058		-4.026		6.159	
O	GLY12	13		-5.622		-4.826		5.87	
A1	ACC	1	12	-4.735	0.64211	-4.262	0.369162	5.9172	0.30204
OG	SER 1	11		-9.556		-5.885		8.172	
OG	SER 2	30		-9.127		-6.766		7.066	
OG	SER 8	36		-9.85		-6.053		8.039	
OG	SER 9	17		-8.437		-6.835		7.057	
A5	ACC	5	4	-9.243	0.6136	-6.385	0.485759	7.5835	0.60521
OD1	ASP 1	65		-1.811		-12.31		14.284	
OD1	ASP 2	78		-2.629		-12.15		15.593	
OD2	ASP 3	68		-1.583		-12.75		16.533	
OD2	ASP 4	59		-2.534		-12.5		15.835	
OD1	ASP 6	60		-2.109		-11.85		15.924	
OD1	ASP 7	64		-2.151		-12.8		14.21	
OD2	ASP 8	58		-2.841		-11.82		15.085	
OD1	ASP 9	70		-2.628		-12.13		15.425	
OD1	ASN10	87		-1.218		-12.17		15.492	

OD1	ASP11	60	-1.044	-12.57	15.088
A20	ACC	20	-2.055	-12.31	0.344913
O	ASN 1	90	-0.231	-1.804	8.763
O	ASN 2	106	-0.349	-1.37	8.814
O	ASN 3	95	0.522	-1.353	8.638
O	ASN 4	86	0.101	-1.425	8.863
O	ALA 5	62	-1.699	-2.266	8.014
O	ASN 6	83	-0.206	-1.697	9.086
O	ALA 7	94	-2.052	-2.486	7.753
O	PHE 8	80	-1.247	-1.892	9.217
O	ASN 9	101	-0.131	-1.52	8.833
O	ASN10	114	0.159	-1.576	9.032
O	ASN11	87	-0.643	-1.744	9.231
O	VAL12	82	-2.283	-1.889	7.62
A24	ACC	24	-0.672	-1.76	0.344669
O	GLY 1	141	2.663	5.67	8.586
O	SER 2	157	2.57	5.524	10.215
O	THR 3	145	2.691	4.785	10.423
O	ILE 4	141	3.141	4.744	10.048
O	GLY 5	106	2.669	4.9	10.086
O	SER 6	135	2.664	4.979	10.231
O	ASP 7	148	2.413	6.773	9.962
O	SER 8	123	3.033	5.584	9.704
O	SER 9	157	2.652	5.344	10.012
O	GLY10	163	3.026	4.753	10.51
O	SER11	138	2.901	4.576	10.07
O	GLY12	132	3.503	4.256	10.366
A32	ACC	32	2.8272	0.30273	5.1573
OG	SER 1	142	1.908	7.501	10.018
OG	SER 2	158	1.217	8.135	12.689
OG	SER 3	146	1.984	7.724	13.294
					13.283
					0.5546
					0.502

OGGETTO: 44460

OG	SER 4	142	2.278	7.462	12.615
OG	SER 5	107	1.06	7.551	13.088
OG	SER 8	124	2.726	8.12	13.565
OG	SER 9	158	1.901	8.072	13.351
OG	SER10	164	1.664	7.735	13.227
OG	SER11	139	1.857	7.578	13.136
A34	ACC	34	9 1.8439 0.50418	7.7642 0.274322	13.139 0.30794
OH	TYR 1	155	-0.171	5.291	14.251
OH	TYR 2	171	-0.291	4.635	13.936
OH	TYR 3	159	0.016	5.509	14.332
OH	TYR 4	155	0.03	4.468	13.891
OH	TYR 5	136	-0.098	3.379	13.966
OH	TYR 6	149	-0.376	4.379	13.778
OH	TYR 8	149	0.166	4.681	13.768
OH	TYR 9	171	-0.28	4.756	13.633
OH	TYR10	178	-0.441	4.469	14.27
OH	TYR11	152	-0.176	4.772	13.685
OH	TYR12	146	0.376	5.384	13.961
A36	ACC	36	12 -0.113 0.24453	4.7021 0.586493	13.952 0.24008
O	CYS 1	185	1.067	9.484	9.076
O	PRO 2	201	0.576	10.012	9.398
O	PRO 3	189	0.411	9.713	9.099
O	SER 4	184	1.319	9.083	8.553
O	PRO 5	163	2.198	10.158	9.311
O	PRO 6	179	0.756	9.916	10.316
O	ALA 7	191	0.898	10.562	9.433
O	TYR 8	177	1.702	10.131	9.844
O	PRO10	208	1.679	9.684	9.536
O	PRO11	182	0.511	9.318	9.88
O	PRO12	178	2.617	9.331	9.856
A38	ACC	38	11 1.2485 0.72569	9.7529 0.441462	9.482 0.48385

Donors

OD2	ASP 4	36	-5.98	-7.048	7.173
OG1	THR 6	38	-6.172	-8.219	7.479
OD2	ASP11	37	-6.23	-6.97	7.91
OD2	ASP12	37	-6.865	-6.862	7.812
A68	ACC	68	-6.27	-7.233	7.5474
		5	0.3454	0.556879	0.30836

Donors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
OG	SER 1	11		-9.556		-5.885		8.172	
OG	SER 2	30		-9.127		-6.766		7.066	
NE	ARG 4	41		-11.43		-6.012		8.513	
OG	SER 8	36		-9.85		-6.053		8.039	
OG	SER 9	17		-8.437		-6.835		7.057	
OG	SER10	63		-10.95		-7.408		8.89	
D5	DON	5	6	-9.892	1.12248	-6.493	0.603878	7.9562	0.75319
N	SER 1	12		-9.161		-3.738		5.795	
N	LYS 2	31		-9.063		-3.703		5.456	
N	ALA 3	21		-8.29		-4.331		5.081	
N	SER 4	15		-8.15		-3.721		5.342	
N	GLY 5	13		-7.45		-3.226		6.074	
N	LYS 6	17		-8.395		-4.321		5.731	
N	ILE 7	16		-9.025		-4.226		5.612	
N	GLY 8	10		-7.76		-3.367		5.536	
N	ARG 9	18		-8.859		-3.975		5.692	
N	ARG10	39		-8.674		-4.044		4.836	
N	ARG11	16		-8.652		-3.889		5.427	
N	GLY12	16		-8.476		-3.851		6.412	
D6	DON	6	12	-8.496	0.5257	-3.866	0.346377	5.5828	0.41764
OG	SER 1	12		-9.666		-1.96		8.113	
OG	SER 4	15		-9.653		-1.726		7.9	

D7	DON	7	2	-9.66	0.00919	-1.843	0.165463	8.0065	0.15061
N	GLY 1	13		-8.789		-0.1		5.426	
N	GLY 2	32		-9.284		-0.05		5.677	
N	GLY 3	22		-8.761		-0.722		5.167	
N	GLY 4	16		-8.685		-0.121		5.731	
N	MET 5	14		-7.572		0.427		6.428	
N	GLY 6	18		-8.768		-0.685		5.543	
N	SER 7	20		-9.948		1.364		5.27	
N	TYR 8	11		-8.49		0.13		6.189	
N	GLY 9	19		-9.129		-0.325		6.034	
N	GLY10	40		-8.828		-0.408		5.459	
N	GLY11	17		-8.878		-0.198		5.546	
N	ALA12	17		-8.931		-0.155		6.586	
D8	DON	8	12	-8.839	0.5466	-0.07	0.552142	5.7547	0.45545
N	ILE 1	14		-5.584		1.406		4.565	
N	ILE 2	33		-6.262		1.734		5.106	
N	ILE 3	23		-6.008		1.568		4.583	
N	LEU 4	17		-5.882		1.991		5.224	
N	VAL 5	15		-5.284		1.794		5.226	
N	ILE 6	19		-5.843		1.286		4.804	
N	ILE 7	21		-6.436		2.018		4.734	
N	ILE 8	12		-6.417		2.039		4.837	
N	PHE 9	20		-6.214		1.631		5.229	
N	ILE10	41		-5.852		1.601		5.016	
N	LEU11	18		-6.037		1.845		5.008	
N	LEU12	18		-6.861		1.117		4.636	
D9	DON	9	12	-6.057	0.41875	1.6692	0.293883	4.914	0.25367
N	LEU 1	36		-4.861		-11.14		5.491	
N	SER 2	52		-5.654		-10.93		6.923	
N	ASP 3	42		-4.048		-10.76		6.515	
N	ASP 4	36		-3.888		-11		6.574	

Report of the Analysis

N	THR 6	38	-3.943	-10.92		6.379
N	PHE 7	41	-6.508	-10.95		7.546
N	ALA 9	42	-4.253	-10.74		6.218
N	TYR10	60	-4.488	-11.11		5.821
N	ASP11	37	-4.55	-10.8		6.546
N	ASP12	37	-5.596	-11.16		7.002
D11	DON	11	-4.779	0.8737	0.15485	0.58747
N	VAL 1	66	0.188	-10.95	6.5015	12.02
N	LEU 2	79	-0.75	-11.93		12.873
N	ILE 3	69	0.555	-10.96		12.368
N	VAL 4	60	0.173	-11.26		12.105
N	LEU 6	61	-0.617	-11.88		13.014
N	VAL 7	65	-0.2	-12.11		11.698
N	ILE 8	59	0.203	-11.54		11.611
N	VAL10	88	0.182	-11.52		12.416
N	VAL11	61	0.252	-11.53		11.99
OH	TYR12	12	0.481	-11.87		9.718
D21	DON	21	0.0467	0.43511	0.342553	0.91633
OG	SER 1	142	1.908	7.501	11.981	12.689
OG	SER 2	158	1.217	8.135		13.294
OG	SER 3	146	1.984	7.724		13.283
OG	SER 4	142	2.278	7.462		12.615
OG	SER 5	107	1.06	7.551		13.088
OG	SER 8	124	2.726	8.12		13.565
OG	SER 9	158	1.901	8.072		13.351
OG	SER10	164	1.664	7.735		13.227
OG	SER11	139	1.857	7.578		13.136
D34	DON	34	1.8439	0.50418	0.274322	0.30794
OH	TYR 1	155	-0.171	5.291	13.139	14.251
OH	TYR 2	171	-0.291	4.635		13.936
OH	TYR 3	159	0.016	5.509		14.332

OH	TYR 4	155	0.03	4.458	13.891
OH	TYR 5	136	-0.098	3.379	13.966
OH	TYR 6	149	-0.376	4.379	13.778
OH	TYR 8	149	0.166	4.631	13.768
OH	TYR 9	171	-0.28	4.756	13.633
OH	TYR10	178	-0.441	4.459	14.27
OH	TYR11	152	-0.176	4.772	13.685
OH	TYR12	146	0.376	5.384	13.961
D38	DON	38	11	-0.113 0.24453 4.7021 0.586493	0.24008 13.952
NZ	LYS 1	159	2.273	1.347	12.922
NZ	LYS 2	175	2.774	1.885	12.501

136

136

molecule #	pdb	type	rmsd from family avg.
1	2CAH	catalyse(Proteus Mirabilis)	0.18
2	8CAT	catalyse (cow)	0.18

atom name	residue- mol. #	total	x	ox	y	oy	z	oz
A3 (D4)	ACC	2	-1.117	0.36133	-3.964	0.13435	-3.882	0.27082
A6 (D7)	ACC	2	-10.03	0.10889	-5.617	0.029698	1.223	0.1895
A17	ACC	2	5.454	0.08697	2.473	0.195161	-0.056	0.58973
A19 (D30)	ACC	2	3.405	0.48366	1.421	0.065761	4.934	0.05586
A21	ACC	2	1.11	0.65478	-7.271	0.181726	-2.784	0.39527
A35	ACC	2	3.372		-7.545		0.205	

atom name	residue- mol. #	total	x	ox	y	oy	z	oz
D4 (A3)	DON	2	-1.117	0.36133	-3.964	0.13435	-3.882	0.27082
D7 (A6)	DON	2	-10.03	0.10889	-5.617	0.029698	1.223	0.1895
D10	DON	2	-6.918	0.49215	-1.253	0.286378	7	0.28284
D11	DON	2	-6.419	0.19163	0.023	0.147078	5.184	0.18173
D14	DON	2	-6.153		3.824		6.584	
D21	DON	2	-2.402		4.522		6.578	
D22	DON	2	-2.704	0.0997	4.738	0.703571	9.015	0.19658
D26	DON	2	4.609	0.02758	2.264	0.350018	-2.894	0.51831
D30 (A19)	DON	2	3.405	0.48366	1.421	0.065761	4.934	0.05586

Table 6C: NAD(P) Conformer Model

atom name	number	x	ox	y	oy	z	oz
PA	2	2.91	0.04	-2.21	0.03	5.65	0.05
O1A	2	2.72	0.06	-3.30	0.15	6.64	0.05
O2A	2	3.84	0.02	-1.14	0.13	6.03	0.21
O5'A	2	1.43	0.11	-1.58	0.12	5.49	0.10
C5'A	2	0.37	0.04	-2.46	0.22	4.99	0.04
C4'A	2	-0.65	0.05	-1.65	0.13	4.29	0.00
O4'A	2	-1.84	0.18	-2.41	0.04	4.08	0.03
C3'A	2	-1.09	0.10	-0.66	0.26	5.21	0.33
O3'A	2	-0.77	0.41	0.64	0.09	5.13	0.06
C2'A	2	-2.37	0.16	-1.05	0.21	5.80	0.03
O2'A	2	-3.24	0.42	0.04	0.54	6.17	0.19
C1'A	2	-3.00	0.12	-1.63	0.23	4.60	0.08
N9A	2	-4.14	0.04	-2.49	0.13	4.54	0.09
C8A	2	-4.58	0.08	-3.42	0.00	5.41	0.04
N7A	2	-5.62	0.12	-4.11	0.07	5.01	0.00
C5A	2	-5.86	0.04	-3.62	0.02	3.74	0.06
C6A	2	-6.85	0.05	-3.94	0.05	2.77	0.07
N6A	2	-7.79	0.12	-4.87	0.11	2.95	0.01
N1A	2	-6.82	0.06	-3.25	0.04	1.61	0.11
C2A	2	-5.88	0.13	-2.29	0.16	1.45	0.15
N3A	2	-4.93	0.16	-1.91	0.18	2.28	0.15
C4A	2	-4.98	0.06	-2.62	0.08	3.43	0.10
O3	2	3.16	0.09	-2.77	0.20	4.19	0.05
PN	2	4.13	0.03	-2.43	0.03	3.00	0.01
O1N	2	5.29	0.18	-3.36	0.17	3.00	0.07
O2N	2	4.47	0.33	-1.02	0.09	2.89	0.03
O5'N	2	3.25	0.11	-2.85	0.18	1.72	0.04
C5'N	2	2.89	0.14	-4.22	0.12	1.54	0.19
C4'N	2	1.52	0.19	-4.31	0.05	0.90	0.20

Table 6D: Polypeptide and Solvent Interactors

Acc ptors									
atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
NE2	HIS 1	173		-1.37		-4.06		-3.69	
NE2	HIS 2	193		-0.86		-3.87		-4.07	
A3	ACC	3	2	-1.12	0.36	-3.96	0.13	-3.88	0.27
OG	SER 1	180		-10.10		-5.60		1.09	
OG	SER 2	200		-9.95		-5.64		1.36	
A6	ACC	6	2	-10.03	0.11	-5.62	0.03	1.22	0.19
O	TRP 1	282		5.52		2.34		-0.47	
O	TRP 2	302		5.39		2.61		0.36	
A17	ACC	17	2	5.45	0.09	2.47	0.20	-0.06	0.59
ND1	HIS 1	284		3.06		1.47		4.97	
ND1	HIS 2	304		3.75		1.38		4.89	
A19	ACC	19	2	3.41	0.48	1.42	0.07	4.93	0.06
O	GLN 1	421		0.65		-7.40		-2.50	
O	GLN 2	441		1.57		-7.14		-3.06	
A21	ACC	21	2	1.11	0.65	-7.27	0.18	-2.78	0.40
OG1	THR 2	444		3.37		-7.55		0.21	
A35	ACC	35	2	3.37		-7.55		0.21	
Donors									
atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
NE2	HIS 1	173		-1.37		-4.06		-3.69	
NE2	HIS 2	193		-0.86		-3.87		-4.07	
D4	DON	4	2	-1.12	0.36	-3.96	0.13	-3.88	0.27
OG	SER 1	180		-10.10		-5.60		1.09	
OG	SER 2	200		-9.95		-5.64		1.36	

Q333T¹ H₂T₂45Q

D7	DON	7	2	-10.03	0.11	-5.62	0.03	1.22	0.19
NH1	ARG 1	182		-7.27		-1.05		6.80	
NH1	ARG 2	202		-6.57		-1.46		7.20	
D10	DON	10	2	-6.92	0.49	-1.25	0.29	7.00	0.28
NH2	ARG 1	182		-6.28		0.13		5.06	
NH2	ARG 2	202		-6.56		-0.08		5.31	
D11	DON	11	2	-6.42	0.19	0.02	0.15	5.18	0.18
NE2	HIS 1	192		-6.15		3.82		6.58	
D14	DON	14	2	-6.15		3.82		6.58	
NH1	ARG 1	216		-2.40		4.52		6.58	
D21	DON	21	2	-2.40		4.52		6.58	
NH2	ARG 1	216		-2.78		4.24		8.88	
NZ	LYS 2	236		-2.63		5.24		9.15	
D22	DON	22	2	-2.70	0.10	4.74	0.70	9.02	0.20
N	TRP 1	282		4.59		2.02		-3.26	
N	TRP 2	302		4.63		2.51		-2.53	
D26	DON	26	2	4.61	0.03	2.26	0.35	-2.89	0.52
ND1	HIS 1	284		3.06		1.47		4.97	
ND1	HIS 2	304		3.75		1.38		4.89	
D30	DON	30	2	3.41	0.48	1.42	0.07	4.93	0.06
NE2	GLN 2	281		3.91		6.03		0.45	
D42	DON	42	2	3.91		6.03		0.45	

Waters										
atom name	residue- mol. #	residue #	total	x	σx	y	σy	z	σz	
O	HOH 1	10		2.76		3.79		-1.73		
W1	WAT	1	2	2.76		3.79		-1.73		
O	HOH 1	12		7.57		-1.98		4.12		
W3	WAT	3	2	7.57		-1.98		4.12		
e 7A: Pharmacofamily 5 Subset										
molecule #	pdb	type		RMSD from Family Avg.						
1	1A80	2,5-Diketo-D- Gluconic Acid Reductase (Cornybacterium		0.21						
2	1AFS	3-a-Hydroxysteroid Dehydrogenase (rat)		0.66						
3	1FRB	Aldo-Keto Reductase (mouse)		0.55						
4	1ADS	Aldose Reductase (human)		0.55						
5	1AH0	Aldose Reductase (pig)		0.56						

Table 7B: Polypeptide and Solvent Interactors (average coordinates)
Acceptors

atom name	residue- mol. #	total	x	ox	y	oy	z	oz
A3	ACC	5	-0.31	0.38	8.08	0.84	-3.93	0.51
A5	ACC	5	-7.54	0.31	10.00	0.16	0.36	0.24
A8 (D6)	ACC	5	-3.86	0.33	10.11	0.12	2.13	0.21
A11 (D11)	ACC	5	-3.42	0.36	10.75	0.31	6.12	0.36
A14 (D15)	ACC	5	-7.65	0.42	8.35	0.28	7.93	0.19
A18	ACC	5	-8.07	0.25	7.90	0.12	3.55	0.09
A32 (D35)	ACC	5	-3.37	0.49	3.38	0.29	-11.88	0.27
A37	ACC	5	-6.70	0.49	-3.63	0.36	-15.32	0.27
A38	ACC	5	-7.25	0.30	-4.35	0.17	-13.39	0.20
A40	ACC	4	-8.26	0.22	-0.78	0.09	-10.85	0.30
A42 (D21)	ACC	4	-4.11	0.29	3.97	0.06	7.45	0.05
A43 (D49)	ACC	4	-3.07	0.46	1.57	0.40	1.87	0.38
A55 (D65)	ACC	3	0.11	0.37	1.56	0.18	-0.35	0.22
A58	ACC	3	1.32	0.18	2.39	0.11	-4.18	0.31
A59	ACC	3	1.96	0.22	4.01	0.11	-5.47	0.31

residue-
mol. #

atom name	residue- mol. #	total	x	ox	y	oy	z	oz
D2	DON	5	-4.83	0.41	9.93	0.42	-4.13	0.06
D3	DON	5	-2.29	0.33	9.76	0.48	-2.96	0.18
D6 (A8)	DON	5	-3.86	0.33	10.11	0.12	2.13	0.21
D11 (A11)	DON	5	-3.42	0.36	10.75	0.31	6.12	0.36
D15 (A14)	DON	5	-7.65	0.42	8.35	0.28	7.93	0.19
D17	DON	5	-4.88	0.29	7.13	0.34	9.26	0.08
D21 (A42)	DON	5	-4.42	0.74	4.02	0.11	7.28	0.39
D22	DON	5	-5.81	0.30	1.79	0.28	0.94	0.10
D24	DON	5	-5.85	0.17	-2.29	0.15	-2.39	0.10
D26	DON	5	-1.59	0.17	-1.52	0.26	-1.17	0.14
D27	DON	1	-0.90	-	2.47	-	1.79	-
D32	DON	5	-5.76	0.30	3.99	0.12	-5.84	0.34
D35 (A32)	DON	5	-3.37	0.49	3.38	0.29	-11.88	0.27
D36	DON	5	-1.89	0.69	6.00	0.37	-11.25	0.14
D43	DON	5	0.35	0.44	0.04	0.54	-12.44	0.04
D47	DON	4	-7.47	0.24	1.06	0.13	-9.91	0.26
D49 (A43)	DON	4	-3.07	0.46	1.67	0.40	1.87	0.38
D64	DON	3	0.37	0.27	4.92	0.07	-3.02	0.15
D65 (A55)	DON	3	0.11	0.37	1.66	0.18	-0.35	0.22

residue-
mol. #

atom name	residue- mol. #	total	x	σ_x	y	σ_y	z	σ_z
W1	WAT	4	0.62	0.21	-3.17	0.55	-8.81	0.66
W9	WAT	4	2.90	0.30	3.03	0.33	-8.84	0.37

Table 7C: NAD(P) Conformer Model

atom name	total	x	ox	y	oy	z	oz
PA	5	-3.59	0.07	1.15	0.06	-3.16	0.09
O1A	5	-3.91	0.07	-0.06	0.08	-2.37	0.06
O2A	5	-4.70	0.10	1.87	0.11	-3.82	0.09
O5'A	5	-2.52	0.10	0.72	0.06	-4.25	0.09
C5'A	5	-1.97	0.11	1.62	0.06	-5.21	0.09
C4'A	5	-1.00	0.13	0.82	0.07	-6.06	0.07
O4'A	5	-1.74	0.17	-0.16	0.08	-6.80	0.06
C3'A	5	-0.24	0.20	1.65	0.08	-7.07	0.11
O3'A	5	1.09	0.17	1.16	0.21	-7.14	0.19
C2'A	5	-0.96	0.21	1.42	0.12	-8.38	0.08
O2'A	5	-0.03	0.25	1.44	0.24	-9.46	0.12
C1'A	5	-1.49	0.16	0.01	0.09	-8.20	0.07
N9A	5	-2.74	0.16	-0.23	0.11	-8.94	0.08
C8A	5	-3.87	0.15	0.51	0.05	-9.04	0.13
N7A	5	-4.77	0.16	-0.07	0.05	-9.80	0.19
C5A	5	-4.20	0.14	-1.23	0.09	-10.20	0.13
C6A	5	-4.67	0.20	-2.26	0.14	-11.02	0.14
N6A	5	-5.88	0.24	-2.27	0.19	-11.55	0.20
N1A	5	-3.84	0.23	-3.30	0.17	-11.24	0.14
C2A	5	-2.64	0.22	-3.33	0.19	-10.69	0.18
N3A	5	-2.13	0.23	-2.39	0.17	-9.90	0.15
C4A	5	-2.94	0.14	-1.35	0.12	-9.67	0.08
O3	5	-2.67	0.10	2.02	0.11	-2.19	0.13
PN	5	-2.64	0.33	3.48	0.09	-1.61	0.18
O2N	5	-1.78	0.43	3.39	0.25	-0.42	0.27
O1N	5	-2.28	0.39	4.43	0.23	-2.64	0.37
O5'N	5	-4.08	0.45	3.75	0.33	-1.10	0.12
C5'N	5	-5.08	0.40	4.38	0.23	-1.89	0.10
C4'N	5	-5.43	0.23	5.74	0.13	-1.36	0.03

O4'N	5	-5.93	0.16	5.65	0.12	-0.02	0.04
C3'N	5	-4.26	0.18	6.68	0.23	-1.23	0.10
O3'N	5	-3.85	0.24	7.22	0.37	-2.47	0.14
C2'N	5	-4.83	0.19	7.72	0.11	-0.32	0.12
O2'N	5	-5.69	0.24	8.58	0.11	-1.05	0.14
C1'N	5	-5.61	0.09	6.86	0.10	0.66	0.03
N1N	5	-4.82	0.08	6.56	0.06	1.86	0.06
C2N	5	-5.21	0.09	7.16	0.08	3.04	0.07
C3N	5	-4.46	0.11	6.94	0.05	4.21	0.09
C7N	5	-4.88	0.17	7.54	0.12	5.51	0.09
O7N	5	-4.17	0.19	7.45	0.25	6.50	0.12
N7N	5	-6.04	0.21	8.19	0.19	5.56	0.07
C4N	5	-3.34	0.13	6.14	0.07	4.16	0.09
C5N	5	-2.95	0.14	5.55	0.14	2.98	0.11
C6N	5	-3.70	0.10	5.76	0.14	1.84	0.10
P2'	5	-0.06	0.34	2.60	0.41	-10.53	0.12
OP1	5	-0.57	0.66	3.20	0.94	-10.55	0.97
OP2	5	0.89	1.15	2.72	0.92	-10.83	0.65
OP3	5	-0.55	0.81	2.71	0.77	-11.09	0.69

Tabl 7D: Polypeptide and Solvent Interactors

Acc ptors	atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
	O	PHE 1	22		-0.22		7.917		-3.902	
	O	THR 2	24		-0.117		9.552		-4.723	
	O	TRP 3	20		-0.078		7.638		-3.451	
	O	TRP 4	20		-0.136		7.449		-3.508	
	O	TRP 5	20		-0.979		7.848		-4.071	
A3		ACC	3	5	-0.306	0.37978	8.0808	0.842719	-3.931	0.51406
OD1		ASP 1	45		-7.465		10.181		0.624	
OD2		ASP 2	50		-7.821		9.947		0.608	
OD2		ASP 3	43		-7.26		10.05		0.226	
OD2		ASP 4	43		-7.257		10.064		0.178	
OD2		ASP 5	43		-7.906		9.75		0.15	
A5		ACC	5	5	-7.542	0.30701	9.9984	0.161751	0.3572	0.23788
OH		TYR 1	50		-3.489		9.992		2.109	
OH		TYR 2	55		-4.193		10.25		2.441	
OH		TYR 3	48		-3.749		9.978		2.218	
OH		TYR 4	48		-3.652		10.133		1.976	
OH		TYR 5	48		-4.239		10.209		1.899	
A8		ACC	8	5	-3.864	0.33454	10.112	0.123743	2.1286	0.21329
NE2		HIS 1	108		-3.007		10.311		6.445	
NE2		HIS 2	117		-3.912		10.677		6.566	
NE2		HIS 3	110		-3.39		11.167		5.845	
NE2		HIS 4	110		-3.153		10.889		5.871	
NE2		HIS 5	110		-3.636		10.73		5.849	
A11		ACC	11	5	-3.42	0.36451	10.755	0.312868	6.1152	0.35899
OG		SER 1	139		-7.14		8.138		8.261	
OG		SER 2	166		-8.27		7.971		7.92	
OG		SER 3	159		-7.772		8.621		7.778	

151

A40	ACC	40	4	-8.259	0.22491	-0.783	0.086815	-10.85	0.30469
OH	TYR 2	216		-4.48		3.904		7.523	
OH	TYR 3	209		-4.079		3.966		7.44	
OH	TYR 4	209		-4.093		4.039		7.418	
OH	TYR 5	209		-3.784		3.971		7.417	
A42	ACC	42	4	-4.109	0.28544	3.97	0.055178	7.4495	0.05014
SG	CYS 2	217		-2.381		1.081		2.263	
OG	SER 3	210		-3.198		1.802		1.827	
OG	SER 4	210		-3.328		1.843		2.013	
OG	SER 5	210		-3.366		1.953		1.365	
A43	ACC	43	4	-3.068	0.46378	1.6698	0.397644	1.867	0.37936
OG	SER 3	214		0.302		1.569		-0.171	
OG	SER 4	214		0.348		1.533		-0.286	
OG	SER 5	214		-0.31		1.864		-0.589	
A55	ACC	55	3	0.1133	0.36734	1.6553	0.181605	-0.349	0.21593
OD1	ASP 3	216		1.445		2.279		-4.029	
OD1	ASP 4	216		1.393		2.409		-3.965	
OD1	ASP 5	216		1.107		2.494		-4.537	
A58	ACC	58	3	1.315	0.182	2.394	0.108282	-4.177	0.31341
OD2	ASP 3	216		2.06		3.9		-5.346	
OD2	ASP 4	216		2.112		3.991		-5.233	
OD2	ASP 5	216		1.712		4.127		-5.826	
A59	ACC	59	3	1.9613	0.21749	4.006	0.114241	-5.468	0.31486

Donors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
N	VAL 1	21		-4.573		10.277		-4.214	
N	THR 2	23		-4.955		10.482		-4.051	
N	THR 3	19		-4.601		9.587		-4.125	
N	THR 4	19		-4.539		9.637		-4.107	
N	THR 5	19		-5.495		9.654		-4.137	
D2	DON	2	5	-4.833	0.40651	9.9274	0.419748	-4.127	0.05884
N	PHE 1	22		-2.163		9.689		-2.98	
N	THR 2	24		-2.234		10.595		-3.208	
N	TRP 3	20		-2.126		9.537		-2.765	
N	TRP 4	20		-2.061		9.403		-2.815	
N	TRP 5	20		-2.861		9.571		-3.033	
D3	DON	3	5	-2.289	0.32582	9.759	0.47832	-2.96	0.17768
OH	TYR 1	50		-3.489		9.992		2.109	
OH	TYR 2	55		-4.193		10.25		2.441	
OH	TYR 3	48		-3.749		9.978		2.218	
OH	TYR 4	48		-3.652		10.133		1.976	
OH	TYR 5	48		-4.239		10.209		1.899	
D6	DON	6	5	-3.864	0.33454	10.112	0.123743	2.1286	0.21329
NE2	HIS 1	108		-3.007		10.311		6.445	
NE2	HIS 2	117		-3.912		10.677		6.566	
NE2	HIS 3	110		-3.39		11.167		5.845	
NE2	HIS 4	110		-3.153		10.389		5.871	
NE2	HIS 5	110		-3.636		10.73		5.849	
D11	DON	11	5	-3.42	0.36451	10.755	0.312868	6.1152	0.35899
OG	SER 1	139		-7.14		8.138		8.261	
OG	SER 2	166		-8.27		7.971		7.92	
OG	SER 3	159		-7.772		8.621		7.778	
OG	SER 4	159		-7.65		8.495		7.82	

[illegible]

THE **NEW** **YORK** **PUBLIC** **LIBRARY**

OH	TYR 4	209	-4.093	4.039	7.418
OH	TYR 5	209	-3.784	3.971	7.417
DD21	DON	21	-4.419	0.73594	4.0154
N	GLY 1	188	-5.543	1.806	1.07
N	CYS 2	217	-5.457	1.307	0.834
N	SER 3	210	-5.913	2.008	0.883
N	SER 4	210	-5.995	1.926	1.01
N	SER 5	210	-6.138	1.889	0.879
DD22	DON	22	-5.809	0.29509	1.7872
N	LEU 1	190	-6.122	-2.167	-2.319
N	LEU 2	219	-5.697	-2.431	-2.521
N	LEU 3	212	-5.848	-2.116	-2.486
N	LEU 4	212	-5.837	-2.313	-2.318
N	LEU 5	212	-5.738	-2.444	-2.315
DD24	DON	24	-5.848	0.1659	-2.294
N	GLN 1	192	-1.835	-1.942	-1.288
N	SER 2	221	-1.633	-1.501	-0.943
N	SER 3	214	-1.557	-1.387	-1.269
N	SER 4	214	-1.543	-1.524	-1.135
N	SER 5	214	-1.368	-1.233	-1.228
DD26	DON	26	-1.587	0.16913	-1.517
NE2	GLN 1	192	-0.903	2.473	1.785
DD27	DON	27	-0.903	2.473	1.785
N	LYS 1	232	-5.402	4.166	-6.054
N	ARG 2	270	-5.952	3.855	-6.343
N	LYS 3	262	-5.685	4.007	-5.639
N	LYS 4	262	-5.623	3.992	-5.582
N	LYS 5	262	-6.162	3.913	-5.584
DD32	DON	32	-5.765	0.29619	3.9866
OG	SER 1	233	-2.688	3.039	-11.94
OG	SER 2	271	-3.273	3.123	-12.31

[illegible]

OG	SER 3	263	-3.404	3.664		-11.79
OG	SER 4	263	-3.447	3.654		-11.8
OG	SER 5	263	-4.061	3.397		-11.59
D35	DON	35	-3.375	0.48964	3.3754	0.290794
N	VAL 1	234	-1.14	5.556		-11.43
N	PHE 2	272	-1.614	5.656		-11.37
N	VAL 3	264	-1.81	6.206		-11.19
N	VAL 4	264	-1.882	6.219		-11.12
N	VAL 5	264	-3.012	6.373		-11.15
D36	DON	36	-1.892	0.68993	6.002	0.369113
NH1	ARG 1	238	0.069	-0.686		-12
NH2	ARG 2	276	1.098	0.722		-13.92
NH1	ARG 3	268	0.415	0.209		-12.73
NH1	ARG 4	268	0.039	-0.27		-11.5
NH2	ARG 5	268	0.142	0.24		-12.05
D43	DON	43	0.3526	0.44234	0.043	0.537777
ND2	ASN 1	242	-7.301	0.978		-10.22
ND2	ASN 3	272	-7.385	1.094		-9.791
ND2	ASN 4	272	-7.367	1.218		-10.01
ND2	ASN 5	272	-7.832	0.939		-9.618
D47	DON	47	-7.471	0.2432	1.0573	0.125771
SG	CYS 2	217	-2.381	1.081		2.263
OG	SER 3	210	-3.198	1.802		1.827
OG	SER 4	210	-3.328	1.843		2.013
OG	SER 5	210	-3.366	1.953		1.365
D49	DON	49	-3.068	0.46378	1.6698	0.397644
NZ	LYS 3	21	0.563	4.894		-2.898
NZ	LYS 4	21	0.487	4.857		-2.975
NZ	LYS 5	21	0.06	4.999		-3.187
D64	DON	64	0.37	0.27114	4.9167	0.073664
OG	SER 3	214	0.302	1.569		-0.171
						-3.02
						0.14966

THE FUTURE

OG	SER 4	214	0.348	1.533	-0.286
OG	SER 5	214	-0.31	1.864	-0.589
D65	DON	65	3	0.1133 0.36734 1.6553	0.181605 -0.349 0.21593

Waters

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	σz
O	HOH 1	396		3.263		2.796		-9.047	
O	HOH 3	536		3.02		2.698		-8.645	
O	HOH 4	484		2.686		3.261		-8.435	
O	HOH 5	586		2.613		3.35		-9.237	
W9	WAT	9	4	2.895	0.30235	3.026	0.326948	-8.841	0.36629
O	HOH 1	307		0.306		-3.84		-7.869	
O	HOH 3	731		0.694		-3.294		-8.887	
O	HOH 4	485		0.782		-3.008		-9.378	
O	HOH 5	483		0.686		-2.519		-9.123	
W1	WAT	1	4	0.617	0.21185	-3.165	0.552036	-8.814	0.66129

Table 8A: Pharmacofamily 6 Subset

Molecule #	pdb	type	RMSD from Family Avg.
1	1AI9	Dihydrofolate Reductase (candida albicans)	0.49
2	1DAJ	DHFR (pneumocystis carinii)	0.8
3	1DLR	DHFR (human)	0.6
4	1DR1	DHFR (chicken)	0.83
5	1DRE	DHFR (E. coli)	0.91
6	3DFR	DHFR (Lactobacillus casei)	0.84

Table 8B: Polypeptide and Solvent Interactors (average coordinates)

Acceptors								
atom name	Name	total	x	σx	y	σy	z	σz
A2	ACC	6	-7.76	0.34	9.50	0.60	15.24	0.31
A3	ACC	6	-3.33	0.36	9.00	0.28	13.41	0.29
A7	ACC	6	4.38	0.42	8.51	0.59	14.79	0.44
A8	ACC	5	0.64	0.44	10.67	0.55	12.99	0.29
A22	ACC	5	1.78	0.52	-12.11	0.61	17.27	0.35
A29	ACC	3	1.38	0.22	-3.65	0.98	10.30	0.42
A45 (D53)	ACC	5	7.52	0.32	-6.82	0.15	17.60	0.52
A64	ACC	1	3.88		7.64		10.73	
Donors								
atom name	Name	total	x	σx	y	σy	z	σz
D2	DON	6	-8.77	0.24	8.47	0.48	17.58	0.39
D5	DON	6	0.31	0.46	10.32	0.28	10.41	0.31
D7	DON	6	4.49	0.64	8.48	0.37	11.28	0.47
D8	DON	6	3.29	0.49	9.75	0.37	13.31	0.28

D10	DON	6	0.75	0.68	11.75	0.20	14.90	0.31
D13	DON	6	0.42	0.31	-1.68	0.29	18.99	0.21
D14	DON	6	3.77	0.31	-2.26	0.30	17.84	0.28
D15	DON	3	9.09	0.30	-3.80	0.34	14.68	0.76
D18	DON	6	4.89	0.37	0.01	0.38	16.50	0.32
D19	DON	3	5.76	0.34	-0.45	1.23	11.73	0.54
D20	DON	6	3.21	0.48	2.15	0.27	17.41	0.31
D24	DON	6	8.21	0.50	-9.32	0.64	16.12	0.77
D25	DON	6	5.73	0.39	-9.28	0.30	16.15	0.47
D27	DON	2	4.63	0.21	-8.88	0.26	11.81	0.22
D35	DON	6	-1.87	0.34	0.75	0.49	16.42	0.33
D37	DON	6	-2.91	0.56	-1.48	0.83	11.81	0.33
D38	DON	6	-3.30	0.47	-3.07	0.64	14.06	0.39
D40	DON	5	-6.32	0.26	3.36	0.48	17.78	0.67
D53 (A45)	DON	5	7.52	0.32	-6.82	0.15	17.60	0.52
D58	DON	2	4.59	0.01	4.70	0.53	10.76	0.38

Waters

atom name	Name	total	x	ox	y	oy	z	oz
W5	WAT	3	3.12	0.69	4.35	0.33	10.23	0.39
W7	WAT	3	2.33	0.11	6.97	0.14	10.21	0.07
W9	WAT	2	1.38	0.94	3.27	0.01	9.07	0.57
W10	WAT	3	-2.58	0.27	-11.63	0.89	15.29	0.33

Table 8C: NAD(P) Conformer Model

atom name	total	x	ox	y	oy	z	oz
PA	6	1.05	0.24	-0.17	0.19	14.67	0.19
O1A	6	1.19	0.24	0.64	0.25	15.88	0.23
O2A	6	-0.20	0.24	-0.90	0.28	14.47	0.18
O5'A	6	2.35	0.21	-1.13	0.14	14.56	0.24
C5'A	6	2.40	0.23	-2.23	0.10	13.62	0.23
C4'A	6	3.42	0.23	-3.27	0.14	14.17	0.18
O4'A	6	2.79	0.36	-3.93	0.29	15.07	0.24
C3'A	6	3.64	0.12	-4.36	0.13	13.07	0.19
O3'A	6	4.70	0.13	-3.76	0.25	12.26	0.24
C2'A	6	4.06	0.05	-5.51	0.17	14.00	0.26
O2'A	6	5.31	0.06	-5.32	0.34	14.57	0.28
C1'A	6	3.05	0.11	-5.32	0.22	15.11	0.22
N9A	6	1.81	0.09	-5.96	0.35	14.84	0.21
C8A	6	0.76	0.17	-5.40	0.56	14.27	0.47
N7A	6	-0.27	0.17	-6.16	0.65	14.17	0.44
C5A	6	0.21	0.15	-7.35	0.53	14.68	0.21
C6A	6	-0.44	0.24	-8.68	0.51	14.89	0.32
N6A	6	-1.69	0.28	-8.92	0.67	14.53	0.44
N1A	6	0.29	0.35	-9.56	0.36	15.44	0.49
C2A	6	1.54	0.34	-9.19	0.25	15.79	0.52
N3A	6	2.22	0.25	-8.09	0.22	15.65	0.34
C4A	6	1.45	0.13	-7.18	0.35	15.09	0.07

Table 8D: Polypeptide and Solvent Interactors

Acceptors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
O	ALA 1	11		-8.25		9.15		15.70	
O	ALA 2	12		-7.62		9.56		15.25	
O	ALA 3	9		-7.84		8.91		15.02	
O	ALA 4	9		-8.02		9.04		15.08	
O	ALA 5	7		-7.34		10.51		14.88	
O	ALA 6	6		-7.50		9.83		15.51	
A2	ACC	2	6	-7.76	0.34	9.50	0.60	15.24	0.31
O	ILE 1	19		-3.73		9.16		13.34	
O	ILE 2	19		-3.77		8.82		13.73	
O	ILE 3	16		-3.18		8.72		13.35	
O	ILE 4	16		-3.34		8.72		13.44	
O	ILE 5	14		-2.92		9.18		12.93	
O	ILE 6	13		-3.03		9.39		13.70	
A3	ACC	3	6	-3.33	0.36	9.00	0.28	13.41	0.29
O	GLY 1	23		3.59		8.74		14.29	
O	ASN 2	23		4.73		8.14		14.25	
O	GLY 3	20		4.28		9.37		15.16	
O	GLY 4	20		4.43		8.58		14.84	
O	ASN 5	18		4.63		8.52		15.30	
O	GLY 6	17		4.64		7.52		14.92	
A7	ACC	7	6	4.38	0.42	8.51	0.59	14.79	0.44
O	LYS 1	24		0.01		11.45		12.52	
O	SER 2	24		0.93		11.05		13.09	
O	ASP 3	21		0.38		10.26		13.30	
O	ASN 4	21		0.78		10.18		13.08	
O	ALA 5	19		1.10		10.42		12.96	
A8	ACC	8	5	0.64	0.44	10.67	0.55	12.99	0.29

Donors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
N	ALA 1	11		-9.06		8.04		18.17	
N	ALA 2	12		-8.79		8.01		17.55	
N	ALA 3	9		-8.95				17.22	
N	ALA 4	9		-8.84		8.16		17.46	
N	ALA 5	7		-8.61		9.19		17.17	
N	ALA 6	6		-8.39		8.86		17.88	
D2	DON	2	6	-8.77	0.24	8.45	0.54	17.58	0.39
N	TYR 1	21		-0.42		10.64		9.86	
N	ARG 2	21		0.01		10.40		10.61	
N	LYS 3	18		0.40		10.07		10.57	
N	LYS 4	18		0.32		9.96		10.47	
N	MET 5	16		0.86		10.62		10.25	
N	LYS 6	15		0.70		10.26		10.69	
D5	DON	5	6	0.31	0.46	10.32	0.28	10.41	0.31
N	GLY 1	23		3.65		9.06		10.80	
N	ASN 2	23		4.05		8.21		10.77	
N	GLY 3	20		4.51		8.63		11.63	
N	GLY 4	20		4.53		8.63		11.24	
N	ASN 5	18		5.57		8.31		11.98	
N	GLY 6	17		4.61		8.02		11.26	
D7	DON	7	6	4.49	0.64	8.48	0.37	11.28	0.47
N	LYS 1	24		2.49		10.14		12.86	
N	SER 2	24		3.18		9.36		13.12	
N	ASP 3	21		3.13		10.15		13.47	
N	ASN 4	21		3.34		9.95		13.37	
N	ALA 5	19		3.82		9.57		13.45	
N	HIS 6	18		3.78		9.34		13.62	

COLETT "T" 4460

N	HIS 5	45	4.53	0.07	16.53	
N	ARG 6	44	4.80	-0.19	16.60	
D18	DON	18	4.89	0.37	0.38	0.32
NZ	LYS 1	57	6.03	-1.79	11.41	
NE2	HIS 5	45	5.83	-0.20	12.35	
NE	ARG 6	44	5.42	0.63	11.42	
D19	DON	19	5.76	0.31	1.23	0.54
N	THR 1	58	4.11	1.68	17.55	
N	THR 2	61	3.07	2.49	17.92	
N	THR 3	56	2.93	2.04	17.18	
N	THR 4	56	3.15	2.15	17.06	
N	THR 5	46	2.73	2.26	17.40	
N	THR 6	45	3.30	2.25	17.33	
D20	DON	20	3.21	0.48	0.27	0.31
OG	SER 1	78	7.51	-8.07	16.81	
N	ASN 2	83	7.95	-9.42	16.07	
N	GLU 3	78	8.83	-9.52	15.37	
N	GLU 4	78	8.58	-9.52	15.10	
N	GLN 5	65	7.90	-9.91	16.99	
N	GLN 6	65	8.50	-9.50	16.42	
D24	DON	24	8.21	0.50	0.64	0.77
N	ARG 1	79	5.13	-9.73	15.64	
N	ARG 2	82	5.51	-9.28	16.87	
N	ARG 3	77	6.17	-9.41	16.02	
N	ARG 4	77	6.01	-9.37	15.82	
N	SER 5	64	5.59	-9.07	16.55	
N	HIS 6	64	6.00	-8.86	15.99	
D25	DON	25	5.73	0.39	0.30	0.47
NH1	ARG 1	79	4.49	-8.70	11.66	
NH1	ARG 2	82	4.78	-9.07	11.97	

[illegible]

D27	DON	27	2	4.63	0.21	-8.88	0.26	11.81	0.22
N	GLY 1	114		-1.20		0.66		16.96	
N	GLY 2	125		-2.08		0.99		16.66	
N	GLY 3	117		-2.08		0.12		16.11	
N	GLY 4	117		-2.00		0.26		16.14	
N	GLY 5	96		-1.87		1.30		16.33	
N	GLY 6	99		-1.99		1.20		16.31	
D35	DON	35	6	-1.87	0.34	0.75	0.49	16.42	0.33
N	GLU 1	116		-2.20		-0.54		11.97	
N	GLN 2	127		-2.51		-1.22		12.03	
N	SER 3	119		-3.51		-2.29		11.74	
N	ALA 4	119		-3.63		-2.67		11.96	
N	ARG 5	98		-2.81		-0.91		11.18	
N	GLN 6	101		-2.81		-1.25		12.00	
D37	DON	37	6	-2.91	0.56	-1.48	0.83	11.81	0.33
N	ILE 1	117		-2.58		-2.52		13.89	
N	LEU 2	128		-3.06		-2.83		14.28	
N	VAL 3	120		-3.71		-3.84		14.05	
N	VAL 4	120		-3.83		-3.92		14.47	
N	VAL 5	99		-3.54		-2.56		13.37	
N	ILE 6	102		-3.10		-2.76		14.27	
D38	DON	38	6	-3.30	0.47	-3.07	0.64	14.06	0.39
OH	TYR 1	118		-5.90		3.37		18.74	
OH	TYR 2	129		-6.34		4.00		17.96	
OH	TYR 3	121		-6.27		3.45		17.00	
OH	TYR 4	121		-6.58		3.42		17.85	
OH	TYR 5	100		-6.50		4.59		17.32	
D40	DON	40	5	-6.32	0.26	3.36	0.48	17.78	0.67
OG1	THR 2	81		7.15		-6.59		18.23	
OG	SER 3	76		7.84		-6.95		17.31	

167

OG	SER 4	76	7.83	-6.93	16.92
OG	SER 5	63	7.26	-6.86	17.98
OG1	THR 6	63	7.53	-6.78	17.57
D53	DON	53	7.52	0.32	0.15
NZ	LYS 3	55	4.59	5.07	10.49
NZ	LYS 4	55	4.60	4.32	11.03
D58	DON	58	4.59	0.01	0.53
					0.38

Wat rg

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
O	HOH 1	360		3.79		4.24		10.23	
O	HOH 4	814		2.42		4.72		9.84	
O	HOH 6	302		3.16		4.08		10.62	
W5	WAT	5	3	3.12	0.69	4.35	0.33	10.23	0.39
O	HOH 3	194		2.39		6.87		10.29	
O	HOH 4	220		2.39		7.13		10.16	
O	HOH 6	208		2.21		6.90		10.19	
W7	WAT	7	3	2.33	0.11	6.97	0.14	10.21	0.07
O	HOH 3	238		2.04		3.26		9.48	
O	HOH 6	301		0.72		3.27		8.67	
W9	WAT	9	2	1.38	0.94	3.27	0.01	9.07	0.57
O	HOH 3	255		-2.28		-11.29		15.13	
O	HOH 4	493		-2.82		-10.95		15.67	
O	HOH 6	266		-2.62		-12.63		15.07	
W10	WAT	10	3	-2.58	0.27	-11.63	0.89	15.29	0.33

Table 9A: Pharmacofamily 7 Subset

Mol cule #	pdb	type	rmsd from Family Avg.
1	1GET	Glutathione Reductase (E. coli)	0.34
2	1GRB	Glutathione Reductase (human)	0.66
3	2NPX	NADH Peroxidase (strep faecalis)	0.82
4	1TDF	Thioredoxin Reductase (E. Coli)	0.89
5	1TYP	Trypanothione Reductase (Crithidia fasciculata)	2.17*

*NAD(P) is in an inactive conformation

Table 9B: Polypeptide and Solvent Interactors (average coordinates)

Acc ptors

atom name	residue- mol. #	total	x	ox	y	oy	z	oz
A11	ACC	4	-3.74	0.43	4.39	1.20	14.96	0.59
A12	ACC	2	-4.46	0.14	6.91	0.01	13.10	0.51
A21	ACC	3	-7.67	0.40	-0.28	0.63	6.97	0.49
A27	ACC	5	-6.51	0.79	8.70	0.33	10.16	0.42
A37	ACC	1	9.32	-	1.02	-	6.96	-
A38	ACC	1	8.04	-	2.39	-	7.96	-
A43 (D46)	ACC	1	-1.72	-	2.70	-	6.02	-

Donors

atom name	residue- mol. #	total	x	ox	y	oy	z	oz
D8	DON	5	0.53	0.17	4.12	0.23	9.87	0.65
D10	DON	4	-0.29	0.12	2.72	0.33	12.17	0.28
D13	DON	4	11.13	0.14	-1.28	0.24	5.56	0.39
D14	DON	4	10.96	0.24	-3.44	0.24	4.80	0.45
D15	DON	4	9.51	0.04	-1.85	0.43	4.07	0.31
D18	DON	3	8.97	1.77	3.01	1.32	1.85	0.48
D23	DON	5	2.38	0.54	-3.84	0.13	9.65	0.30
D46 (A43)	DON	1	-1.72	-	2.70	-	6.02	-
D58	DON	1	3.70	-	2.30	-	3.85	-
D62	DON	1	-5.70	-	2.24	-	2.88	-

Waters

atom name	residue- mol. #	total	x	ox	y	oy	z	oz
W2	WAT	3	0.36	0.44	-3.68	0.38	12.46	0.18
W4	WAT	4	2.93	0.16	1.13	0.26	10.91	0.18

W6	WAT	5	-9.38	0.47	6.86	0.35	8.83	0.85
W10	WAT	2	0.45	0.22	3.40	0.19	5.75	0.60
W13	WAT	3	-6.28	0.08	-3.16	0.26	9.68	0.49

Table 9C: NAD(P) Conformer Model

atom name	total	x	ox	y	oy	z	oz
PA	5	0.93	0.13	-0.09	0.32	6.93	0.27
O1A	5	0.14	0.09	1.08	0.42	6.77	0.65
O2A	5	1.08	0.29	-1.04	0.52	5.87	0.08
O5'A	5	2.38	0.11	0.41	0.17	7.37	0.16
C5'A	5	3.43	0.24	-0.49	0.18	7.71	0.15
C4'A	5	4.73	0.18	0.09	0.26	7.34	0.36
O4'A	5	5.80	0.27	-0.54	0.45	7.99	0.17
C3'A	5	5.07	0.14	-0.04	0.62	5.96	0.38
O3'A	5	4.90	0.67	0.84	0.92	5.36	0.96
C2'A	5	6.35	0.42	-0.33	0.34	5.72	0.24
O2'A	5	6.88	0.18	0.71	0.74	5.16	0.35
C1'A	5	6.90	0.27	-0.63	0.31	7.08	0.22
N9A	5	7.56	0.16	-1.93	0.24	7.16	0.17
C8A	5	7.19	0.18	-3.11	0.27	6.55	0.20
N7A	5	7.98	0.18	-4.12	0.22	6.87	0.22
C5A	5	8.90	0.17	-3.57	0.15	7.72	0.19
C6A	5	10.00	0.19	-4.16	0.07	8.39	0.21
N6A	5	10.34	0.27	-5.42	0.05	8.23	0.27
N1A	5	10.72	0.16	-3.34	0.07	9.17	0.23
C2A	5	10.42	0.10	-2.04	0.11	9.27	0.21
N3A	5	9.45	0.10	-1.39	0.13	8.66	0.19

00222T "PT4460

C4A	5	8.68	0.13	-2.21	0.16	7.90	0.17
O3	5	0.38	0.10	-0.91	0.20	8.17	0.20
PN	5	-0.15	0.14	-0.48	0.48	9.57	0.41
O2N	5	0.14	0.49	0.83	0.44	9.75	0.95
O1N	5	0.30	0.16	-1.45	1.05	10.42	0.24
O5'N	5	-1.69	0.09	-0.59	0.27	9.56	0.17
C5'N	5	-2.47	0.06	-1.57	0.23	8.85	0.37
C4'N	5	-3.70	0.14	-0.94	0.26	8.22	0.15
O4'N	5	-4.71	0.05	-0.62	0.08	9.19	0.03
C3'N	5	-3.46	0.22	0.35	0.46	7.53	0.17
O3'N	5	-3.17	0.71	0.29	0.62	6.28	0.17
C2'N	5	-4.65	0.52	1.11	0.18	7.65	0.18
O2'N	5	-5.28	0.75	0.98	0.55	6.52	0.28
C1'N	5	-5.38	0.18	0.60	0.07	8.82	0.16
N1N	5	-5.34	0.08	1.60	0.06	9.91	0.18
C2N	5	-5.97	0.21	2.80	0.05	9.75	0.25
C3N	5	-5.93	0.17	3.83	0.08	10.68	0.26
C7N	5	-6.64	0.26	5.15	0.08	10.42	0.36
O7N	5	-7.25	0.57	5.32	0.37	9.88	1.12
N7N	5	-6.58	0.34	6.07	0.28	10.81	0.74
C4N	5	-5.15	0.02	3.67	0.21	11.82	0.22
C5N	5	-4.45	0.21	2.46	0.27	11.97	0.23
C6N	5	-4.58	0.19	1.45	0.20	11.02	0.20
P2'	3	8.26	0.32	1.61	0.37	4.55	0.21
OP1	3	8.14	0.53	1.73	0.94	3.60	0.75
OP2	3	9.03	0.56	1.00	0.50	4.62	1.13
OP3	3	8.62	0.79	2.41	1.40	4.94	0.68

Table 9D: Polypeptide and Solvent Interactors
Acceptors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
OE1	GLU 1	181		-3.88		5.25		14.75	
OE1	GLU 2	201		-4.15		5.48		14.38	
OE1	GLU 3	163		-3.79		3.89		15.77	
OE1	GLU 4	159		-3.14		2.93		14.95	
A11	ACC	11	4	-3.74	0.43	4.39	1.20	14.96	0.59
OE2	GLU 1	181		-4.37		6.90		13.45	
OE2	GLU 2	201		-4.56		6.92		12.74	
A12	ACC	12	2	-4.46	0.14	6.91	0.01	13.10	0.51
O	GLU 1	309		-8.06		0.25		7.52	
O	LEU 2	337		-7.71		-0.11		6.85	
O	ALA 3	297		-7.26		-0.97		6.55	
A21	ACC	21	3	-7.67	0.40	-0.28	0.63	6.97	0.49
OE2	GLU 1	309		-4.36		-3.87		5.45	
A23	ACC	23	1	-4.36		-3.87		5.45	
O	VAL 1	342		-7.20		8.83		10.41	
O	VAL 2	370		-6.94		8.48		9.46	
O	GLY 3	328		-6.79		9.23		10.09	
OE2	GLU 4	183		-5.19		8.47		10.50	
O	ALA 5	365		-6.46		8.51		10.35	
A27	ACC	27	5	-6.51	0.79	8.70	0.33	10.16	0.42
OD1	ASP 3	179		9.32		1.02		6.96	
A37	ACC	37	1	9.32		1.02		6.96	
OD2	ASP 3	179		8.04		2.39		7.96	
A38	ACC	38	1	8.04		2.39		7.96	
OH	TYR 3	188		-1.72		2.70		6.02	
A43	ACC	43	1	-1.72		2.70		6.02	

Donors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
N	TYR 1	177		0.42		4.12		9.29	
N	TYR 2	197		0.54		3.95		9.16	
N	TYR 3	159		0.39		3.86		9.94	
N	ASN 4	155		0.81		4.22		10.27	
N	TYR 5	198		0.50		4.45		10.69	
D8	DON	8	5	0.53	0.17	4.12	0.23	9.87	0.65
N	ILE 1	178		-0.30		3.00		11.99	
N	ILE 2	198		-0.19		3.01		11.87	
N	ILE 3	160		-0.46		2.46		12.45	
N	THR 4	156		-0.21		2.41		12.37	
D10	DON	10	4	-0.29	0.12	2.72	0.33	12.17	0.28
NE	ARG 1	198		10.97		-1.63		5.67	
NE	ARG 2	218		11.27		-1.15		5.31	
NE	ARG 4	176		11.22		-1.28		5.21	
NE	ARG 5	222		11.04		-1.09		6.07	
D13	DON	13	4	11.13	0.14	-1.28	0.24	5.56	0.39
NH1	ARG 1	198		11.24		-3.80		4.93	
NH1	ARG 2	218		10.89		-3.37		4.77	
NH1	ARG 4	176		10.67		-3.32		4.21	
NH1	ARG 5	222		11.05		-3.27		5.30	
D14	DON	14	4	10.96	0.24	-3.44	0.24	4.80	0.45
NH2	ARG 1	198		9.54		-2.45		4.11	
VAL 1	ARG 2	218		9.46		-1.77		4.00	
NH2	ARG 4	176		9.50		-1.43		3.70	
NH2	ARG 5	222		9.55		-1.74		4.46	
D15	DON	15	4	9.51	0.04	-1.85	0.43	4.07	0.31
NE	ARG 4	177		10.99		4.32		2.39	
NH1	ARG 1	204		8.17		3.03		1.71	

174

NH1	ARG 5	228	7.75	1.68	1.45
D18	DON	18	3	1.77	1.32
N	GLY 1	262	8.97	3.01	1.85
N	GLY 2	290	2.72	-3.76	9.55
N	GLY 3	243	2.62	-3.74	9.51
N	GLY 4	244	2.38	-4.07	9.32
N	GLY 5	286	1.45	-3.80	10.09
D23	DON	23	2.74	-3.85	9.80
OH	TYR 3	188	5	0.54	0.13
D46	DON	46	2.38	-3.84	9.65
NH1	ARG 4	181	-1.72	2.70	6.02
D58	DON	58	1	2.70	6.02
ND2	ASN 4	260	3.70	2.30	3.85
D62	DON	62	1	2.30	3.85
			-5.70	2.24	2.88
			1	2.24	2.88

Waterg

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	σz
O	HOH 1	35		0.68		-3.50		12.51	
O	HOH 2	511		0.54		-3.42		12.61	
O	HOH 3	461		-0.15		-4.12		12.26	
W2	WAT	2	3	0.36	0.44	-3.68	0.38	12.46	0.18
O	HOH 1	70		2.74		1.12		10.80	
O	HOH 2	524		3.09		1.48		10.72	
O	HOH 3	901		2.86		1.06		11.09	
O	HOH 4	618		3.03		0.35		11.05	
W4	WAT	4	4	2.93	0.16	1.13	0.26	10.91	0.18
O	HOH 1	115		-9.62		7.01		9.04	
O	HOH 2	514		-9.26		6.65		7.93	
O	HOH 3	499		-8.71		7.08		8.17	
O	HOH 4	861		-9.99		6.36		10.10	

O	HOH 5	121	-9.33	7.20	8.93	
W6	WAT	6	5	0.47	0.35	0.85
O	HOH 1	171	0.30	3.54	6.18	
O	HOH 2	984	0.61	3.27	5.33	
W10	WAT	10	2	0.22	0.19	0.60
O	HOH 1	250	-6.35	-3.18	10.09	
O	HOH 2	500	-6.31	-2.89	9.82	
O	HOH 3	467	-6.19	-3.41	9.14	
W13	WAT	13	3	0.08	0.26	0.49

Table 10A: Pharmacofamily 8 Subset

Molecule #	pdb	type	rmsd from family avg.
1	1QGA	Ferredoxin Reductase (pea)	0.61
2	P450'	P450 reductase (rat)	0.35

Table 10B: Polypeptide and Solvent Interactors (average coordinates)

Acceptors

atom name	residue- mol. #	total	x	ox	y	oy	z	oz
A2	ACC	2	0.63	0.38	-6.60	0.21	-7.09	0.16
A8	ACC	2	-2.87	0.25	-3.55	0.64	-0.51	0.02
A11	ACC	2	-4.28	0.30	8.10	0.34	3.52	0.33
A14	ACC	2	-7.58	0.10	8.62	0.24	3.69	0.19
A18	ACC	2	-12.53	0.11	8.89	0.59	0.72	0.62
A21	ACC	2	-8.28	0.08	9.45	0.25	-6.25	0.84
A23	ACC	2	-1.15	0.00	-2.54	0.21	-7.56	0.09
A29	ACC	2	-1.63	0.84	-6.66	0.42	-10.70	0.06
A31	ACC	2	-7.49	0.70	-5.59	0.66	-9.88	0.66
A32	ACC	1	-8.95	-	-3.74	-	-4.78	-

Donors

atom name	residue- mol. #	total	x	ox	y	oy	z	oz
D2	DON	2	0.63	0.38	-6.60	0.21	-7.09	0.16
D4	DON	2	-6.69	0.23	-1.87	0.78	5.73	0.27
D8	DON	2	-1.98	0.25	-0.80	0.53	-0.07	0.05
D9	DON	2	-2.87	0.25	-3.55	0.64	-0.51	0.02
D15	DON	2	-7.58	0.10	8.62	0.24	3.69	0.19
D18	DON	2	-10.73	0.10	5.15	0.70	6.85	0.21
D21	DON	2	-12.39	0.55	8.95	0.83	4.42	0.46
D23	DON	2	-12.53	0.11	8.89	0.59	0.72	0.62
D26	DON	2	-10.08	0.70	9.97	0.39	-5.61	0.35

Table 10C: NAD(P) Conformer Model

atom name	number	x	ox	y	oy	z	oz
PA	2	-6.90	0.19	1.29	0.01	2.19	0.44
O1A	2	-8.23	0.13	0.84	0.28	2.29	1.01
O2A	2	-6.22	0.68	1.25	0.00	3.45	0.19
O5'A	2	-6.94	0.05	2.74	0.01	1.67	0.46
C5'A	2	-5.96	0.32	3.31	0.21	0.99	0.16
C4'A	2	-6.21	0.28	4.77	0.19	0.81	0.08
O4'A	2	-7.07	0.21	4.93	0.07	-0.33	0.12
C3'A	2	-6.95	0.32	5.45	0.19	1.99	0.09
O3'A	2	-6.38	0.22	6.74	0.20	2.25	0.09
C2'A	2	-8.36	0.28	5.60	0.08	1.51	0.12
O2'A	2	-9.02	0.09	6.71	0.01	2.15	0.10
C1'A	2	-8.10	0.23	5.82	0.11	0.05	0.07
N9A	2	-9.26	0.18	5.67	0.07	-0.81	0.09
C8A	2	-10.48	0.15	5.08	0.02	-0.58	0.05
N7A	2	-11.35	0.01	5.15	0.09	-1.61	0.14
C5A	2	-10.62	0.05	5.84	0.01	-2.55	0.11
C6A	2	-10.98	0.07	6.27	0.00	-3.84	0.10
N6A	2	-12.17	0.06	6.02	0.00	-4.36	0.08
N1A	2	-10.08	0.13	6.95	0.04	-4.59	0.09
C2A	2	-8.88	0.12	7.22	0.07	-4.10	0.04
N3A	2	-8.46	0.02	6.87	0.15	-2.90	0.02
C4A	2	-9.35	0.07	6.17	0.04	-2.06	0.07
O3	2	-6.11	0.32	0.30	0.20	1.21	0.13
PN	2	-5.73	0.14	-1.29	0.24	1.48	0.01
O1N	2	-6.50	0.06	-1.63	0.42	2.69	0.13
O2N	2	-4.30	0.14	-1.48	0.06	1.62	0.06
O5'N	2	-6.26	0.37	-2.13	0.26	0.26	0.06
C5'N	2	-5.67	0.29	-2.09	0.15	-1.01	0.07
C4'N	2	-6.63	0.26	-2.81	0.33	-1.93	0.11
O4'N	2	-6.11	0.28	-2.90	0.27	-3.27	0.09

C3'N	2	-6.95	0.06	-4.24	0.38	-1.45	0.14
O3'N	2	-8.35	0.03	-4.47	0.60	-1.50	0.32
C2'N	2	-6.22	0.01	-5.16	0.30	-2.41	0.06
O2'N	2	-7.01	0.15	-6.29	0.42	-2.74	0.07
C1'N	2	-5.90	0.11	-4.29	0.22	-3.62	0.04
NN1	2	-4.55	0.05	-4.52	0.01	-4.21	0.01
C2N	2	-4.50	0.03	-5.07	0.06	-5.47	0.05
C3N	2	-3.29	0.08	-5.32	0.10	-6.13	0.01
C7N	2	-3.24	0.24	-5.90	0.02	-7.52	0.03
O7N	2	-3.24	1.75	-6.01	0.02	-8.11	0.03
NN7	2	-3.18	1.32	-6.31	0.10	-8.11	0.04
C4N	2	-2.09	0.01	-5.00	0.39	-5.44	0.02
C5N	2	-2.15	0.06	-4.44	0.46	-4.14	0.07
C6N	2	-3.40	0.11	-4.21	0.25	-3.54	0.08
P2'	2	-10.21	0.02	6.47	0.10	3.22	0.06
OP1	2	-10.72	1.21	5.88	0.71	3.20	1.26
OP2	2	-10.31	0.01	7.62	0.12	4.24	0.11
OP3	2	-10.73	1.02	5.69	1.01	3.24	0.93

Table 10D: Polypeptide and Solvent Interactors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
OG	SER 1	90		0.366		-6.74		-6.97	
OG	SER 2	457		0.899		-6.45		-7.20	
A2	ACC	2	2	0.633	0.38	-6.60	0.21	-7.09	0.16
OG1	THR 1	166		-2.694		-4.00		-0.53	
OG1	THR 2	535		-3.041		-3.09		-0.50	
A8	ACC	8	2	-2.867	0.25	-3.55	0.64	-0.51	0.02
O	VAL 1	198		-4.071		7.86		3.28	
O	CYS 2	566		-4.494		8.34		3.75	
A11	ACC	11	2	-4.282	0.30	8.10	0.34	3.52	0.33
OG	SER 1	228		-7.649		8.79		3.55	
OG	SER 2	596		-7.509		8.45		3.83	
A14	ACC	14	2	-7.579	0.10	8.62	0.24	3.69	0.19
OH	TYR 1	240		-12.45		9.30		1.16	
OH	TYR 2	604		-12.61		8.47		0.29	
A18	ACC	18	2	-12.53	0.11	8.89	0.59	0.72	0.62
OE1	GLN 1	242		-8.226		9.28		-6.85	
OE1	GLN 2	606		-8.34		9.63		-5.65	
A21	ACC	21	2	-8.283	0.08	9.45	0.25	-6.25	0.84
SG	CYS 1	266		-1.15		-2.68		-7.63	
SG	CYS 2	630		-1.148		-2.39		-7.50	
A23	ACC	23	2	-1.149	0.00	-2.54	0.21	-7.56	0.09
OE1	GLU 1	306		-1.033		-6.96		-10.66	
OD1	ASP 2	675		-2.227		-6.36		-10.74	
A29	ACC	29	2	-1.63	0.84	-6.66	0.42	-10.70	0.06
O	VAL 1	307		-7.979		-5.12		-9.41	
O	VAL 2	676		-6.991		-6.05		-10.34	
A31	ACC	31	2	-7.485	0.70	-5.59	0.66	-9.88	0.66

Donors

atom name	residue- mol. #	residue #	total	x	ox	y	oy	z	oz
OG	SER 1	90		0.366		-6.74		-6.97	
OG	SER 2	457		0.899		-6.45		-7.20	
D2	DON	2	2	0.633	0.38	-6.60	0.21	-7.09	0.16
NZ	LYS 1	110		-6.847		-2.42		5.92	
NH1	ARG 2	298		-6.526		-1.32		5.54	
D4	DON	4	2	-6.687	0.23	-1.87	0.78	5.73	0.27
N	THR 1	166		-1.805		-1.18		-0.10	
N	THR 2	535		-2.152		-0.42		-0.03	
D8	DON	8	2	-1.978	0.25	-0.80	0.53	-0.07	0.05
OG1	THR 1	166		-2.694		-4.00		-0.53	
OG1	THR 2	535		-3.041		-3.09		-0.50	
D9	DON	9	2	-2.867	0.25	-3.55	0.64	-0.51	0.02
OG	SER 1	228		-7.649		8.79		3.55	
OG	SER 2	596		-7.509		8.45		3.83	
D15	DON	15	2	-7.579	0.10	8.62	0.24	3.69	0.19
NH1	ARG 1	229		-10.66		5.64		7.00	
NH2	ARG 2	597		-10.81		4.65		6.71	
D18	DON	18	2	-10.73	0.10	5.15	0.70	6.85	0.21
NZ	LYS 1	238		-12		9.53		4.09	
NZ	LYS 2	602		-12.78		8.36		4.75	
D21	DON	21	2	-12.39	0.55	8.95	0.83	4.42	0.46
OH	TYR 1	240		-12.45		9.30		1.16	
OH	TYR 2	604		-12.61		8.47		0.29	
D23	DON	23	2	-12.53	0.11	8.89	0.59	0.72	0.62
NE2	GLN 1	242		-9.587		10.24		-5.36	
NE2	GLN 2	606		-10.58		9.70		-5.85	
D26	DON	26	2	-10.08	0.70	9.97	0.39	-5.61	0.35

Coordinates for the conformer and pharmacophore models and data used in their construction is presented in Tables 3-10 above. Part A of each Table lists subset of structures used in constructing the model including molecule numbers for cross-referencing between parts A-C, the PDB accession number, the name of the polypeptide, and the RMSD from the pharmacocluster average. Part B of each Table lists the average coordinates for heteroatoms and waters of the pharmacophore model and includes the atom name (cross referenced to part D), designation of interaction ("ACC," acceptor; "DON," donor; and "WAT," water), total number of atoms included in the calculation of the average, and X, Y, Z coordinates with respective standard deviations (σ). Part C of each Table lists the coordinates of the conformer model using the atom designations of Figure 2 and X, Y, Z coordinates with respective standard deviations (σ). Part D of each Table lists the coordinates for interacting molecules used to determine the pharmacophore model including the atom name, residue molecule # (which identifies the residue type and molecule number cross-referenced to Part A), residue number from the PDB structure, total number of atoms summed for the average coordinates, and X, Y, Z coordinates with respective standard deviations (σ). The bolded entries in part D correspond to the average values reported in part B. Atom names are identified according to IUPAC recommendations as described for example in Markley et al., Pure and Appl. Chem. 70:117-142 (1998).

Throughout this application various publications have been referenced. The disclosures of these publications in their entireties are hereby incorporated by reference in

Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific details are only illustrative of the invention. It is understood that modifications which do not substantially affect the activity of the various embodiments of this invention are also included within the definition of the invention provided herein. Therefore, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.